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Abstract 
The transdifferentiation of pancreatic acinar cells towards hepatocytes is an 
event that occurs in vitro and in vivo in rodents. The B-13 cell line is a model for 
studying this phenomenon in vitro; it readily transdifferentiates into hepatocyte-
like cells in response to glucocorticoids such as dexamethasone (DEX).  The 
transdifferentiation event is dependent on a transient suppression of Wnt 
signalling followed by induction of Serine/threonine-protein kinase 1(SGK1) via 
interactions with the glucocorticoid receptor. This thesis has aimed to further 
explore pancreatic to hepatic transdifferentiation, using the B-13 cell as a model 
and also investigated the phenomenon in human cells.   
As hepatic stellate cells are involved in liver regeneration and may support the 
progenitor niche in liver, coculture experiments were conducted to assess their 
effects on B-13 transdifferentiation. Transdifferentiation was enhanced in 
cocultures and found to be dependent on cell-cell interaction that resulted in 
further suppression of the Wnt signalling pathway by myofibroblasts.  
B-13 transdifferentiation was shown to be able to take place in vivo for the first 
time; cells were found to engraft only into the liver and pancreas of NOD/SCID 
mice. Interestingly, only cells within the liver environment showed expression of 
hepatocyte-specific genes. 
B-13 cells were also cultured in 3D bioreactor devices where they 
transdifferentiated into functional hepatocyte-like cells with gene expression at 
levels comparable to primary rat hepatocytes.   
Elucidating the mechanisms involved during B-13 transdifferentiation will 
support the isolation of an equivalent human pancreatic cell. Studies with a 
human cell line and primary exocrine cells demonstrated that glucocorticoids 
also induce hepatocyte-gene expression, and thus the generation/isolation of a 
human equivalent to the B-13 is a realistic goal. 
Acknowledgements 
iv 
 
Acknowledgements 
 
Thank you to the MRC for my ITTP MRC studentship, without which this project 
would not have been possible. 
 
I would like to give a special thank you to my supervisor Professor Matthew 
Wright for his constant support, motivation and guidance throughout the past 4 
years. Matt has helped me grow as a scientist during my PhD, and I know I will 
never work with anyone else quite like him, it’s been a pleasure.  
In addition I would like to thank all the other members of team Wright, both past 
and present- Karen Wallace, Izzy-Lugs Swidenbank, Philip Probert, Anne 
Lakey, Aiman Amer, Stephen Hill, Stephanie Meyer, Andy Axon, Helen Tovey, 
and Dave Cowie. I know I’ve gained some lifelong friends and I would like to 
thank them all for their support and banter over the years, both in and outside of 
the lab.  
 
Special acknowledgments must go to the whole of Katrin Zeilinger’s group in 
Berlin with particular thanks to Stefan Hoffman and Marco Richter with whom I 
performed the bioreactor work with (Chapter 3.4). It was a great experience to 
work in their lab and I was lucky to make some great friends whilst doing so, 
Vielen Dank!!  Likewise I would like to acknowledge the contributions by Claire 
Schwab and Christine Harrison from the James Spence Institute who patiently 
helped me with the cytogenetics work (Chapter 3.2). 
 
Finally I would like to dedicate this thesis to my family, in particular to my Mam, 
Dad and sister Kate, to whom I am hugely grateful for their countless love, 
support and guidance.  
 
 
 
 
 
 
Table of contents 
v 
 
Table of contents 
Declaration ----------------------------------------------------------------------------- ii 
Abstract --------------------------------------------------------------------------------- iii 
Acknowledgements ----------------------------------------------------------------- iv 
List of figures-------------------------------------------------------------------------- xi 
List of tables ----------------------------------------------------------------------- xviii 
Abbreviations ----------------------------------------------------------------------- xix 
SI units ------------------------------------------------------------------------------ xxiii 
1 Introduction ----------------------------------------------------------------------- 1 
1.1 Stem cells --------------------------------------------------------------------------------- 3 
1.1.1 Embryonic Stem Cells ------------------------------------------------------------- 3 
1.1.2 Adult Stem Cells --------------------------------------------------------------------- 5 
1.1.3 Induced Pluripotent Stem (iPS) Cells ---------------------------------------- 8 
1.2 Endodermal origins of the adult liver and pancreas ----------------------- 9 
1.2.1 Liver development ------------------------------------------------------------------ 9 
1.2.2 Pancreas development ---------------------------------------------------------- 11 
1.3 The adult pancreas; anatomy and physiology ----------------------------- 12 
1.4 The adult liver; anatomy and physiology ------------------------------------ 15 
1.4.1 Liver structure and functional units ---------------------------------------- 16 
1.4.2 Functions of the liver ------------------------------------------------------------ 18 
1.4.3 Cells of the liver ------------------------------------------------------------------- 19 
1.4.4 Liver disease and current therapies ---------------------------------------- 22 
Table of contents 
vi 
 
1.4.5 Regenerative capacity of the liver ------------------------------------------- 24 
1.4.6 Stem cells in the liver ------------------------------------------------------------ 25 
1.5 Alternative cell types for generation of hepatocyte cells -------------- 27 
1.5.1 Oval cells/hepatic progenitor cells ------------------------------------------ 28 
1.5.2 Hepatoblasts ------------------------------------------------------------------------ 29 
1.5.3 Embryonic stem cells ------------------------------------------------------------ 29 
1.5.4 iPS cells ------------------------------------------------------------------------------ 30 
1.5.5 Extra-hepatic adult stem cells. ----------------------------------------------- 30 
1.6 Transdifferentiation of the pancreas to liver ------------------------------- 32 
1.6.1 The AR42J-B-13 (B-13) cell line ---------------------------------------------- 33 
1.6.2 Wnt signalling in transdifferentiation of pancreas to liver --------- 36 
1.6.3 Glucocorticoids in transdifferentiation of pancreas to liver ------- 38 
2 Materials and Methods ------------------------------------------------------- 42 
2.1 Animal work ---------------------------------------------------------------------------- 43 
2.1.1 Ethics ---------------------------------------------------------------------------------- 43 
2.1.2 Housing ------------------------------------------------------------------------------- 43 
2.1.3 C57B16 (wild type) mice -------------------------------------------------------- 43 
2.1.4 Green Fluorescent Protein/ C57B16 mice -------------------------------- 43 
2.1.5 Non-Obese Diabetic Severe Combined immune-deficient (NOD-
SCID) mice ------------------------------------------------------------------------------------ 43 
2.2 Cell Culture ----------------------------------------------------------------------------- 44 
2.2.1 AR42J-B-13 (B-13) Cells -------------------------------------------------------- 44 
2.2.2 Induction of a hepatic phenotype in B-13 cells ------------------------- 44 
2.2.3 Primary human hepatic stellate cells (hHSCs) -------------------------- 44 
2.2.4 Primary mouse and rat hepatic stellate cells (m/rHSCs) ------------ 45 
2.2.5 Primary mouse and rat hepatocytes --------------------------------------- 45 
2.2.6 HPAC cells --------------------------------------------------------------------------- 46 
2.2.7 Primary human pancreatic acinar cells ----------------------------------- 46 
2.2.8 HepG2 Cells ------------------------------------------------------------------------- 46 
2.2.9 Cell passage ------------------------------------------------------------------------ 46 
2.2.10 Cell storage and revival --------------------------------------------------------- 47 
Table of contents 
vii 
 
2.2.11 Cell viability and number ------------------------------------------------------- 47 
2.2.12 Coculture of B-13red cells with GFP activated HSCs 
(myofibroblasts) ---------------------------------------------------------------------------- 48 
2.2.13 GFP myofibroblast conditioned media and its treatments --------- 48 
2.3 Cell transfection ---------------------------------------------------------------------- 48 
2.3.1 Transfection using Effectene reagent (QIAGEN) ----------------------- 48 
2.3.2 Production of stable transformed cell line ------------------------------- 49 
2.3.3 TOP/FLOP flash transfection and dual luciferase assay (Promega)
 49 
2.4 Plasmid DNA constructs ---------------------------------------------------------- 50 
2.4.1 TCF/LEF (TOPFLASH and FLOPFLASH) transcriptional activity 
reporter gene. ------------------------------------------------------------------------------- 50 
2.4.2 pDsRed2-C1 ------------------------------------------------------------------------- 51 
2.4.3 pCAG2LMKOSimO ---------------------------------------------------------------- 52 
2.4.4 Transformation of TOP10 competent cells ------------------------------- 52 
2.4.5 Storage of DNA plasmids and glycerol stocks ------------------------- 52 
2.4.6 Miniprep purification of plasmid DNA ------------------------------------- 53 
2.4.7 Maxiprep purification of plasmid DNA ------------------------------------- 53 
2.5 Cytogenetic analysis of B-13 cells --------------------------------------------- 54 
2.5.1 Preparation of metaphase spreads ----------------------------------------- 54 
2.6 Soft agar anchorage assay ------------------------------------------------------- 54 
2.6.1 Culture in soft agar --------------------------------------------------------------- 54 
2.7 RNA and DNA isolation/ quantification --------------------------------------- 55 
2.7.1 RNA isolation ----------------------------------------------------------------------- 55 
2.7.2 Quantification of RNA concentration and integrity ------------------- 55 
2.7.3 DNase treatment of RNA -------------------------------------------------------- 56 
2.7.4 DNA isolation ----------------------------------------------------------------------- 56 
2.7.5 Quantification of DNA concentration and integrity ------------------- 56 
2.7.6 Reverse transcription, 1st strand DNA synthesis (cDNA) ----------- 57 
2.7.7 Polymerase Chain Reaction (PCR) ------------------------------------------ 57 
2.7.8 PCR primer design --------------------------------------------------------------- 58 
Table of contents 
viii 
 
2.7.9 Agarose gel electrophoresis -------------------------------------------------- 58 
2.7.10 Real-time PCR (SYBR Green qRT-PCR). ---------------------------------- 59 
2.8 Protein isolation and quantification ------------------------------------------- 64 
2.8.1 Preparation of whole tissue samples -------------------------------------- 64 
2.8.2 Preparation of cell extracts ---------------------------------------------------- 64 
2.8.3 Lowry protein assay ------------------------------------------------------------- 64 
2.8.4 Sodium-dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) ---------------------------------------------------------------------------------- 65 
2.8.5 Sample preparation and electrophoresis --------------------------------- 65 
2.8.6 Electrotransfer --------------------------------------------------------------------- 66 
2.8.7 Immunodetection------------------------------------------------------------------ 66 
2.9 Immunohistochemistry and immunocytochemistry --------------------- 67 
2.9.1 Immunohistochemistry --------------------------------------------------------- 67 
2.9.2 Haematoxylin and eosin staining (H&E) ---------------------------------- 67 
2.9.3 Sodium citrate antigen retrieval --------------------------------------------- 68 
2.9.4 Fluorescent immunocytochemistry ---------------------------------------- 68 
2.9.5 DAPI staining of DNA ------------------------------------------------------------ 69 
2.9.6 Double staining -------------------------------------------------------------------- 69 
2.10 Fluorescent in situ hybridisation (FISH) staining ------------------------- 70 
2.10.1 FISH staining ----------------------------------------------------------------------- 70 
2.11 Culturing B-13 cells in bio-artificial liver device -------------------------- 73 
2.11.1 Bioreactor and perfusion equipment --------------------------------------- 73 
2.11.2 Running of bioreactor ----------------------------------------------------------- 74 
2.11.3 Inoculation of B-13 cells -------------------------------------------------------- 75 
2.11.4 Assessment of CYP450 activity and other parameters -------------- 75 
2.11.5 Opening of Bioreactor ----------------------------------------------------------- 79 
3 Results ---------------------------------------------------------------------------- 80 
3.1 Investigating the effects of B-13 and activated HSC (myofibroblasts) 
cocultures on the transdifferentiation towards the B-13/H phenotype ----- 81 
3.1.1 Generation of the B-13red cell line ------------------------------------------- 84 
Table of contents 
ix 
 
3.1.2 Coculture of B-13red cells with myofibroblasts ------------------------- 88 
3.1.3 Affects of coculture on Wnt signalling in B-13 cells ------------------ 93 
3.1.4 Identifying factors influencing enhanced transdifferentiation in 
coculture experiments ------------------------------------------------------------------- 95 
3.1.5 Chapter discussion ------------------------------------------------------------- 101 
3.2 Investigations into cytogenetics and tumour-like behaviour of B-
cells 105 
3.2.1 Cytogenetic analysis of B-13 cells ---------------------------------------- 107 
3.2.2 Agar anchorage assay -------------------------------------------------------- 111 
3.2.3 In vivo assessment of tumour forming potential -------------------- 113 
3.2.4 Chapter discussion ------------------------------------------------------------- 116 
3.3 Investigations for the in vivo potential of the B-13 cell line as a liver 
progenitor cell -------------------------------------------------------------------------------- 118 
3.3.1 Determination of paracetamol and B-13red cell dosage ------------ 120 
3.3.2 The B-13 cell is able to engraft to the liver independent of 
paracetamol treatment.----------------------------------------------------------------- 124 
3.3.3 Amylase positive cells within the livers are of B-13 origin ------- 130 
3.3.4 B-13 cells engraft to the liver and pancreas but show hepatocyte-
like phenotype in the liver only. ----------------------------------------------------- 133 
3.3.5 Chapter discussion ------------------------------------------------------------- 137 
3.4 Culture of B-13 cells in  3D bio-artificial liver devices ---------------- 139 
3.4.1 Establishing optimal culture conditions for bioreactor cultures 142 
3.4.2 Pilot study in bioreactor (BR) 176 ----------------------------------------- 146 
3.4.3 Identifying factors affecting B-13 culture in BR176 ----------------- 156 
3.4.4 Culturing of B-13 and B-13/H cells in 3D environment ------------- 159 
3.4.5 Chapter discussion ------------------------------------------------------------- 174 
3.5 Culture of human pancreatic acinar cells for generation of human 
hepatocyte-like cells ----------------------------------------------------------------------- 176 
3.5.1 The human pancreatic acinar cell (HPAC) line shows slowed 
proliferation in response to DEX. --------------------------------------------------- 178 
3.5.2 Expression of liver-specific markers is induced in HPACS 
following DEX treatment and is depedent on activation of the GR. ---- 180 
Table of contents 
x 
 
3.5.3 Expression of liver specific markers through DEX treatment is 
inhibited in cocultures with liver myofibroblasts. ---------------------------- 186 
3.5.4 Expression of pluripotency inducing factors in HPACS ---------- 189 
3.5.5 Culture of human primary acinar cells.---------------------------------- 194 
3.5.6 Chapter discussion ------------------------------------------------------------- 197 
4 General Discussion --------------------------------------------------------- 200 
5 References --------------------------------------------------------------------- 207 
6 Publications and abstracts ----------------------------------------------- 222 
7 Published manuscripts ---------------------------------------------------- 228 
 
List of Figures 
xi 
 
List of figures 
 
Figure 1. 1: The cell lineage of a typical pluripotent stem cell ............................ 5 
Figure 1. 2: Pathways involved in tissue regeneration in the mammalian adult. 6 
Figure 1. 3: The intestinal stem cell niche .......................................................... 7 
Figure 1. 4: The early development of the liver and pancreas from the 
endodermal germ layer. .................................................................................... 10 
Figure 1. 5: Basic anatomy of the pancreas. .................................................... 12 
Figure 1. 6: Basic anatomy of the liver. ............................................................ 15 
Figure 1. 7: Schematic diagrams representing the hepatic lobule (A) and the 
liver acinus (B) .................................................................................................. 17 
Figure 1. 8:  Fibrosis during liver injury ............................................................ 23 
Figure 1. 9: The potential uses of stem cell-derived hepatocytes for treatment 
of liver disease and in vitro toxicity testing ........................................................ 28 
Figure 1. 10: The typical morphology of B-13 cells before and after DEX 
treatment ........................................................................................................... 35 
Figure 1. 11: The canonical Wnt signalling pathway.. ...................................... 37 
Figure 1. 12: Crosstalk between the Wnt and glucocorticoid signalling pathways 
in the induction of B-13 to B-13/H transdifferentiation.. ..................................... 40 
 
Figure 2. 1: Luciferase reaction. ....................................................................... 50 
Figure 2. 2: Vector map for (TOPFLASH catalog # 21-170) ............................ 51 
Figure 2. 3: Vector and restriction map for pDsRed2-C1 ................................. 51 
Figure 2. 4: Vector map for pCAG2LMKOSimO............................................... 52 
Figure 2. 5: Images to show  A) a typical jellyfish bioreactor employed for 3D 
culture studies; B) the set up of the bioreactor and the perfusion tubing within 
the processor-controlled perfusion device with electronic pressure, media flow 
regulation and waste pump operation. .............................................................. 73 
Figure 2. 6: A schematic diagram to show the organisation of the bioreactor 
devices used for 3D-culture .............................................................................. 74 
Figure 2. 7: Images to show the metabolism pathways for the drugs 
Phenacetin[194], Bupropion[195], Diclofenac[196] and Midazolam[197] which were 
List of Figures 
xii 
 
used in metabolism assays during the  pilot bioreactor run. Images are adapted 
from the cited references. ................................................................................. 78 
 
Figure 3.1 1: The effect of various G418 disulphate concentrations on B-13 cell 
viability. ............................................................................................................. 85 
Figure 3.1 2: The expression of red fluorescent protein in the B-13red cell line. 
Cells are treated with and without DEX treatment, with B-13 cells as controls. 85 
Figure 3.1 3: RT-PCR and Western blot analysis for the expression of liver 
specific markers in B-13red with or without DEX treatment. ............................... 86 
Figure 3.1 4: The expression of the pancreatic marker amylase and liver 
markers albumin and CYP2E1 in B-13red and B-13/Hred cells shown by 
immunocytochemistry. ...................................................................................... 87 
Figure 3.1 5: The average number of hepatocyte-like cells per random field of 
view  comparing B-13red cells alone, activated HSCs (myofibroblasts) alone or 
cocultures with or without DEX treatment for 7 days ......................................... 88 
Figure 3.1 6: Haematoxylin and eosin (H&E) staining of B-13red, activated 
HSCs (myofibroblasts) and cocultures after 7 days of culture with or without 
DEX. ................................................................................................................. 89 
Figure 3.1 7:  Cultures of B-13red activated HSCs (myofibroblasts) and 
cocultures with or without DEX treatment for 7 days. ........................................ 91 
Figure 3.1 8:  RT-PCR and Western blot analysis for the expression of liver 
specific markers in coculture experiments with or without DEX after 7 days .... 92 
Figure 3.1 9: Wnt signalling activity in B-13 cells cultured with or without 
myofibroblasts after 24 or 48 hours of DEX treatment ...................................... 94 
Figure 3.1 10: The effects of myofibroblast conditioned media on the rate of B-
13 transdifferentiation ....................................................................................... 95 
Figure 3.1 11: The average number of hepatocyte-like cells per random field of 
view  comparing B-13red cells alone, B-13red cells treated with myofibroblast 
conditioned media or cocultures, with or without DEX treatment for 7 days ..... 96 
Figure 3.1 12: RT-PCR and Western blot analysis for the expression of liver 
specific markers in coculture experiments with dead myofibroblasts with or 
without 10µM DEX for 7 days ........................................................................... 97 
List of Figures 
xiii 
 
Figure 3.1 13: The average number of hepatocyte like cells per random field of 
view  comparing B-13red cells alone, B-13red cells with dead myofibroblasts or 
cocultures with or without DEX treatment for 7 days ......................................... 98 
Figure 3.1 14: The expression of amylase and CYP2E1 in B-13 cells after 
cocultures shown by immunohistochemistry ................................................... 100 
 
Figure 3.2 1:  A typical G-banded metaphase spread of B-13 chromosomes.
 ........................................................................................................................ 107 
Figure 3.2 2: Metaphase spreads from B-13 cells, rat myofibroblasts and the 
human HepG2 cell line .................................................................................... 108 
Figure 3.2 3:  A typical G-banded karyotype of the B-13 cells ....................... 109 
Figure 3.2 4: PCR for the sex chromosomes in B-13 cells ............................. 109 
Figure 3.2 5: Crystal violet staining to show colony formation after culture in 
agar ................................................................................................................. 111 
Figure 3.2 6: The presence of cells or cell colonies after growth in soft agar for 
14 days ........................................................................................................... 112 
Figure 3.2 7: Colony formation after growth in soft agar ................................ 112 
Figure 3.2 8: RT-PCR and Western blot analysis of the expression for the 
pancreatic marker amylase in organs from NOD-SCID mice injected with B-13 
cells, HepG2 cells and PBS ............................................................................ 114 
Figure 3.2 9: The expression of amylase and CYP2E1 in tumours formed in B-
13 injected NOD/SCID mice shown by immunohistochemistry ....................... 115 
 
Figure 3.3 1: Levels of alkaline phosphatase and alanine transaminase in 
paracetamol treated mice ............................................................................... 120 
Figure 3.3 2: Morphology of livers from paracetamol treated mice and a non-
treated control ................................................................................................. 121 
Figure 3.3 3: B-13red cells were visualised under the DsRed wavelength using 
an in vivo imaging system (ivis) ...................................................................... 122 
Figure 3.3 4: Total fluorescence detected in varying numbers of B-13red cells 
under DsRed wavelengths using an in vivo imaging system (ivis) .................. 122 
Figure 3.3 5: Western blot analysis and immunohistochemistry for the 
pancreatic marker amylase in pilot studies for injections of B-13red cells into 
NOD/SCID mice .............................................................................................. 123 
List of Figures 
xiv 
 
Figure 3.3 6: The expression of the pancreatic marker amylase in WT rat 
pancreas and liver and B-13red injected NOD/SCID mouse pancreas, liver, heart 
and lung shown by immunohistochemistry ..................................................... 125 
Figure 3.3 7: The expression of the pancreatic marker amylase detected within 
the livers of NOD/SCID mice after intravenous injections of B-13red cells shown 
by immunohistochemistry ............................................................................... 126 
Figure 3.3 8: The expression for the pancreatic marker amylase in B-13red 
injected NOD/SCID mice shown by RT-PCR .................................................. 126 
Figure 3.3 9: Expression of amylase at the protein level in various organs of 
NOD/SCID mice after B-13 injections and non injected controls shown by 
Western blot .................................................................................................... 127 
Figure 3.3 10: Organs from NOD/SCID mice injected with Cellvue® NIR815 
conjugated B-13 cells were visualised under the near infrared wavelength using 
an in vivo imaging system (ivis) ...................................................................... 128 
Figure 3.3 11: Total radiance detected from the organs of Cellvue® NIR815 B-
13 cell injected NOD/SCID mice and non-injected controls ............................ 129 
Figure 3.3 12: Fluorescent in situ hybridisation (FISH) staining performed on rat 
liver (male and female), mouse liver (male) and B-13 cells ............................ 131 
Figure 3.3 13: Fish and amylase staining in serial sections from B-13 injected 
NOD/SCID mice livers .................................................................................... 132 
Figure 3.3 14: Sections of liver and pancreas from B-13red injected NOD/SCID 
mice visualised under the DsRed wavelength show evidence of B-13 cell 
engraftment. .................................................................................................... 133 
Figure 3.3 15: Rat specific amylase and CYP2E1 mRNA was detected in the 
livers and pancreata of B-13red injected NOD/SCID mice ............................... 135 
Figure 3.3 16: DsRed and albumin expression in B-13red injected NOD/SCID 
mice ................................................................................................................ 136 
 
Figure 3.4 1: Typical cell morphology of B-13 cells treated with 10µM DEX in 
media containing 10% or 2.5% FCS ............................................................... 143 
Figure 3.4 2: Proliferation of B-13 cells in 10% or 2.5% FCS containing media 
with or without 10µM DEX treatment............................................................... 143 
List of Figures 
xv 
 
Figure 3.4 3: RT-PCR and Western blot analysis for the expression of liver 
specific markers after culture with 10% or 2.5% FCS containing media ±10µM 
DEX ................................................................................................................ 144 
Figure 3.4 4: Cytochrome P450-carbon monoxide complexes in B-13/H cells 
and primary rat hepatocytes............................................................................ 145 
Figure 3.4 5: The timescale of the pilot bioreactor study (BR 176) and the 2D 
parallel cultures ............................................................................................... 146 
Figure 3.4 6: Cell metabolism of the B-13 cells cultured in bioreactor 176 and 
parallel 2D cultures ......................................................................................... 147 
Figure 3.4 7: Enzyme release from B-13 cells cultured in bioreactor 176 and 
parallel 2D cultures ......................................................................................... 150 
Figure 3.4 8: Urea production by B-13 cells cultured in bioreactor 176 and 
parallel 2D cultures ......................................................................................... 151 
Figure 3.4 9: H&E stains of B-13 cells cultured in BR176 shown at x10 and x40 
magnification ................................................................................................... 152 
Figure 3.4 10: Typical DAB staining for samples from BR176 and parallel 2D 
cultures. .......................................................................................................... 153 
Figure 3.4 11: RT-PCR analysis of mRNA samples from BR176 and parallel 2D 
cultures ........................................................................................................... 154 
Figure 3.4 12: CYP450 metabolism assay of B-13 cells in BR176 and parallel 
2D cultures at 8 days ...................................................................................... 155 
Figure 3.4 13: RT-PCR analysis for the expression of liver specific markers 
CYP2E1, CPS-1, and albumin, and the pancreatic marker amylase, at the 
mRNA level in B-13 cells cultured with a range of different 10µM DEX solutions.
 ........................................................................................................................ 157 
Figure 3.4 14: Comparison of absolute levels of DEX (nM) measured in media 
samples from BR176 and parallel 2D cultures of B-13 cells on days 2, 4 and 6 
of culture. ........................................................................................................ 157 
Figure 3.4 15: The effect of seeding density on the rate of B-13 
transdifferentiation. ......................................................................................... 158 
Figure 3.4 16: The timescale of bioreactor cultures 196-199 and the 2D parallel 
cultures ........................................................................................................... 159 
List of Figures 
xvi 
 
Figure 3.4 17: Cell metabolism of bioreactors 196, 197, 198 and 199 over 8/15 
days. Bioreactors 196 and 197 were inoculated with B-13 cells, bioreactor 198 
with B-13/H cells and bioreactor 199 with rat hepatocytes .............................. 160 
Figure 3.4 18: The enzyme release in bioreactors 196, 197, 198 and 199 over 
8/15 days ........................................................................................................ 163 
Figure 3.4 19: Urea production in bioreactors 196, 197, 198 and 199 over 8/15 
days. ............................................................................................................... 164 
Figure 3.4 20: H&E staining of bioreactors 199, 196, 197 and 198 ................ 165 
Figure 3.4 21: Typical images of DAB immunohistochemistry for bioreactors 
196-199 after 8/15 days culture ...................................................................... 166 
Figure 3.4 22: RT-PCR and Western blot analysis for the expression of liver 
specific markers in bioreactors 196-199. ........................................................ 168 
Figure 3.4 23: Fold changes of CYP2E1 mRNA detected by real time PCR in 
different bioreactor cultures 196, 197, and 198  compared to B-13 cells ........ 169 
Figure 3.4 24: Fold changes of albumin mRNA detected by real time PCR in 
different bioreactor cultures 196, 197, and 198 compared to B-13 cells ......... 169 
Figure 3.4 25: Fold changes of CPS-1 mRNA detected by real time PCR in 
different bioreactor cultures 196, 197, and 198 compared to B-13 cells ......... 170 
Figure 3.4 26: Fold changes of C/EBPβ mRNA detected by real time PCR in 
different bioreactor cultures 196, 197, and 198 compared to B-13 cells ......... 170 
Figure 3.4 27: Fold changes of amylase mRNA detected by real time PCR in 
different bioreactor cultures 196, 197, and 198 compared to B-13 cells. ........ 171 
Figure 3.4 28: EROD CYP450 assay for bioreactors 196, 197, 198 and 199 
performed on day 1, day 8 and day 15 of bioreactor cultures ......................... 172 
 
Figure 3.5 1: HPAC cell proliferation with 10μM DEX treatment or ethanol 
vehicle controls. .............................................................................................. 179 
Figure 3.5 2: Typical morphology of HPACs treated with ethanol vehicle and 
HPACs treated with 10μM DEX for 7 days ...................................................... 179 
Figure 3.5 3: RT-PCR and Western blot analysis for the expression of liver 
specific markers in HPACs and HPACs treated with DEX .............................. 181 
Figure 3.5 4: Immunocytochemistry for CYP2E1 in B-13 and HPAC cells with or 
without DEX .................................................................................................... 182 
List of Figures 
xvii 
 
Figure 3.5 5: RT-PCR analysis for the expression of nuclear receptors in HPAC 
cells. ................................................................................................................ 183 
Figure 3.5 6: Immunocytochemistry for the glucocorticoid receptor (GR) in 
control and DEX treated HPACs ..................................................................... 184 
Figure 3.5 7: RT-PCR analysis for the expression of liver specific markers in 
HPACs treated with various nuclear receptor activators ................................. 185 
Figure 3.5 8: Cocultures of control and DEX treated HPACs and liver 
myofibroblasts ................................................................................................. 186 
Figure 3.5 9: RT-PCR analysis for the expression of liver-specific markers in 
HPAC coculture experiments .......................................................................... 187 
Figure 3.5 10: Immunocytochemistry for CYP2E1 and albumin in HPACs and 
cocultures of myofibroblasts and HPACs ± 10μM DEX ................................... 188 
Figure 3.5 11: Visualisation of HPAC and pCAG HPAC cells under 
excitation/emission 549 and 565nm respectively ............................................ 189 
Figure 3.5 12. Bright field images of pCAG HPACS in standard or DEX treated 
cultures ........................................................................................................... 190 
Figure 3.5 13: RT-PCR analysis for the expression of liver specific markers and 
pluripotency markers in WT and pCAG HPACS ............................................. 191 
Figure 3.5 14: Immunocytochemistry in HPAC and pCAG HPAC cells with and 
without DEX treatment .................................................................................... 193 
Figure 3.5 15: Typical morphology of human primary acinar cells cultured over 
21 days ........................................................................................................... 194 
Figure 3.5 16: RT-PCR analysis for the expression of liver, pancreatic  and 
fibroblast specific markers in primary acinar cells ........................................... 195 
Figure 3.5 17: Co-expression of amylase and CYP2E1 in primary acinar cells 
shown by immunohistochemistry .................................................................... 196 
List of Tables 
xviii 
 
List of tables 
 
Table 2. 1: DNA oligonucleotide sequences employed in RT-PCR or genomic 
PCR. ................................................................................................................. 63 
Table 2. 2:  Primary and secondary antibody specifications for Western blot 
(WB) and immunohistochemistry/immunocytochemistry (IHC/ICC). ................. 72 
Table 2. 3: Specifications of the bioreactors and running conditions used for 3D 
culture of B-13 cells .......................................................................................... 75 
Table 2. 4: A summary of the substrates and their concentrations used for 
assessment of CYP450 activity in bioreactor cultured B-13 cells and their 2D 
parallels. ........................................................................................................... 77 
Table 2. 5: A summary of the drugs, their products and the CYP450 enzymes 
involved for the CYP450 assays to test liver functionality in bioreactor 176 
metabolism studies. .......................................................................................... 77 
 
Table 3.2 1: The average number of chromosomes per metaphase spread 
analysed from each cell type........................................................................... 108 
Table 3.2 2: Summary of the B-13 cell karyotype. .......................................... 110 
 
Table 3.4 1: A summary of the bioreactor cultures carried out with details of the 
length of culture, cell type and cell number. ............ Error! Bookmark not defined. 
Abbreviations 
xix 
 
Abbreviations 
AFF- 2-acetylaminofluorene  
ALT- Alanine transaminase 
AP- Alkaline phophotase  
APC- Adenomatous polyposis coli  
α-sma- Alpha-smooth muscle actin  
AST- Aspartate transaminase 
B-13- AR42J-B13 cell  
BMP- Bone morphogenic protein  
BMPRII- type II bone morphogenic receptor 
BR- bioreactor 
BSA- Bovine serum albumin  
CAR- constitutive adrostane receptor 
CBC- Comparative biology centre 
cDNA-  complementary Deoxyribonucleic acid 
C/EBP- CCAAT/enhancer-binding protein 
CPS-1- Carbamoyl-phosphate synthetase 1  
CYP450- Cytochrome P450  
DAB- 3,3'-Diaminobenzidine  
DAPI- 4',6-Diamidino-2-phenylindole  
DEX- Dexamethasone  
DMEM- Dulbecco’s modified eagle media 
DMSO- Dimethyl sulfoxide 
DNA- Deoxyribonucleic acid  
ds DNA- double stranded deoxyribonucleic acid 
Dsh- Dishevelled 
DTT- Dithiothreitol 
EB- Embryonic bodies  
EBSS- Earl’s balanced salt solution 
ECM- Extra-cellular matrix  
ECOD- 7- ethoxycoumarin O-deethylase 
EDTA- Ethylenediamine tetraacetic acid 
EGTA- Ethylene glycol tetraacetic acid 
Abbreviations 
xx 
 
EPCAM- Epithelial cell adhesion molecule 
ERB- Electrode running buffer 
EROD- 7- ethoxyresorufin-O-deethylase  
ESCs- Embryonic Stem Cells  
Fah-/- -Fumarlyacetoacetate-hydrolase-deficient  
FCS- Foetal calf serum 
FGF- Fibroblast growth factor  
FISH- Fluorescent in situ hybridisation 
FITC- Fluorescein isothiocyanate  
Foxa- Forkhead box protein 
FXR- farnesoid X receptor 
GAPDH- Glyceraldehyde 3-phosphate dehydrogenase 
Gata4- GATAb binding protein 4 
G-banding- Giesma banding  
GFP- Green fluorescent protein 
GLDH- Glutamate dehydrogenase  
GR- Glucocorticoid receptor  
GS- Glutamine synthetase  
GSH- Glutathione 
HBSS- Hank’s balanced salt solution 
H&E- Haematoxylin and eosin  
HEPES- 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HGF- Hepatocyte growth factor  
HLSCs- Human liver stem cells  
HMSCs- Hematopoietic stem cells  
HNF- Hepatocyte nuclear factor  
HPACs- Human pancreatic acinar cells 
HPCs- Hepatic progenitor cells  
HRP- Horse-radish peroxidase 
HSCs- Hepatic stellate cells  
ICC- Immunocytochemsitry 
ICM- Inner cell mass 
IHC- Immunohistochemistry 
Ihh- Indian hedgehog  
Abbreviations 
xxi 
 
i.p.- Intraperitoneal  
iPS- Induced pluripotent stem  
ivis- in vivo imaging system 
KLF4- Krüppel-like factor-4  
k/o- knockout 
LARII- Luciferase assay reagent  
LB- Luria broth 
LDC- Liver dendritic cell 
LDH- Lactic acid dehydrogenase 
Lgr5+- leucine-rich repeat-containing G protein-coupled receptor 5+  
LRP5/6- Low density lipoprotein receptor-related protein 5 or 6  
MAPK- Mitogen- activated protein kinase  
MET- metyrapone 
MMLV- moloney murine leukemia virus 
MMPs- Matrix metalloproteinase’s  
MNAR- modulator of non-genomic action of the estrogen receptor 
MR- Mineralcorticoid receptor   
mRNA- Messenger Ribonucleic acid 
MSCs- Mesenchymal stem cells  
NK- Natural killer cells 
NCAM- Neural cell adhesion molecule 
Neurog3- Neurogenin-3  
NOD/SCID- Non-obese diabetic/severe combined immunodeficient 
OCT4- Octamer-4   
PB- phenobarbital 
PBS- phosphate buffered saline 
PCR- Polymerase chain reaction 
Pdx1- Pancreatic and duodenal homeobox 1  
PDGF- Platelet derived growth factor 
PH- Partial heptectomy 
Ptf1a- Pancreas transcription factor 1-alpha  
PXR- pregnane X receptor 
RA- Retinoic acid  
RIF- rifampicin 
Abbreviations 
xxii 
 
rmh- Rat/mouse/human  
RNA- Ribonucleic acid 
ROS- Reactive oxygen species  
RT-PCR- Reverse transcription polymerase chain reaction 
SD- standard deviation 
SDS- Sodium dodecyl sulfate 
SDS-PAGE- Sodium dodecyl sulphate- polycrylamide gel electrophoresis 
SECs- Sinusoidal endothelial cells 
SGK1- Serine/threonine-protein kinase 1  
Shh- Sonic hedgehog 
siRNA- small interfering RNA 
S.O.C- Super Optimal broth with Catabolite repression 
SOX2- Sex determining region Y-box 2  
SSC- standard saline citrate 
TEMED- Tetramethylethylenediamine 
TGFβ1- Transforming growth factor beta  
TNFα- Tumour necrosis factor alpha  
TRITC- Tetramethyl rhodamine iso-thicyanate 
VEGF- Vascular endothelial growth factor 
WME- William’s Medium E  
WT- wildtype 
 
 
SI Units 
xxiii 
 
SI units 
Units: 
 
 
Prefixes: 
 
 
 
 
 
Subject Name  
 
Symbol 
length metre  m 
Mass kilogram  kg 
Time second  s 
Amount of substance 
 
mole    M 
Volume litre   l 
Factor Name  
 
Symbol 
103 kilo  k 
10-3 milli  m 
10-6 micro  μ 
10-9 
 
nano    n 
10-12 femto   f 
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With increases in over 25% in the last decade, liver disease is now the 
fifth biggest killer in England and Wales and is the only major cause of 
death that is still rising year-on-year. Due to the liver’s complexity and 
numerous metabolic roles it is susceptible to a variety of diseases 
including hepatitis, cirrhosis, fatty liver, liver cancer and genetic diseases. 
Although the occurrence of liver disease is growing, liver transplantation 
remains the only effective treatment for end stage liver disease, however 
treatment is limited due to the lack of available organs for transplantation. 
In addition hepatocytes, the main cell of the liver, are difficult to maintain 
in culture and consequently alternative sources are desperately required 
for liver cell replacement. Advances in the field of regenerative medicine 
bring hope of novel treatments through the use of stem cell-derived 
hepatocytes in transplantation procedures and extracorpeal liver devices. 
The generation of a limitless supply of stem cell-derived hepatocytes for 
uses in clinic and in vitro toxicity testing would hopefully provide 
successful therapeutics to reduce the impending threat of liver disease. 
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1.1 Stem cells 
Stem cells have been identified in both embryonic tissue and in numerous adult 
tissues including the bone marrow, muscle and skin[1]. Stem cells are distinct 
from any other cell in that they possess the unique capacity to give rise to 
multiple cell types through a process termed differentiation, and have the ability 
of ‘self-renewal’; a method of limitless duplication without losing the  potential to 
differentiate into other cell types (figure 1.1). The potential range of progeny that 
can arise from a stem cell population is known as the ‘potency’ where 
embryonic stem cells (ESCs) that can give rise to all body cell types are termed 
pluripotent while adult stem cells are often more restricted and so are described 
as multipotent or unipotent[2]. This restriction corresponds to the idea that 
development is hierarchical, where cells of the early blastula can give rise to all 
cell types and are then progressively restricted in their potency by numerous 
inductive signals[3]. Stem cells from both adult tissues and embryonic sources 
have proven to be powerful research tools in recent years alongside new 
exciting research in induced pluripotent stem (iPS) cell technologies[4]. The 
multi-lineage potential of stem cells, along with their capacity for self-renewal 
makes them a promising tool for regenerative medicine and cellular therapies 
as well as advancing our understanding of the underlying molecular 
mechanisms of stem cells and developmental biology. 
1.1.1 Embryonic Stem Cells 
Following the formation of the blastula, there is a phase in embryonic 
development termed gastrulation, here the cells undergo a series of movements 
that converts the simple ball of cells, termed the inner cell mass (ICM), into a 
three layered structure known as the gastrula. The three layers formed are 
termed the ‘germ layers’ which are comprised of the ectoderm, mesoderm and 
endoderm; at this stage of development the general body plan is set with 
regions of committed cells although no differentiation has yet taken place[5]. 
 
During development a population of pluripotent cells appear as a cell cluster 
within the blastocyst known as the inner cell mass, which is the source of 
embryonic stem cells (ESCs) (figure 1.4). ESCs are true pluripotent cells as 
they are capable of differentiating into all three tissue lineages of the germ 
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layer, thus they have the ability to generate any cell of the body. Extra-
embryonic tissues (i.e. the placenta), however can only be derived from the 
zygote; the one true totipotent cell.  
 
Through explanting the ICM of mice, a number of groups created the first ESCs 
in 1981[6, 7] and since the advent of human ESCs in 1998[8] research in the field 
has advanced at a great pace. ESCs have now been established from a 
number of species including the rat, hamster, rabbit, dog and chicken, however 
most ESCs are different to mouse ESCs in that they have flatter morphologies 
and different growth factor demands[9]. Research has now advanced so that 
standard protocols for future applications have been developed including 
maintenance in culture in the absence of animal-derived components[10]. Due to 
the pluripotency of these cells there is a great interest in their potential for 
clinical use as they could be employed in regenerative medicine, and also 
provide models for basic developmental biology. Clinical trials have already 
taken place which involved replacing lost functionality through ESCs for 
disorders such as Parkinson’s disease[11] and spinal cord injury[12].  However 
many limitations for the use of these cells exist. Firstly as they are derived from 
the blastocyst many ethical issues primarily concerning the creation, treatment, 
and destruction of human embryos are raised. Secondly as ESCs are not 
derived from genetically identical sources to the patients, then problems with 
immuno-compatibility may be common.   
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Figure 1. 1: The cell lineage of a typical pluripotent stem cell. Pluripotent stem cells display 
the ability to self-renew the stem cell population, whilst also giving rise to transit amplifying cells 
and various specialised differentiated cells. Figure adapted from Slack
[5]. 
 
1.1.2 Adult Stem Cells 
In contrast to ESCs, adult stem cells are discrete cell populations found in 
specialised niches (controlled microenvironments) specific to the tissue in which 
they reside. They are often  developmentally restricted to the tissues/organs in 
which they reside such as hematopoietic stem cells (HMSCs), which contribute 
to the blood system only[13]. Adult stem cells show some advantages over 
working with ESCs as they are derived from adult tissue and so evade the 
ethical issues associated with ESCs and can also be patient-specific and thus 
avoid immuno-rejection concerns. 
 
In the mammalian adult there are a number of mechanisms employed for the 
normal homeostasis and maintenance of organs and tissues as well as for 
replacing lost or damaged cells (figure 1.2). Depending on the tissue type, these 
mechanisms can be highly dependent on adult stem cells, for example high 
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turnover tissues such as the skin, intestine and blood have well established 
stem cell sources generating mature cells. Other tissues such as the pancreas 
and liver have less active stem cell populations, for example within the 
pancreas, mature cells have been shown to transiently de-differentiate into 
precursor cells before re-differentiating into mature cells during pancreatitis[14] 
and in the liver the primary source of regeneration and repair is  primarily 
through the replication of mature resident cells, the hepatocytes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 2: Pathways involved in tissue regeneration in the mammalian adult. Tissues can 
regenerate new cell populations upon damage or during normal tissue turnover through several 
mechanisms. A: Transient de-differentiation of resident mature cells into precursor cells 
followed by re-differentiation to generate new cells. This mechanism has been reported to occur 
in pancreatitis
[14]
. B: Resident adult stem/progenitor cells can be signalled to expand and 
differentiate upon damage and injury to the tissue. This method of tissue regeneration is 
established in high turnover tissues such as the intestine and blood system 
[15]
. C: Recovery 
from injury within a tissue is also possible through expansion of pre-existing differentiated cells. 
This method is found in the liver where mature hepatocytes are responsible for the majority of 
repair in response to injury. Figure adapted from Dor and Stanger
[15]
. 
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Adult stem cells are known to reside in a microenvironment known as the niche 
which was first described by Schofield in 1978 as a ‘physiologically-limited 
environment that supports stem cells’[16]. The niche is thought to be critical for 
the maintenance of stem cell populations through a number of factors and 
signals secreted from neighbouring ‘companion’ cells. For example cycling 
leucine-rich repeat-containing G protein-coupled receptor 5+ (Lgr5+) stem cells 
found at the bottom of the intestinal crypt are maintained in a microenvironment 
with high Wnt activity[17], whilst bone morphogenic protein (BMP) signalling is 
inhibited by production of noggin and gremlin from tissue below the crypts[18] 
(figure 1.3). It is evident that a large number of adult stem cell populations exist 
within the mammalian adult and are very important for tissue maintenance and 
repair, however the availability of stem cells between tissues is highly variable 
and thus repairing damage to some tissues is a much greater challenge.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 3: The intestinal stem cell niche. Cycling Lgr5+ crypt base columular stem cells are 
maintained in a microenvironment of high Wnt signalling surrounded by companion paneth 
cells. BMP signalling is inhibited by noggin and gremlin produced by submucosa tissues below 
the crypts. Figure adapted from Li et al
[19]
. 
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1.1.3 Induced Pluripotent Stem (iPS) Cells 
In 2006, a revolutionary study by Takahashi and Yamanaka successfully 
reprogrammed a somatic cell into a pluripotent cell using a retro-viral 
transduction technique; these cells were termed induced pluripotent stem (iPS) 
cells[4]. The cells were reprogrammed by forced over-expression of four  genes 
octamer-4 (OCT4), sex determining region Y-box 2 (SOX2), krüppel-like factor-
4 (KLF4) and c-Myc. In a second set of experiments through reselection with 
master pluripotent factors OCT4 and Nanog, a second generation of iPS cells 
were formed[20] which demonstrated true pluripotency by contributing to chimera 
formation. Since the first iPS cells were reported, many groups have replicated 
the process and they have now even been generated from several patients with 
genetic disorders[21]; this new technology brings hope for future individualised 
cell based therapy. Nevertheless much caution is still needed as there have 
been many reported problems with regards to genome integrity due to the two 
additional phases where genetic alterations may occur, these are the original 
somatic differentiation and the reprogramming events[22]. Another risk 
associated with iPS cells involves the pro-viral integrations of oncogenes 
particularly c-Myc which has previously been connected to many forms of 
cancer[23] and chimeras with iPS cells have been shown to be prone to tumour 
formation[24] . Currently, efforts are focused on finding methods that do not 
require permanent transgene integration such as via adenovirus (replication 
incompetent) or piggybac transposon technologies[25]. Although the initial iPS 
work has been very exciting and promising, much work is needed to deal with 
the current risks before the research can advance further into the clinic.   
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1.2 Endodermal origins of the adult liver and pancreas 
It is from the endoderm, the innermost of all the three germ layers, in which the 
liver and pancreas originate along with the epithelial lining of the gut and the 
respiratory system (figure 1.4). The development of the endoderm into both liver 
and pancreas is tightly regulated through a number of signalling pathways and 
transcription factors. It is evident that the liver and pancreas show a close 
developmental relationship and this may explain the observed 
transdifferentiation of cell types in adulthood discussed in section 1.6[26].  
1.2.1 Liver development 
The liver bud arises from the ventral diverticulum of the foregut through 
endoderm-mesoderm signalling. Fibroblast growth factor (FGF) is secreted from 
the adjacent cardiac mesoderm and has been shown to be essential in the 
induction of hepatic gene expression[27]. Albumin, transthyretin and α-fetoprotein 
are amongst the earliest genes expressed during mammalian hepatic 
differentiation; the induction of hepatic gene expression through FGF signalling 
acts specifically through the mitogen- activated protein kinase (MAPK) 
pathway[28]. Later on in development, the septum transversum develops 
between the liver primodium and the cardiac mesoderm which acts as a barrier 
to high FGF levels; where the higher levels of FGF lead to lung development[29]. 
Elevated FGF levels also suppress the development of the pancreas by 
activating expression of sonic hedgehog (Shh) which in turn suppresses the 
pancreatic growth factor pancreatic and duodenal homeobox 1  (Pdx1)[30].  
Other signals, including BMP4 have also been shown to be important in liver 
development and the zinc finger transcription factor GATA-4 is highly expressed 
in the septum transversum which is regulated by BMP4[31]. 
 
After the formation of the liver bud through FGF and BMP4 signalling, further 
hepatic development has been shown to be dependent on Wnt  signalling [5]. 
The contribution of Wnt signalling in liver development is complex and 
dependent on the stage of development, however it has been shown to be 
critical for the initiation of liver bud formation in zebra fish where Wnt22b 
mutants have inhibited liver bud development[32]. 
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Figure 1. 4: The early development of the liver and pancreas from the endodermal germ 
layer. During gastrulation the inner cell mass of the blastula undergoes rearrangements into the 
three germ layers, the ectoderm, mesoderm and endoderm. The liver and pancreas are both of 
endodermal origin with the key molecular mechanisms to drive their development shown. Figure 
adapted from Katsumoto et al
[9]
. 
Many transcription factors are also essential in liver development; for example 
Forkhead box proteins, Foxa1 and Foxa2 have been shown to be responsible 
for establishing the competence of the foregut to respond to hepatic-inducing 
signals, and double knockout mice showed no liver bud formation[33]. Other 
transcription factors such as Sox17, Gata4, Gata6 and Hnf1b have also been 
shown to be essential in liver initiation and development[9].  
In the post natal liver, hepatocyte growth factor (HGF) is produced by non-
parenchymal cells and is responsible for liver growth through the induction of 
hepatocyte maturation and proliferation[34],[35].  
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1.2.2 Pancreas development 
The pancreas originates from the duodenum as a large dorsal and a small 
ventral bud, which expand before fusing to form the pancreas. The earliest 
pancreatic marker expressed is the transcription factor Pdx1 and lineage tracing 
experiments have shown that all pancreatic cells are derived from Pdx1 
expressing precursor cells[36]. The dorsal bud of the pancreas has been shown 
to arise in an area where the notochord contacts the gut roof, within this region 
Shh and Indian hedgehog (Ihh) levels are suppressed, allowing the expression 
of Pdx1 to drive pancreatic specification[37]. The ventral bud of the pancreas is 
formed in areas adjacent to the liver bud too distant from the cardiac mesoderm 
to receive FGF signals that hepatic promote development. Once pancreatic bud 
formation is initiated there is a continued outgrowth which is dependent on the 
close proximity of the pancreatic mesenchyme with expressed islet-1 and FGFs. 
Retinoic acid (RA) is also essential for early pancreatic development[9] along 
with vascular endothelial growth factor (VEGF), a well-known maturation signal 
for the dorsal pancreas[38].  
 
Endocrine precursors from the pancreas express Neurogenin-3 (Neurog3) and 
all pancreatic endocrine cells have been shown to originate from Neurog3 
positive cells[36]. High levels of Neurog3 cause suppression of endocrine 
development in neighbouring cells through notch signalling and thus lead to 
exocrine development in the majority of the pancreas[9]. In comparison to 
endocrine development fewer transcription factors have been found to be 
involved in acinar development, although pancreas transcription factor 1-alpha 
(Ptf1a) has been shown to be essential. To date the Wnt signalling pathway is 
the only reported extrinsic cue with an explicit role in acinar specification, and 
exocrine development fails early when Wnt signalling is blocked through k/o of 
the intracellular Wnt signal protein β-catenin[39]. 
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1.3 The adult pancreas; anatomy and physiology 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 5: Basic anatomy of the pancreas. 
The pancreas is a large, elongated, aciniform organ that is located in the left 
hypochondrium of the abdomen behind the stomach, between the spleen and 
duodenum. The right side of the organ termed the head lies in close proximity to 
the curve of the duodenum whilst the body of the pancreas extends slightly 
upwards resulting in the tail of the organ being situated close to the spleen. The 
pancreas consists of two functionally and morphologically distinct cell 
populations, the exocrine and endocrine cells. The exocrine cells make up 
around 95-99% of the total pancreas whilst the endocrine cells, which compose 
the islets of Langerhans, scattered in the exocrine tissue, make up about 1-5% 
of the pancreas[40]. 
The exocrine portion of the pancreas is composed of acinar cells and duct cells 
that play essential roles in the secretion of digestive enzymes; acinar cells are 
dedicated to synthesis, storage and the regulated release of approximately 24 
enzymes and accessory proteins[37]. The acini secrete a number of digestive 
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enzymes including, lipase, amylase, trypsinogen, and phospholipase, which 
cleave peptides, lipids and large carbohydrates before they are subsequently 
secreted in a ‘pro-form’ into the intestine through the ductal system. Alongside 
the secretion of digestive enzymes from the pancreas, the mature duct cells 
leading from the acini secrete bicarbonate and mucins[41]. The combined 
product, pancreatic juice, is then transported through a ductal network towards 
the duodenum where the bicarbonate ions act to neutralise the stomach acid in 
the duodenum. Due to their role in synthesis, storage and secretion of a large 
number of enzymes, acinar cells are packed with rough endoplasmic reticulum, 
have a large Golgi apparatus and mitochondrial compartment[42]. 
The endocrine compartment of the pancreas is composed of five different 
hormone secreting cell types which are difficult to distinguish through standard 
staining techniques, but can be classified by their secretion. The five cell types 
include the glucagon secreting α-cell, insulin secreting β-cells, somatostatin 
releasing δ-cells, ghrelin-producing ε-cells and the pancreatic polypeptide 
secreting PP-cells which all aggregate into the islets of Langerhans; where each 
islet is made up from a central core of beta cells surrounded by the other 
endocrine cells[9]. Islets are networked by a rich blood supply as all of the 
endocrine hormones play roles in the regulation of nutrient metabolism and 
glucose homeostasis[41, 43]. 
Insulin, produced by the β-cells, and glucagon, produced by the α-cells of the 
islets are the main hormones involved in glucose homeostasis. During periods 
of elevated blood glucose, insulin is secreted from the pancreas in order to 
increase the uptake of glucose into insulin-responsive tissues such as adipose 
tissue, muscle and liver. Glucose is exploited by these organs as a source of 
cellular energy via glycolysis or is stored as glycogen or fat in the liver and 
muscle cells, and adipose tissue[44]. During periods of low blood glucose, the 
hormone glucagon is released to raise glucose levels back to normal 
physiological levels. Glucagon acts principally on the liver where it acts to 
increase the breakdown of glycogen to glucose in a process known as 
glycogenolysis, resulting in the release of glucose back into the bloodstream 
alongside gluconeogenesis which involves the production of glucose from non-
carbohydrate carbon substrates such as  glucogenic amino acids, glycerol, 
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lactate and pyruvate[45].  The δ-cells of the islets secrete the inhibitory hormone 
somatostatin which inhibits the secretion of both glucagon and insulin in 
addition to supressing the exocrine secretory action of pancreas. 
The failure of the islets of Langerhans to produce sufficient amounts of insulin 
results in the condition known as diabetes mellitus which leads in the failure to 
maintain blood glucose within the normal physiological levels. There are two 
major forms of diabetes mellitus, type I results from the body's failure to produce 
insulin, usually due to the loss of β-cells, and type II is insulin resistance 
characterised by a defective responsiveness of body tissues to insulin. As well 
as disorders in the endocrine functions, exocrine pancreatic disorders can lead 
to serious digestive problems such as pancreatitis where the pancreatic juice 
digests the tissue of the organ resulting in necrosis, inflammation and fibrosis.  
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1.4 The adult liver; anatomy and physiology 
Figure 1. 6: Basic anatomy of the liver. 
The liver is both the largest internal organ and gland of the body, weighing 
between 1300-1700g in the adult depending on gender and body size and is 
situated in the right upper quadrant of the abdominal cavity. The liver is multi-
lobed in most mammalian species; in humans the liver is divided into two major 
lobes, the left and right, which are divided by the falciform ligament. To reduce 
friction against other organs the liver is encapsulated within a thin double 
layered membrane termed the visceral peritoneum which folds back on itself to 
form the falciform ligament. 
 
The liver receives a dual blood supply from the hepatic portal vein and the 
hepatic artery. The portal vein supplies the liver with approximately 75% of its 
blood which is drained from the spleen, pancreas and gastrointestinal tract thus 
the liver receives blood enriched in nutrients and toxins. Arterial blood is 
supplied to the liver via the hepatic artery, and blood from both sources flow 
through the liver sinusoids (hepatic capillaries) towards the efferent central 
Falciform Ligament 
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veins. Bile produced by the liver is collected in bile canniculi (bile capillaries) 
which merge into bile ducts to allow the collection for storage in the gall bladder 
or drainage into the duodenum. 
1.4.1 Liver structure and functional units 
The liver possesses a unique vascular pattern in which afferent and efferent 
blood vessels are arranged within the parenchymal tissue and are connected by 
smaller capillary sized vessels known as the liver sinusoids.  The homogenous 
landscape of hepatocytes infiltrated with vascular tissue and bile ducts masks 
the complex architecture of the liver. The two widely recognised units of the liver 
are the ‘lobule’ which was first described by Kiernan and the liver ‘acinus’ 
proposed by Rappaport[46] (figure 1.7).  
 
The liver lobule is described as a hexagonal plate of hepatocytes which is lined 
by the sinusoidal capillaries radiating towards the efferent central vein.  The 
lobules are perfused with blood in each of the corners known as the portal triads 
which consists of the portal vein, bile ducts and hepatic arteries; blood flows 
from the portal vein and hepatic arteries through the sinusoidal capillaries 
before reaching the central vein.  The sinusoids of the liver are lined by 
specialised endothelial cells which control the flow of materials to and from the 
space between the hepatocytes and endothelial cells known as the space of 
Dissè[47]. Whilst the portal lobule is descriptive of the afferent blood supply and 
bile drainage by the vessels of the portal tract, the acinus model emphasises 
the secretory functions of the liver and is favoured by histo-pathologists as it 
aids in the explanation of many pathological lesions[46].The liver acinus is a 
smaller functional unit than the lobule and in contrast to the lobule, blood 
entering the acinus is thought to remain within the acinar units with nutrient and 
oxygen levels falling as the blood flows from zone 1 to zone 3 as its progresses 
towards the central vein. 
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Figure 1. 7: Schematic diagrams representing the hepatic lobule (A) and the liver acinus 
(B). A: Blood enters the lobule through the portal vein and hepatic artery at the portal triad and 
flows through the sinusoids, with nutrient and oxygen levels falling as the blood flows towards 
the central vein. Note that blood may flow into other adjacent lobules. B: In contrast to the 
lobule, blood entering the acinus is believed to remain within the acinar unit with nutrient and 
oxygen levels falling as it flows through zones 1-3 towards the efferent central vein. Adapted 
from Wallace et al
[46]
. 
 
Within the liver there is heterogeneous expression of genes along the sinusoid 
resulting in metabolic zonation along the lobule/acinus. The lobule is often 
divided into three zones based on gene expression. The periportal zone (zone 
1) surrounds the afferent vessels and the portal triad where hepatocytes are 
first exposed to the nutrient and oxygen rich blood entering from the portal vein 
and hepatic artery. The intermediate zone (zone 2) lies between the periportal 
and the centrilobular zone (zone 3). The expression of cytochrome P450 
(CYP450) genes is a model example for this heterogeneous expression, where 
CYP450 expression is highest in hepatocytes surrounding the central vein 
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within the centrilobular zone[48], consequently although hepatocytes within the 
periportal zone may be first exposed to xenobiotics, it is the centrilobular zone 
where damage is observed as it is here the specific enzymes needed for the 
metabolism are expressed. Due to the fact that the majority of toxin exposure is 
through pro-toxins that require subsequent conversion mediated by specific 
enzymes, the damage is observed in the zones where the enzyme is 
expressed[46]. 
1.4.2 Functions of the liver 
The liver exhibits both endocrine and exocrine properties. Endocrine functions 
include the secretion of hormones such as the insulin-like growth factors, 
angiotensinogen and thrombopoietin, and the major exocrine secretion is in the 
form of bile. Other crucial roles of the liver include drug detoxification, glycogen 
storage, metabolic control, urea metabolism, regulation of cholesterol and 
secretion of a number of plasma proteins such as albumin as well as playing a 
role in digestion and the body’s immune defence.  
 
One of the pivotal functions in intermediary metabolism by the liver is the 
clearance of xenobiotics which regularly exposes the liver to high levels of 
toxins and pathogens which can trigger inflammatory responses. Drug 
metabolism involves the conversion of lipophilic chemical compounds into more 
readily excreted hydrophilic products through a series of phase I and phase II 
reactions. Phase I metabolism includes oxidation, reduction, hydrolysis and 
hydration reactions and often involves the CYP450 family of enzymes in 
oxidation reactions[49]. In general, CYP450 enzymes use molecular oxygen to 
monoxygenate xenobiotics, also producing H2O
[50]. Phase II reactions, also 
known as conjugation reactions, are usually detoxicating in nature, and involve 
conjugation of phase I metabolites  with charged species such as glutathione 
(GSH), sulfate, glycine, or glucuronic acid. Due to the high levels of drug 
metabolism in the liver and the high number of enzymes needed for these roles 
the smooth endoplasmic reticulum is the most abundant organelle of the 
hepatocytes[51]. 
Another essential function of the liver is the maintenance of blood ammonia 
levels within narrow limits. Ammonia is the product of amino acid metabolism 
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and the removal of it from the liver is a tightly regulated process via two 
pathways. The first is the urea cycle, which is a cycle of biochemical reactions 
to convert ammonia into urea through five different catalysed steps. The initial 
two steps of the cycle occur within the mitochondria of the hepatocytes with the 
remaining three in the cytosol[52]. During liver injury the urea cycle can become 
disrupted and high levels of ammonia can be detected within the blood.  In 
addition to the urea cycle glutamine synthetase is involved in the metabolism of 
ammonia by catalysing the condensation of glutamate and ammonia to form 
glutamine.   
 
The synthesis of bile acids occurs exclusively within the liver and is localised 
within the centrilobular hepatocytes[53], where through a series of enzymatic 
reactions hydrophobic cholesterol is converted into more hydrophilic and 
lipophilic compounds catalysed by the CYP450 enzyme CYP7A1[54].  Bile acids 
have also been shown to play numerous other roles and are now recognised as 
hormones in various metabolic pathways including triglyceride, glucose and 
energy homeostasis[55].  
1.4.3 Cells of the liver 
The liver is composed of at least 8 cell types, the hepatocytes, sinusoidal 
endothelial cells, hepatic stellate cells, Kupffer cells, pit cells, liver dendritic 
cells, cholangiocytes and hepatic progenitor cells, all of which are essential for 
the normal function and turnover of the organ.  
Hepatocytes are polarised epithelial cells and are the most populous cell found 
within the liver, they make up around 80% of the livers total mass and the 
average human liver is predicted to contain around 1011 hepatocytes[56]. 
Hepatocytes are responsible for the majority of synthetic and metabolic 
functions of the liver; due to their numerous metabolic roles they contain a large 
number of mitochondria, peroxisomes, lysosomes, endoplasmic reticulum and 
Golgi complexes[57]. As a result of the numerous and crucial roles of 
hepatocytes they are strategically positioned between two different 
environments: the blood plasma on the sinusoidal side and the bile on the 
caninicular side, giving the hepatocyte surface asymmetry and polarisation. 
Hepatocytes are arranged in cords which are held together by intercellular 
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adhesion complexes at the apical membranes, these form a permeability barrier 
between the perisinusoidal space of Dissè and the bile canaliculi. Around 35% 
of the hepatocyte surface faces the sinusoids and this surface area is greatly 
enhanced by microvilli which facilitates the transfer of secretions into the blood 
stream[58]. Around 13% of the hepatocyte surface faces the bile canaliculus 
which is responsible for the collection of bile acids and bile salts which are then 
transported through the bile ducts towards the portal triad and subsequently the 
gall bladder and intestine. Hepatocytes also show a remarkable capacity to 
proliferate and regenerate the liver upon injury, this remarkable ability is 
discussed further is section 1.4.5.  
Sinusoidal endothelial cells (SECs) constitute the sinusoidal wall, also known 
as the endothelium. SECs play an active and central role in regulating the 
exchange of macromolecules, solutes and fluid between the blood and 
surrounding hepatocytes. SECs also play a central role in the delivery of oxygen 
to the relatively hypoxic environment, and clearance of drugs, macromolecules 
and antigens. SECs have a morphological phenotype that is unique to 
mammalian endothelial cells, and are the only endothelial cells with open 
fenestrae which allow the easy passage of molecules and oxygen to the 
hepatocyte surface, thus the liver microcirculation is the most porous of all 
endothelial barriers[47]. As well as fenestrae the high permeability is also 
reflected by the presence of special transporting systems including numerous 
vesicles and channels.  
Hepatic stellate cells (HSCs) reside within the perisinusoidal space (space of 
Dissè) between the hepatocytes and the sinusoidal endothelial cells. In the 
normal liver they are described as quiescent and their roles include storage of 
vitamin A and modulation of the hepatic microcirculation in response to 
endothelial signalling[59]. Upon liver injury, HSCs transdifferentiate into a 
myofibroblast like cell or ‘activated’ HSC which are the main contributors of liver 
fibrosis.  Activated HSCs (myofibroblasts) lose vitamin A droplets and begin to 
express alpha-smooth muscle actin (α-sma), an actin isoform expressed in 
smooth muscle cells only[60]. This transdifferentiation to a myofibroblast-like cell 
phenotype is triggered by a release of reactive oxygen species (ROS) and 
cytokines and chemokines such as platelet derived growth factor (PDGF) and 
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transforming growth factor beta (TGFβ1). Once activated, HSCs are pivotal to 
collagen synthesis, a major component of scar tissue, and HSCs play a central 
role in both the development and resolution of the fibrotic response[61]. 
Kupffer cells are resident macrophages of the liver located in the sinusoids. 
Kupffer cells are activated in response to liver injury, leading to the release of a 
number of pro-inflammatory cytokines such as tumour necrosis factor alpha 
(TNFα) which promotes collagen synthesis in activated stellate cells 
(myofibroblasts)[62]. Although Kupffer cells have been shown to have a major 
role in fibrosis they have also been shown to play a role in the disease reversal 
as Kupffer cell depletion inhibits the normal reversal of the disease[63]. 
Pit cells are the liver specific natural killer (NK) cells and belong to the group of 
sinusoidal cells together with SECs and Kupffer cells. They contain specific 
granules and so are classed as larger granular lymphocytes and are dependent 
on Kupffer cells[64]. 
Liver dendritic cells (LDCs) are the antigen presenting cells of the liver, 
although the phenotype and function of liver dendritic cells is still poorly 
understood. LDCs are immature and tolerogenic in normal liver, however during 
chronic liver injuries a proinflammatory population prevails[65].  
Cholangiocytes (biliary epithelial cells) are found lining the intrahepatic bile 
ducts which are a complex network that function to deliver bile to the gall 
bladder and intestine. The cells play a role in the formation of bile which 
involves a number of secretory and absorptive processes contributing to the 
final composition of bile[54].  Cholangiocytes also play a role in inflammatory 
responses and interact with other liver cell types through the release of a 
number of growth factors, peptides and pro-inflammatory and chemotactic 
cytokines[66].  
Hepatic progenitor cells/oval cells are a population of stem cells that reside 
within the canals of Hering within the terminal bile ductules[67]. This population 
of stem cells is thought to act as a second line of defence when the resident 
hepatocytes are no longer able to proliferate and aid in liver regeneration, these 
cells are discussed further in section 1.4.6. 
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1.4.4 Liver disease and current therapies 
A wide range of insults injure the liver leading to inflammation and fibrosis 
including alcohol, viruses, poor diet and autoimmune diseases. Irrespective of 
the cause, liver damage regularly results in a wound healing response 
characterised by an accumulation of extra-cellular matrix (ECM) proteins [68]. 
The build-up of scar tissue encapsulating the area of injury inhibits the normal 
functions of the liver and the gradual accumulation of scar tissue leads to 
cirrhosis and eventual hepatic failure.  
 
During liver injury, hepatocytes, the functional cells of the liver, are targeted by 
hepatotoxins and undergo both necrosis and apoptosis. Signals released from 
dying cells and intracellular fragments lead to Kupffer cell activation in areas of 
damage, thus resulting in activation of both resident and circulating leucocytes 
by the release of cytokines and chemokines[69]. The liver architecture is 
drastically altered in response to injury such as the loss of microvilli on 
hepatocyte surfaces and loss of fenestrae in the sinusoidal endothelial lining of 
the sinusoids which all result in impaired function of the liver (figure 1.8). In 
addition, the accumulation of ECM proteins, synthesised by myofibroblasts, 
leads to a distorted hepatic architecture and vascular structure by the formation 
of fibrous scar tissue, eventually leading to cirrhosis and liver failure.  
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Figure 1. 8:  Fibrosis during liver injury. A:  The normal cellular architecture of a healthy liver 
sinusoid. The microvilli of hepatocytes are important for their normal cellular function to increase 
surface area for uptake. Hepatocytes are separated from the sinusoidal endothelium by the 
space of Dissè where quiescent hepatic stellate cells (HSCs) reside, fenestrae of the 
endothelial cells permits the passage of large macromolecules towards the hepatocytes. Tissue 
macrophages, Kupffer cells, are found within the sinusoidal space. B: During liver injury a 
fibrotic response is seen where HSCs lose their vitamin A and become activated where they are 
the primary source of ECM, leading to an accumulation of scar matrix. This leads to a widening 
of the space of Dissè and loss of endothelial fenestrae, consequently reducing transport across 
the sinusoidal wall. Activation of Kupffer cells contributes to activation of HSCs. Figure adapted 
from Hui and Friedman
[68]
. 
Chapter 1: Introduction 
24 
 
The process of fibrosis is reversible upon the removal of the primary injury, 
where the liver has the great capacity for regeneration to repair any damage. In 
the rat model of fibrosis caused by treatment with carbon tetrachloride the 
hepatic architecture appeared to be normal within weeks after cessation of 
carbon tetrachloride dosing[70]. Reversal of fibrosis in animal models is often 
associated with the apoptosis of HSCs, and the stimulation of HSC apoptosis 
using a fungal toxin (gliotoxin) resulted in rapid recovery from fibrosis, thus HSC 
apoptosis may be an effective therapeutic approach to liver injury[71]. 
 
There are currently no therapeutics indicated for the treatment of fibrosis 
although a number of treatments are in clinical trials. At the cirrhotic level of 
organ damage the liver loses the ability to regenerate and the only option at 
present is organ transplantation. The UK has one of the lowest organ donation 
rates in Europe with only 24% of the population registered as donors, thus a 
lack of organs limits the number of transplants available for those suffering from 
liver damage/disease[72]. Currently there are numerous studies dedicated to 
finding new therapies for the treatment of liver diseases. Drugs targeting 
specific cells such as HSCs have been proposed however many of the 
proposed targets are expressed on other cells and so problems of drug 
specificity arise[46]. Multiple candidate cells have been explored for use in 
regenerative medicine where the key goal would be to repopulate the damaged 
liver with progenitor cells[73]. As well as cell transplantation, extracorpeal liver 
devices containing hepatocytes or stem cell-derived hepatocytes could be used 
to bridge the gap between liver failure and organ transplantation[74]. 
 
1.4.5 Regenerative capacity of the liver 
Regeneration involves re-establishing the normal form, function and size of an 
organ that has been impaired or lost through damage[15]. Within the mammalian 
system, regeneration often requires a pre-existing scaffold allowing healthy re-
growth after diffuse injury; however this cannot take place after amputation in 
organs such as the skin, intestine and pancreas. The liver is exceptional to this 
and has the unique capacity to regenerate and re-grow after removal of up to 
two thirds of the liver, where the remaining hepatocytes are able to proliferate 
and reconstitute the organ[75]. Depending on the form of injury to the liver, there 
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are two different physiological forms of regeneration. In the majority of injuries 
such as exposure to hepatotoxins, resections or viral diseases, hepatocytes 
undergo replication to regenerate the liver. Following severe liver injury 
hepatocytes reach cellular senescence and can no longer proliferate and 
contribute to the regeneration of the liver, thus a second line of defence against 
liver failure is employed. A reserve population of liver stem cells which reside 
within a quiescent compartment of the liver can contribute to re-growth and 
maintenance of the organ [75, 76].  
1.4.6 Stem cells in the liver 
The concept of a progenitor cell population within the liver has been recognised 
since 1956 where Farber noted the presence of small cells with a high nuclear 
to cytoplasmic ratio and termed them ‘oval’ cells[77]. Since the observation of 
oval cells within the rodent, the human equivalent has been identified and were 
termed hepatic progenitor cells (HPCs); these cells are reported to reside within 
the terminal bile ductules known as the canals of Hering[67]. Liver progenitor 
cells  have been shown to be bipotent where they can give rise to both 
hepatocytes and bile duct cells similarly to hepatoblasts during liver 
development[78]. 
 
As the liver has a great capacity to regenerate, the liver progenitor population is 
thought to act as a reserve rather than an active stem cell population for normal 
tissue homeostasis. HPCs are required only when the resident hepatocytes are 
unable to repair and regenerate the liver either due to senescence or cell cycle 
arrest caused by some hepatotoxins[79]. In animal models of liver injury, oval cell 
populations have been demonstrated to actively proliferate[77, 80] after treatment 
with the carcinogens ethionine 2-acetylamino-fluorene, and 3'-methyl-4-
dimethylaminoazobenzene. Despite the increasing evidence for liver progenitor 
cells the extent of their contribution to liver repair and how they are activated to 
proliferate is still not known. One theory known as the ‘streaming hypothesis’ is 
that upon activation, the progenitor cells proliferate within the smallest branches 
of the intrahepatic biliary tract before migrating towards the central vein as 
progressively differentiated daughter hepatocytes,[81] and this concept is 
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supported by mitochondrial DNA mutation tracking experiments within normal 
and diseased human liver[82]. 
 
The stem cells niche for HPCs is found within the canals of Hering and here the 
companion cells of the niche are likely to be mesenchymal cells such as the 
portal fibroblasts, stellate cells or vascular endothelial cells[83]. In vitro studies 
have shown evidence that cells co-expressing CD117 and VEGF2 such as 
angioblasts may be responsible for maintaining HPCs in their native stem cell 
state whereas stellate cells support their differentiation[84], however there is little 
in vivo evidence for this process. Identification and isolation of HPC populations 
has been difficult due to the large variation of markers that have been reportedly 
expressed within the isolated populations. A number of groups have reported a 
common human derived progenitor cell population expressing EPCAM, CK19 
and CD44[85-87], and all of these cells have been shown to differentiate into 
mature hepatocytes and bile duct cells in injured livers[83].  
 
The origin of liver progenitor cells has been much debated and early 
investigations suggested that they may originate from bone marrow stem cells, 
as early studies demonstrated that bone marrow derived stem cells are capable 
of regenerating the damaged liver[88]. Oval cells also express a number of 
markers that are typically associated with hematopoietic stem cells such as 
CD34 and Thy-1 thus supporting evidence for a bone marrow origin[89]. 
However more recent work has shown that the previous observations were 
likely due to fusion with bone marrow derived cells and the weight of evidence 
now suggests that the contribution of bone marrow stem cells during liver 
regeneration is insignificant[90]. Another origin for hepatic stem cells proposed is 
of a mesenchymal lineage due to the expression of both epithelial and 
mesenchymal markers. Fate mapping experiments have failed to show any 
evidence of mesenchymal to epithelial transition during liver injury and so this 
suggested origin is still highly debated[91, 92].  
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1.5 Alternative cell types for generation of hepatocyte cells  
The key goal of stem cell therapy for liver disease is the repopulation of the 
damaged liver with healthy, functional hepatocytes. Hepatocytes have been 
utilised in a number of clinical trials, and to date over 20 patients have received 
hepatocyte transplants[93]. Although modest improvements have been observed 
in both biochemical and clinical parameters, definitive clinical benefits such as 
improved patient survival are still lacking[93]. The long term effects of hepatocyte 
transplant are unclear and the integration of cells into the liver with beneficial 
outcomes are needed to provide the proof of concept that cellular therapy is a 
viable alternative to organ transplantation. Although some success has been 
shown through hepatocyte transplantation, the modality of treatment is limited 
by the availability of human hepatocytes as any available healthy liver grafts are 
used for organ transplantation[94]. In addition to a limited supply, hepatocytes 
are notoriously difficult to maintain in ex vivo cultures as they are unable to 
proliferate and de-differentiate into non hepatic cells. The cells also do not 
tolerate cryopreservation[95]. These characteristics add further incentive for 
finding an alternative source of hepatocytes. Currently a number of cell lines are 
used as alternatives to primary hepatocytes which include the hepatoblastoma 
derived HepG2 cell line and the human hepatoma derived HepaRG cell line. 
Although HepaRG cells demonstrate liver-specific functions and overall better 
performances than many other cell alternatives, they still fail to predict human 
toxicology accurately[96]and due to their origin are not suitable for use in clinical 
therapy. 
 
There are multiple candidate cell sources that could be used in place of 
hepatocytes. Isolation of a functional and proliferating hepatocyte-like cell 
source could provide a limitless supply of cells for cellular transplantation, 
culture in bioartificial liver devices, gene therapy, drug testing and insights into 
the mechanisms of normal liver development (figure 1.9). 
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Figure 1. 9: The potential uses of stem cell-derived hepatocytes for treatment of liver 
disease and in vitro toxicity testing. Stem cell-derived hepatocytes could be isolated and 
expanded from a number of sources including embryonic stem cells, adult stem cells and 
reprogrammed iPS cells. The therapeutic potential would be great including use in cell 
transplants, seeding into bioartificial liver devices and gene therapy. Figure adapted Zhou et 
al
[97]
. 
1.5.1 Oval cells/hepatic progenitor cells 
Oval cells or HPCs have been shown to differentiate by inhibiting the replication 
of resident hepatocytes through chemical injury such as retrorsine[98] and 2-
acetylaminofluorene (AFF)[99], upon which the progenitor cell populations can 
then be isolated for culture. Isolated HPCs from both rodents and humans have 
displayed bipotency, both in vitro and in vivo[100]. Using epithelial cell adhesion 
molecule (EPCAM) and neural cell adhesion molecule (NCAM) as markers, 
Schmelzer et al, isolated human HPCs which were capable of repopulating the 
livers in animal models of injury[86, 101]. In addition the success of hepatic 
differentiation has been shown to be enhanced through 3-D cultures[80] or 
cultures with hepatic stellate cells[102] which may mimic the stem cell niche or 
liver micro-environment, thus promoting the hepatic phenotype. HPCs show 
promise for cellular therapy, however the lack of distinct markers for their 
isolation coupled with the scarcity of the cells available and their 
dedifferentiation in culture makes progress challenging. 
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1.5.2 Hepatoblasts 
Hepatoblasts are derived from foetal liver and have the same bipotency as 
HPCs and are able to generate both hepatocytes and cholangiocytes[103, 104] and 
therefore represent another source of hepatocyte-like cells. Bipotent cell lines 
have been established from both rats[105] and mice[106] which are AFP, CK19 and 
albumin positive. In vivo studies have shown that hepatoblasts from both 
rodents[107] and humans[108] are capable of repopulating livers upon 
transplantation after cryopreservation. Even more promising, 6 months post 
transplantation in rats, hepatoblasts were shown to make up to 5-10% of the 
liver and generate bile structures which became integrated into the host biliary 
system[107]. Although hepatoblasts and HPCs show similar potency, 
hepatoblasts may be more attractive for clinical use as adult-derived cells may 
have accumulated mutations and shortened telomeres. Yet, this argument has 
to be counterbalanced by the ethical issues associated with the use of foetal-
derived cells along with the limitations of the low cell number and poor 
expansion in vitro. 
1.5.3 Embryonic stem cells 
ESCs have been demonstrated to differentiate into endodermal lineages by 
several groups using both in vitro and in vivo techniques. The first reported 
differentiation into hepatocyte-like cells from ESCs was in 2002 where Jones et 
al, utilized a liver-specific marker to demonstrate that murine ES cells can 
differentiate into hepatocytes in vitro.[109]. Since 2002 more established and 
robust procedures have been developed to differentiate ESCs into hepatocyte-
like cells, including the formation of embryonic bodies (EB) or monolayer 
adherent culture systems with subsequent directed differentiation towards the 
hepatic lineage[110-114]. ESCs cultured as EBs have been shown to express 
AFP, transferin, and albumin[115-117] and this work has been successfully 
repeated using human ESCS[118, 119]. Directly differentiating ESCs, thus avoiding 
the EB stage has proved more successful by producing high yields of 
hepatocyte-like cells exhibiting improved hepatic function both in vitro and in 
vivo [110]. In vivo studies have provided evidence that hepatocyte-like cells 
derived from ESCs can engraft into the damaged liver of mice[117] and rats[120] 
and improve liver function. Although promising, there are still many concerns 
Chapter 1: Introduction 
30 
 
that undifferentiated ESCs transplanted could give rise to teratomas, yet recent 
studies have shown that selection and removal of undifferentiated cells with 
oct3/4 expression, reduced teratoma formation[121]. In addition the ethical issues 
associated with ESCs cannot be escaped and the differentiation procedures 
remain inefficient with low yields and large cellular heterogeneity. 
1.5.4 iPS cells 
Since the development of iPS technology, many groups have successfully 
generated hepatocyte-like cells from somatic cells and have shown high hepatic 
function[110, 122]. Rashid et al have developed hepatocyte-like cells from iPS cells 
that exhibit disease mutations to model metabolic disorders that affect the liver 
such as tyrosinemia, glycogen storage disease and alpha-1-antitrypisin 
deficiency, which have accurately reflected elements of the disease process[123].  
 
In two separate studies, mouse fibroblast cells were directly converted into 
hepatocyte-like cells without induction of cellular potency first. This induction 
was directed by Gata4, HNF1α and foxa3[124] or HNF4α with Foxa1, Foxa2 and 
Foxa3[125]; cells exhibited hepatic gene expression and function and rescued 
over 50% of fumarlyacetoacetate-hydrolase-deficient (Fah-/-) mice after 
transplantion[124]. Although iPS derived hepatocyte-like cells have been shown 
to proliferate extensively they are unable to contribute significantly to liver 
regeneration and carry the threat of tumour formation[126]. Another risk 
associated with iPS cell therapy is that given their adult origin the cells may 
contain an epigenetic ‘memory’ of the donor tissue and therefore this may 
restrict their differentiation potential and utility[127, 128]. 
1.5.5 Extra-hepatic adult stem cells. 
Adult stem cells, from tissues other than the liver, represent a large source of 
available cells that could be used to generate an unlimited supply of 
hepatocyte-like cells. There are numerous sources of stem cells throughout the 
adult body, however the two most accessible and highly available sources are 
from the bone marrow which contains both hematopoietic stem cells (HMSCs) 
and mesenchymal stem cells (MSCs). 
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Several reports have shown that HMSCs can be transplanted and contribute to 
partial correction of hepatic function[129]. There has been much deliberation over 
the contribution of HMSCs as many reports have shown that the repair process 
was primarily due to fusion and not transdifferentiation of the bone marrow 
cells[130]. Cre-lox studies have shown that it is possible for bone marrow to 
contribute to the liver however they have minimal contribution in normal 
physiology[131]. Phase I clinical trials have now taken place for patients with end 
stage liver disease and have reported improvements in bilirubin and albumin 
levels[132-134],yet no overall survival was observed. More recently studies have 
found evidence to suggest that HMSCs may contribute significantly to the 
myofibroblast and stellate cell population and thus may accelerate the fibrotic 
process rather than resolve it[135], raising concern for HMSCs use in liver 
therapy. 
 
MSCs are multipotent and are capable of mesodermal, neuro-ectodermal and 
endodermal differentiation depending on the surrounding environment[136]. 
MSCs are derived from a number of sources including adipose tissue, umbilical 
cord blood and the bone marrow, and MSCs from all of these sources have 
been successfully differentiated into hepatocyte-like cells and integrated into 
animal models of injury[137, 138]. Similar to HMSCs, MSCs have been 
successfully used in patients with end stage liver disease in phase I and II 
clinical trials[139-141], where treatment was reportedly well tolerated and hepatic 
function was shown to improve during the follow up[139]. However long term 
hepatic function has not been rescued and particular diseases such as hepatitis 
B show no improvements suggesting that MSCs may not be applicable for the 
treatment for all forms of liver disease. 
 
The use of extra hepatic-derived hepatocyte-like cells is currently very 
promising with clinical trials undergoing, still the need for safety and clinical 
improvements was highlighted when a phase I clinical trial was prematurely 
stopped due to a patient developing radiocontrast nephropathy and liver failure 
following bone marrow transplantations[142]. 
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1.6 Transdifferentiation of the pancreas to liver 
The phenomenon of metaplasia is essentially the reversible transformation of all 
cell types and occurs almost always in tissues that have been subjected to 
traumas such as infection. Many examples of metaplasia have been recognised 
for several decades and in the 1980s Slack proposed a theory that metaplasia 
involves a combination of changes in expression of regulatory genes[143].  With 
advances in molecular biology in recent times, the mechanisms been have 
investigated and now several examples are well understood such as 
transdetermination in Drosophila melanogaster, intestinal metaplasia, B-
lymphocyte into macrophage and exocrine pancreas to hepatocytes[144]. 
Transdifferentiation is a form of metaplasia that involves the switching of one 
differentiated cell type directly into another without undergoing an intermediate 
pluripotent state [145]. Transdifferentiation was first described by Selman and 
Kaftos[146] who observed a switch in cell type during metamorphosis in the silk 
moth. 
 
The transdifferentiation of exocrine pancreas to hepatocytes has been 
frequently observed where foci of hepatocytes appear within the pancreas 
during regeneration following toxic damage[147, 148]. The ability to switch cell 
types between the two tissues likely reflects the close developmental 
relationship[143], thus changes in the expression of only a few or just one 
transcription factor may be required to promote transdifferentiation[149]. One of 
the first experiments that showed the potential for pancreatic to hepatic 
transdifferentiation was carried out by Scarpelli and Rao (1981)[147] during 
induction of pancreatic regeneration in the hamster. Hepatocyte-like cells were 
observed within the pancreas that expressed the hepatocyte marker albumin 
and showed a variety of hepatic morphological features such as well developed 
bile canaliculi.  Since these findings, a number of methods have been 
established to induce hepatocytes within the pancreas in vivo which  include 
treatment with peroxisome proliferators[150], treatment with carcinogens[151, 152] 
and transplantation of epithelial cells into the liver[153]. To date the most studied 
in vivo model of pancreatic to hepatic transdifferentiation is through copper 
depletion in rats. This model is highly reproducible and results in an almost 
complete loss of acinar cells after copper depletion, followed by the 
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development of numerous hepatocytes during the recovery phase; in some 
studies over 60% of the pancreatic volume has been shown to be 
hepatocytes[154]. Pancreatic hepatocytes from copper-depleted rats are reported 
to express several hepatocyte transcription factors such as HNF-1, HNF3ɑ, 
HNF3β, HNF4, and C/EBPɑ,β and γ [155, 156] which suggests that they may be 
involved in the mechanisms of transdifferentiation.  Some of these transcriptions 
factors are also expressed within the normal pancreas and thus may not be 
important in transdifferentiation, however C/EBP-β is not found in the normal 
pancreas and has been shown to be essential in transdifferentiation in in vitro 
models[157]. Furthermore, in support of rodent studies, the appearance of 
pancreatic hepatocytes has also been observed in humans with pancreatic 
tumours[158]. 
 
A number of cellular origins have been suggested for the pancreatic 
hepatocytes, including exocrine acinar cells, endocrine cells or ductular cells, of 
which the most widely accepted origin for pancreatic hepatocytes is an exocrine 
origin[159]. An acinar cell origin is supported by observations where the forced 
expression of the pancreatic specific transcription factor Pdx1[160] resulted in 
hepatic to exocrine pancreas cell switching. 
 
The transdifferentiation of pancreas to hepatocytes shows potential as another 
source of hepatocyte cells. As well as a wide range of in vivo studies, a cell line 
known as the AR42J-B-13 (B-13) cell line has provided an invaluable cell model 
for studying the transdifferentiation of pancreas to hepatocytes in vitro. 
1.6.1 The AR42J-B-13 (B-13) cell line 
The AR42J-B-13 (B-13) cell line is a pancreatic acinar cell line that is able to 
transdifferentiate into hepatocyte-like cells, termed B-13/H cells, upon treatment 
with glucocorticoids such as dexamethasone (DEX).  The B-13 cell line was 
originally derived from the AR42J parent cell line which was generated by 
administering azaserine to Wistar/Lewis rats in 1979[161]. Here pancreatic 
adenocarcinomas were minced before re-transplantation into the same strain of 
rats. The cells isolated from the tumours were then seeded into culture vessels 
and one cell line, the AR42J cell line, showed high expression of exocrine 
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enzymes such as amylase. The B-13 cell line was subsequently cloned by the 
Kojima lab when they observed that some cells were able to convert into insulin 
producing cells after culture with Activin A and beta-cellulin[162]. The first 
observations of B-13 transdifferentiation into hepatocyte-like cells was reported 
in 2000 by Shen et al[157].  
 
The B-13 cell is of exocrine pancreas origin which supports in vivo studies 
showing that pancreatic hepatocytes originate from acinar cells.  Furthermore 
following a combined treatment of DEX and EGF some B-13 cells have been 
reported to have duct cell-like features[163]. Thus the B-13 cell shows similar 
potency to hepatoblasts and may even be less developmentally restricted as 
they also have pancreatic potential and so may possess an endodermal 
progenitor phenotype. 
 
Transdifferentiation of B-13 cells into B-13/H cells can be promoted under 
relatively simple culture conditions requiring no cocktails of growth factors or 
monolayers which makes them an ideal in vitro model. Upon treatment with 
DEX, B-13 cells stop proliferating and alter their morphology to resemble 
hepatocyte-like cells with a high cytoplasm to nuclear ratio (figure 1.10). The 
expression of a number of hepatocyte-specific genes can be detected within ~3 
days of DEX  treatment including transferrin, UGT and CYP2E1, whilst albumin 
expression is not observed until later, at around day 9, showing the full 
transdifferentiation event takes time[164]. Co-localisation of amylase and albumin 
following the conversion into B-13/H cells has suggested the change to be a 
true transdifferentiation event which has been further supported by cell lineage 
experiments. The acinar cell-specific elastase promoter was used to drive green 
fluorescent protein (GFP) expression in B-13s and after treatment with DEX it 
was possible to detect GFP and liver-specific proteins within the same cells, 
showing that the B-13/H cells were originally derived from exocrine pancreatic 
cells[157].  
 
A number of liver-enriched transcription factors have been associated with 
conversion to B-13/H cells, however the key component identified thus far is 
CCAAT/enhancer-binding protein beta (C/EBPβ) which has also been identified 
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as playing an important role in transdifferentiation in vivo[156]. The increase in 
C/EBPβ expression is detectable after 4-5 weeks of copper depletion which is 
just before the appearance of  hepatocytes suggesting a critical early role[159].  
To verify the action of C/EBPβ, transfection of the dominant negative form into 
the B-13 cells was carried out; these experiments resulted in a failure of the B-
13 cells transdifferentiating upon DEX treatment which highlights the vital role of 
C/EBPβ induction to drive the hepatocyte phenotype[157].  
 
The role of Wnt signalling in transdifferentiation has also been examined as 
nuclear receptors such as glucocorticoid receptors are known to cross-talk with 
the Wnt signalling pathway[165]. During hepatic development the protein Wnt3A 
is critical and this protein was shown to be highly expressed by B-13 cells[166].  
Wallace et al[167] showed that Wnt3A expression was repressed following DEX 
treatment of B-13s, leading to a rise in β-catenin phosphorylation and thus 
reductions in β-catenin localisation to the nucleus and Tcf/Lef transcriptional 
activity. The roles of Wnt signalling in this process were further confirmed when 
a small molecule Wnt agonist was shown to block glucocorticoid dependent 
transdifferentiation[167]. Furthermore Wnt signalling was shown to play an 
upstream role to C/EBPβ as  knockdown of β-catenin expression resulted in the 
induction of the transcription factor and conversion to B-13/H cells. 
 
Elucidating the basic mechanisms that allow the B-13 cell to transdifferentiate is 
of key importance with the hope of finding a human equivalent which provides 
the basis of this thesis. 
 
 
 
 
 
 
 
 
Figure 1. 10: The typical morphology of B-13 cells before and after DEX treatment. B-13 
cells have a high nucleus to cytoplasm ratio and have rounded morphology. After DEX 
treatment B-13/H cells show typical hepatocyte morphology with a large cytoplasm to nuclear 
ratio. Figure taken from Wallace et al
[168]
. 
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1.6.2 Wnt signalling in transdifferentiation of pancreas to liver 
Wnt signalling was first identified in Drosophila melanogaster  and is a highly 
conserved pathway found in all phyla across the animal kingdom[169]. Wnt 
signalling regulates cell fate decisions, has critical roles in creating normal body 
patterns during embryonic development, and is also important in the 
maintenance of tissue homeostasis in the adult. In addition Wnt signalling 
interacts with many other pathways during development; the Wnt/β-catenin 
cascade integrates signals from pathways including retinoic acid, FGF, TGF-β, 
and BMP in a range of cell-types and tissues.  Wnts are a family of secreted 
glycoproteins which bind their receptors at the cell membrane leading to 
intracellular Wnt signalling. The signals are transduced via two distinct 
pathways termed the canonical pathway and non-canonical pathway. The 
canonical pathway is centred around regulating levels of intracellular β-catenin,  
a transcriptional co-regulator[170], and it  is this pathway that shall be focused on 
as it has been recognised to play a role in transdifferentiation of B-13 cells[167]. 
 
In the absence of Wnt ligands, β-catenin is sequestered within the cytoplasm by 
the axin destruction complex composed of axin, adenomatous polyposis coli 
(APC), and GSK3β. CK1 and GSK3β  phosphorylate β-catenin targeting it for 
ubiqutination and proteasomal degradation[171]; resulting in no free cytoplasmic 
β-catenin to reach the cell nucleus and drive expression of transcription factors 
through Tcf/Lef signalling. In the presence of Wnt ligands, Wnts bind to the 
transmembrane receptor, frizzled, and the frizzled co-receptor low density 
lipoprotein receptor-related protein 5 or 6 (LRP5/6) where they from a Wnt-
firzzled-LRP5/6 complex.  The complex is able to recruit the scaffolding protein 
dishevelled (Dsh), which is a phosphoprotein and leads to the phosphorylation 
of LRP5/6. Next the axin degradation complex is recruited displacing GSK3β 
preventing the binding and subsequent phosphorylation of β-catenin. 
Consequently in the presence of a Wnt ligand, levels of β-catenin stabilise and 
accumulate within the cytoplasm where it can translocate via Rac-dependent 
mechanisms to the nucleus where it forms a complex with Tcf/Lef transcription 
factors and activates target genes for expression (figure 1.11). 
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Figure 1. 11: The canonical Wnt signalling pathway. In the absence of a Wnt ligand, β-
catenin is held in the cytoplasm by the axin destruction complex. GSK3β and CK1 
phosphorylate β-catenin targeting it for ubiquitination and proteasomal degradation. In the 
presence of a Wnt ligand, Wnts bind to the transmembrane receptor frizzled where they form a 
Wnt-frizzled-LRP5/6 complex which is able to recruit dishevelled (Dsh) followed by the axin 
destruction complex displacing GSK3β. β-catenin then stabilises and accumulates within the 
cytoplasm  before translocating to the nucleus and activating gene expression of target genes.  
 
Wnt signalling is known to be involved in both pancreatic and hepatic 
development, but in addition Wnts have been found to be essential in many 
aspects of the postnatal liver homeostasis[172]. Several Wnt ligands have been 
shown to be expressed by various liver cells including hepatocytes, Kupffer 
cells, stellate cells, SECs and BECs suggesting potential cross-talks between 
different cell types of the liver[173]. Wnt signalling plays roles in many of the key 
functions of the liver including ammonia and nitrogen metabolism, bile acid 
homeostasis and drug detoxification. Hepatic zonation has been shown to be 
dependent on Wnt signalling, as mice lacking APC expression exhibited 
extensions of the normal perivenous zone of glutamine synthetase (GS) 
expression towards the portal region[174]. In addition to normal liver 
homeostasis, Wnt signalling has been associated with progenitor-mediated liver 
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regeneration, where a role has been observed both experimentally and 
clinically[175]. These observations are further supported in vivo where a loss of β-
catenin resulted in the delayed liver regeneration in partial heptectomy (PH) 
rats, and expression of a stable β-catenin resulted in accelerated recovery[176]. 
Within the pancreas, canonical Wnt signalling has been shown to be critical for 
the development of the exocrine portion of the pancreas but not for the 
endocrine cell population[39, 177]. Mice lacking β-catenin showed a loss of early 
exocrine cell differentiation and loss of exocrine specific markers such as 
amylase.   
 
It has been shown that the transdifferentiation into B-13/H like cells is 
dependent of a transient repression of Wnt signalling which is actively 
repressed upstream of C/EBPβ[167].  When Wnt agonists were used the 
glucocorticoid mediated transdifferentiation was inhibited and a si-RNA 
mediated knockdown of β-catenin could substitute glucocorticoid effects and 
lead to the B-13/H phenotype. Furthermore, Wnt signalling was shown to be 
upstream of C/EBPβ induction as knockdown of β-catenin using siRNA resulted 
in the induction of C/EBPβ. Once the transdifferentiation events have taken 
place Wnt expression is regained, showing that only a transient repression is 
needed for a conversion from pancreas to liver, before Wnt signalling is 
restored, possibly for normal hepatic function.  
 
As discussed previously the Wnt signalling pathway has been shown to interact 
with many other cell signalling pathways and some nuclear receptors, including 
the glucocorticoid receptors, have been show to interact with components of the 
Wnt signalling pathway[165].  Therefore the role of glucocorticoid signalling and 
its interaction with the Wnt signalling pathway are of interest with regards to the 
transdifferentiation of pancreas to liver, especially within the B-13 model system 
which is dependent on glucocorticoid treatment.  
1.6.3 Glucocorticoids in transdifferentiation of pancreas to liver 
Glucocorticoids are a class of steroid hormones that are able to bind to and 
modulate the transcriptional function of nuclear receptors such as the 
glucocorticoid (GR) and mineralcorticoid (MR) receptors[178].  Glucocorticoids 
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are primarily secreted from the adrenal gland and play many roles including 
regulation of intermediary metabolism such as gluconeogenesis in the liver[179]. 
During development, glucocorticoid levels are maintained at low levels by 
placental 11-beta hyroxysteroid dehydrogenase type 2, and at high levels they 
have potent effects upon tissue development, most notably in the lung[180-182]. 
 
The transdifferentiation of B-13 to B-13/H cells has been shown to be a 
glucocorticoid-dependent mechanism, and other classes of steroids do not 
result in a hepatocyte phenotype[183].  In addition the response to DEX has been 
shown to act through the GR and not the MR[184]. B-13 cells have been reported  
to express high levels of GR mRNA in contrast to low levels of MR mRNA and 
when treated with the GR antagonist, mifepristone, transdifferentiation was 
prevented[184], however treatment with the MR antagonist, spironolactone, had 
no effect. Further analysis at the mRNA level by microarray has shown a 
marked increase in the glucocorticoids regulated kinase, Serine/threonine-
protein kinase 1 (SGK1), mRNA transcripts in B-13/H cells, which are barely 
detectable in B-13 cells. Inhibition of SGK1 through transfection with siRNA, 
resulted in a loss of the transdifferentiation response suggesting that the 
conversion into B-13/H cells is dependent on a SGK1 induction after 
glucocorticoid interactions with the GR.  B-13 cells were transfected with human 
SGK1 isoforms to further confirm a role of SGK1 in B-13 to B-13/H 
transdifferentiation. Expression of either C or F isoforms significantly inhibited 
Wnt signalling resulting in Tcf/Lef transcriptional activity at levels similar to DEX 
treated B-13 cells. Mutant versions of the isoforms were also transfected that 
lacked kinase activity and resulted in no altered phenotype, demonstrating that 
the kinase function of SGK1 is essential for promoting the transdifferentiation 
events. 
 
Observations have shown an importance for both glucocorticoid and Wnt 
signalling pathways in the conversion of pancreatic to hepatocyte phenotypes in 
the B-13 cell line after treatment with glucocorticoids. Nuclear receptors such as 
GR are able to crosstalk with the Wnt signalling pathway and are able to 
interact directly with components of the Wnt cascade[165]. SGK1 has also been 
shown to phosphorylate β-catenin in vitro providing a potential mechanisms of 
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crosstalk between the two pathways which both act to direct the 
transdifferentiation, and one possible route is the direct phosphorylation of β-
catenin by SGK1 upon its induction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 12: Crosstalk between the Wnt and glucocorticoid signalling pathways in the 
induction of B-13 to B-13/H transdifferentiation. Glucocorticoid signals such as DEX interact 
with the GR and lead to an induction of SGK1 expression. In turn the SGK1 acts to 
phosphorylate β-catenin through a kinase dependent mechanism targeting it for proteosomal 
degradation. β-catenin is then unable to translocate to the nucleus and activate Tcf/Lef 
transcriptional activity allowing instead transcription and expression of hepatocyte specific 
transcription factors such as CEBP/β which drive the hepatocyte phenotype. 
 
The role of glucocorticoids in the transdifferentiation of pancreas to hepatocytes 
has been investigated in vivo and upon treatment with glucocorticoids 
pancreatic hepatocytes have been observed in both rodents [154] and 
humans[183]. Treatment of mouse embryonic pancreatic buds with 
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glucocorticoids was reported to induce the transdifferentiation towards 
hepatocytes[157] which demonstrates that this effect is not simply an artefact of 
in vitro B-13 studies.  Rats treated with DEX for 25 days were found to have 
expression of hepatocyte markers such as CYP2E1, CPS-1 and albumin within 
occasional acinar cells of the pancreas[166]  and rats showed an increase in liver 
weight and decrease in pancreas weight. The expression of hepatocyte-specific 
markers was restricted to single or small clusters of cells providing evidence of 
pancreatic to hepatocyte transdifferentiation.  To further test the effects of 
glucocorticoids, a transgenic mouse Tg(Crh) that over expresses the rat 
corticotrophin releasing hormone under the control of the mouse 
metalotheienin-I-promoter[185] was examined[186]. Mice with high circulating 
endogenous levels of glucocorticoids were found to have significantly smaller 
pancreata than wild type mice and extensive areas of the exocrine pancreas 
were shown to express hepatocyte-specific markers. Furthermore the 
observations from these studies were proven to be glucocorticoid dependent as 
Tg(Crh) adrenolectomised mice failed to develop the appearance of hepatocyte-
like cells within the pancreas[186].  In addition to the evidence shown in rodent 
work, pancreas biopsies from patients undergoing long term glucocorticoid 
treatments have also shown hepatocyte-specific gene expression[183]. Together 
the evidence shows that the response of the B-13 cells to glucocorticoids is a 
real pathophysiological response in adult cells and thus these observations 
could have important clinical implications in striving to find an alternative 
hepatocyte-like cell for the use in treating end stage liver disease.
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2.1 Animal work 
2.1.1 Ethics 
All animal work was carried out adhering to Home Office regulations as outlined 
in both the project license (PPL 60/3907) and personal license (PIL 60/12598). 
Protocols were individually designed for each study and the senior animal 
technician consulted before the study commenced. 
2.1.2 Housing 
Animals were housed in the Comparative Biology Centre (CBC) at Newcastle 
University. All animals were cared for as per Home Office regulations and were 
kept at 20 ± 3° with a humidity of 50±10 % with 12 hour light/dark cycles. 
2.1.3 C57B16 (wild type) mice 
Mice were purchased from Harlan and housed in the CBC at Newcastle 
University. Mouse were bred in house. 
2.1.4 Green Fluorescent Protein/ C57B16 mice 
The GFP/C57B16 transgenic strain was bred within house at the CBC at 
Newcastle University. All cell types in this animal express GFP. Animals were 
housed as described in 2.1.3.  
2.1.5 Non-Obese Diabetic Severe Combined immune-deficient (NOD-
SCID) mice 
NOD-SCID mice were purchased from Harlan and housed within the CBC at 
Newcastle University. As the mice were immune-deficient, they were housed in 
a separate area to other animals where all food, water and equipment was 
autoclaved for sterilisation before animals were exposed. Mice were kept in an 
air conditioned environment of 20 ± 3oC with a humidity of 50 ± 10% and a 12 
hour light/dark cycle.  Animals were cared for as per Home Office regulations. 
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2.2 Cell Culture 
2.2.1 AR42J-B-13 (B-13) Cells 
B-13 cells were routinely cultured in Dulbecco’s Modified Eagle Media (DMEM) 
(Sigma D5546) 1000mg/L glucose, supplemented with 10% (v/v) foetal calf 
serum (FCS), and 80U/ml of penicillin and streptomycin and 2mM L-glutamine 
in 75cm2 nunc culture flasks or 6-well plates. Cells were maintained in a 
humidified atmosphere at 37°C, 5% CO2 in air. Cell culture media was changed 
every 2-3 days. 
2.2.2 Induction of a hepatic phenotype in B-13 cells 
B-13 cells were cultured as described in 2.2.1 with the addition of 10nM or 
10µM DEX (Sigma). 10μM or 10mM stock of DEX in 100% ethanol was diluted 
1:1000 into media to give a final working concentration of 10nM or 10µM 
respectively. After 5 days of culture with DEX the appearance of hepatocyte-like 
cells was observed within cultures. Fresh media and DEX was given to the cells 
every 2-3 days. Control cells were grown in parallel with the supplementation of 
0.1% EtOH.  
2.2.3 Primary human hepatic stellate cells (hHSCs) 
Hepatic stellate cells were prepared from human liver samples received after 
surgical resection. The liver samples were perfused with Hank’s Balanced Salt 
Solution (HBSS)- 1L contains: 900ml dH2O, 100ml 10X HBSS w/o Ca
2+ /Mg 2+ 
(NaCl, 80g/L; KCl, 4g/L; glucose, 10g/L; KH2PO4, 600mg/L; Na2HPO4, 475mg/L 
and phenol red, 170mg/L),  6mls of 1M sterile 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES),  and 4.6mls of 7.5%(w/v) NaHCO3) to 
remove any remaining blood. The tissue was then cut into smaller fragments 
and incubated with 40mg pronase, 10mg collagenase B and 1mg of DNaseI, 
suspended in 50ml of (HBSS)+ (HBSS- with  1ml/L of 1M CaCl2). After cutting 
up the liver, it was transferred into the enzyme solution and left at 37°C, 220rpm 
for 30 minutes. Once digested the samples were centrifuged at 400g for 7 
minutes before re-suspending the cells in culture medium. Cells were then 
plated out into 6 well plates and grown in DMEM with 4.5g/L glucose, 110mg/L 
sodium pyruvate, and 110mg/L sodium bicarbonate, supplemented with 20% 
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(v/v) FCS, 10mg/L penicillin/streptomycin and 2mM L-glutamine. Cells were 
incubated in a humidified atmosphere at 37oC and 5% CO2. 
2.2.4 Primary mouse and rat hepatic stellate cells (m/rHSCs) 
HSCs were prepared from the livers of mice and rats. After killing by schedule 1 
the liver of each rodent was removed and cut into small fragments to ease 
digestion. 40mg pronase, 10mg collagenase B and 1mg of DNaseI were 
suspended into 50ml of HBSS+. After cutting up the liver it was transferred into 
5ml of the enzyme solution and left at 37°C, 220rpm for 30 minutes. Once 
digested the samples were centrifuged at 400g for 7 minutes before re-
suspending the cells in culture medium. Cells were then plated out into 6 well 
plates and maintained in conditions described in 2.2.3. 
2.2.5 Primary mouse and rat hepatocytes 
Rat hepatocytes were prepared by collagenase perfusion; in brief, rats were 
anaesthetised by Intraperitoneal (i.p.) injection with 60mg sodium 
phenobarbitone per kg of body weight, the animal was then cut open and the 
internal organs exposed. A cannula was inserted into the hepatic portal vein 
and held in place using surgical suture. The liver was perfused with Ca2+Mg2+ 
free Earl’s Balanced Salt Solution (EBSS-) supplemented with 500μM ethylene 
glycol tetraacetic acid (EGTA) pH 7.4 followed by EBSS-. The perfusate was 
maintained at 37°C and passed through a bubble trap before entering the liver. 
Once all blood was cleared from the liver it was dissected from the body and 
further perfused with EBSS+ (with 1.8mM Ca2+ and 0.8mM Mg2+) supplemented 
with 10mg collagenase A for 20mins or until digested (no longer than 30mins). 
The liver was dispersed in EBSS+ containing 2% bovine serum albumin (BSA) 
and filtered through 75μm sterile nylon mesh. The homogenate was centrifuged 
at 50g for 4 minutes at 4°C, the pellet was re-suspended in fresh William’s 
Medium E (WME) to wash and centrifuged at 50g for 4 minutes at 4°C. Cells 
were re-suspended in WME supplemented with 10% FCS, 1μg/ml insulin, 
80U/ml penicillin and 80μg/ml streptomycin and plated on to collagen type I 
coated plates (bio-coat). Cells were incubated for 2 hours to allow attachment 
before the medium was replaced with serum - and insulin-free medium. Cells 
were routinely maintained in culture for 24 to 48 hours. 
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2.2.6 HPAC cells 
The Human Pancreatic Acinar Cell line (HPACs) were purchased from 
American Type Culture Collection (ATTC®) Catalogue No. CRL-2119.  The cells 
originate from a pancreatic adenocarcinoma from a 64 year old Caucasian 
female. The cell line was derived in 1985 from a nude mouse xenograft of the 
primary tumour[187]. HPAC cells were cultured in the same media used for B-13 
culture i.e. DMEM (Sigma D5546) 1000mg/L glucose, supplemented with 10% 
(v/v) FCS, and 80U/ml of penicillin and 2mM L-glutamine with a media change 
every 2-3 days. Dexamethasone treatment of the cells was also carried out as 
described in 2.2.2.  
2.2.7 Primary human pancreatic acinar cells 
Acinar cell samples were received from Guo Cai Huang at the Department of 
Diabetes and Endocrinology; Kings College London after islet cells had been 
prepared for transplantation. The exocrine cell suspension was filtered through 
sterilised nybolt fabric before centrifugation at 50g for 4 minutes at 4°C. The 
cells were then re-suspended into DMEM media containing 1000mg/L glucose, 
supplemented with 10% (v/v) FCS, and 80U/ml of penicillin and 2mM L-
glutamine. Cells were cultured in high volumes of media to reduce enzymatic 
levels in the culture vessels and media was changed daily. 
2.2.8 HepG2 Cells 
The HepG2 (ATCC® HB8065 ™) cell line is a continuous human hepatoma cell 
line derived from the liver tissue of a fifteen year old male with differentiated 
hepatocellular carcinoma[188].  The cell line is a suitable in vitro model for 
polarised human hepatocytes. HepG2 cells were cultured in DMEM- (Sigma 
D5546 1000mg/L glucose) supplemented with 10% FCS and 80U/ml of 
penicillin and streptomycin and 2mM L-glutamine. Media was changed every 2-
3 days and cells were passaged when 90% confluent using 2x Trypsin- 
Ethylenediamine tetraacetic acid (EDTA) (Sigma) as described in section 2.2.9. 
2.2.9 Cell passage 
Once cultured cells reached a confluency of 80-100% they were passaged. The 
cell media was aspirated from the cells before washing twice with sterile 1x 
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phosphate buffered saline (PBS) (8.0g/L NaCl; 0.2g/L KCl; 0.2g/L KH2PO4; 
1.15g/L Na2HPO4) pH 7.4. Cells were incubated with 1 x Trypsin-EDTA 
(Sigma), diluted in 1x PBS until the cells began to detach from the culture 
vessel. Trypsin was inactivated by adding an equal volume of FCS- containing 
culture media to the cell suspension (4mls per 752 flask and 0.5ml per well of a 
6-well plate). The cell suspension was then transferred to a 50ml Falcon tube 
and centrifuged at 2000rpm for 5 minutes. Supernatant was discarded and the 
cell pellet was re-suspended in fresh media. The cells were seeded accordingly 
for cell maintenance or frozen down for cell storage. 
2.2.10 Cell storage and revival 
Cell stocks for all cell lines were routinely frozen down and stored long term in 
liquid nitrogen. Cells were detached and pelleted by centrifugation as previously 
described (2.2.9), before re-suspending in freezing media (90% FCS 10% 
Dimethyl sulfoxide (DMSO)), typically 3mls per pellet from a confluent t75 flask. 
The suspension was then aliquoted out into sterile cryovials (1.5ml/cryovial). 
Aliquots were placed in an isopropanol filled cooling aid (Mr Frosty™, Nalgene) 
and left in the -80°C overnight; cells were cooled at a rate of approximately 1°C 
per hour and then transferred to liquid nitrogen for long term storage.  
For revival, cells were removed from liquid nitrogen and rapidly thawed at 37°C, 
re-suspended in 50ml of fresh warmed media and transferred to a 50ml falcon 
tube. The cell suspension was then centrifuged for 4 minutes at 600rpm and the 
supernatant was discarded. The cell pellets were re-suspended in fresh media 
and transferred to a culture vessel. Cells were allowed to attach overnight 
before the media was changed after a minimum of 12 hours. Cells were initially 
seeded into small culture vessels e.g. 6-well plates.  
2.2.11 Cell viability and number 
Cell viability was assessed by the ability of a cell to exclude trypan blue. Freshly 
isolated cells were re-suspended in 100μl of fresh media, 100μl of 0.4% trypan 
blue (Gibco) solution and 200μl of media was added giving a final concentration 
of 0.1% (w/v) trypan blue. The cell suspension was then placed into a 
haemocytometer and the determination of non-viable cells was made based on 
their ability to exclude trypan blue. Total cell number and the number of non-
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viable cells in a known volume of cell suspension were calculated and used to 
determine the percentage viability of the freshly isolated cells along with the 
total cell number.  
2.2.12  Coculture of B-13red cells with GFP activated HSCs (myofibroblasts) 
For coculture experiments activated liver HSCs derived from GFP mice were 
cultured together with B-13red cells (see section 2.3.2) to investigate whether 
they have any effects on the transdifferentiation into B-13/H cells. 6-well plates 
were used for the coculture experiments and were initially seeded with the 
mouse myofibroblasts which were left to reach around 60-70% confluency 
before B-13red cells were seeded onto the HSC layer. During coculture cells 
were all treated with standard B-13 media composed of DMEM (Sigma D5546) 
1000mg/L glucose, supplemented with 10% (v/v) FCS, and 80U/ml of penicillin 
and streptomycin and 2mM L-glutamine. Cultures were either treated with 10nM 
DEX or control 0.1% ethanol for 7 days, before RNA and protein samples were 
collected for analysis. Cultures of B-13red and GFP myofibroblasts were also 
cultured separately as controls. 
2.2.13  GFP myofibroblast conditioned media and its treatments 
To confirm whether or not myofibroblatss are required for the effects observed 
in coculture or whether a secreted factor was being produced, the media used 
to culture myofibroblasts was collected and used for B-13 culture. The 
conditioned media was collected from the cell cultures and centrifuged to 
remove any cell debris before supplementing with 10% FCS. The media was 
then added to the B-13 cells which were cultured for 7 days as described in 
section 2.2.12. 
2.3 Cell transfection 
2.3.1 Transfection using effectene reagent (QIAGEN) 
B-13 cells were transfected as detailed in the manufacturer’s protocol and 
cultured under conditions described in 2.2.1. After seeding the cells into fresh 
752 flasks or 6-well plates the cells were left for 24 hours to adhere to the 
surface. Effectene (Qiagen, Southampton, UK.) was routinely used for B-13 cell 
transfections. DNA (plasmid of interest), EC buffer and enhancer were then 
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mixed as a ratio of 1μg DNA: 150μl EC buffer: 10μl enhancer. The mixture was 
vortexed to mix, and left to incubate at room temperature for 10 minutes, after 
which effectene was added at a ratio of 15μl per 1μg of DNA. The solution was 
left at room temperature for a further 20 minutes before the master mix was 
added to the flasks/6-well plates in a drop wise manner, along with fresh media 
and left for 24-48 hours as optimised.  
2.3.2 Production of stable transformed cell line 
Cells were transfected with the relevant plasmid using effectene as described in 
2.3.1 and left for 36 hours, after which cells were washed with 1xPBS. Fresh 
media supplemented with 250μg/ml of G418 was then given to the cells to start 
selection for positive cells.  Selection was carried out for 1 month to ensure all 
surviving cells were stably transfected. To confirm cells were 
DsRed/pCAG2LMKOSimO positive cells were routinely checked under a 
fluorescent microscope.  
2.3.3 TOP/FLOP flash transfection and dual luciferase assay (Promega) 
A dual luciferase assay was performed to assess the activity of Wnt signalling in 
various experimental setups. Dual reporter systems work to increase 
experimental accuracy where two individual reporter enzymes are 
simultaneously expressed. The dual luciferase® assay (Promega) utilises the 
luciferase activities of both firefly (photinus pyralis) and renilla (renilla reniformis, 
sea pansy) detecting the activities of both sources respectively (figure 2.1). A 
difference in the structure of the two luciferase enzymes allows the 
discrimination between their respective bioluminescence. A transfection ratio of 
no less than 6:1 for experimental to control plasmid DNA vectors was employed 
as standard, in order to ensure independent genetic expression and suppress 
any trans-effects between the promoter elements (i.e TOPFLASH and 
Luciferase containing reporter gene: RL-TK). Both firefly and renilla luciferase 
follow michaelis-menten kinetics, maximum light output is not achieved until 
substrates (above Km) and cofactor are present in a large excess.  
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Figure 2. 1: Luciferase reaction. 
 
Transfected cells were washed twice in 1 x PBS before 1 x passive lysis buffer 
(5 x stock diluted 1:4 with dH2O) was added to each well (500μl/well of 6 well 
plate, 100μl/well of 24 well plate) and shaken on an orbital shaker for 15 
minutes to disrupt the cell membrane and lyse the cells. Luciferase assay 
reagent (LAR II) was prepared by resuspending the luciferase assay substrate 
with the luciferase assay buffer. 100μl of LAR II was then pipetted into a 
polypropylene tube and 100μl of cell lysate was added and mixed. The 
luciferase activity was measured using a luminometer. Firefly luciferase activity 
was then quenched using a pre-diluted stock of stop and glo reagent containing 
the substrate for renilla luciferase. The luciferase activity of the RL-TK was 
subsequently measured and recorded. For all transfections, the relative 
luciferase of the experimental plasmid DNA construct (e.g. TOPFLASH) was 
normalised to RL-TK levels by dividing the firefly measurement by the renilla 
value. All values were then further normalised to the control cells (FLOPFLASH) 
and data expressed as a fold change in luciferase activity in response to 
individual treatments.  
2.4 Plasmid DNA constructs 
2.4.1 TCF/LEF (TOPFLASH and FLOPFLASH) transcriptional activity 
reporter gene. 
T cell factor (TCF) reporter plasmid (TOPFLASH catalog # 21-170) and control 
plasmid (FLOPFLASH catalog # 21-169) were purchased from Upstate (Millipore) 
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Laboratories (New York, USA).   The TOPFLASH reporter plasmid contains 2 sets 
(second set in reverse orientation) of three copies of the wild type TCF binding site 
upstream of  a thymidine kinase (TK) minimal promoter and a luciferase open 
reading frame. FOPFLASH was used as negative control and contains two full and 
one incomplete mutated copy of the TCF binding site followed by 3 copies in the 
reverse orientation upstream of the TK minimal promoter and luciferase open 
reading frame.  
 
 
 
 
 
 
 
 
 
 
Figure 2. 2: Vector map for (TOPFLASH catalog # 21-170). Upstate (Millipore) Laboratories. 
2.4.2 pDsRed2-C1 
The pDsRed2-C1 vector was purchased from Clontech Laboratories (USA). The 
vector contains red fluorescent protein derived from Discosma sp. to allow cells 
transfected with the vector to be detected by fluorescent microscopy 
excitation/emission maxima: 558/583nm. 
 
 
 
 
 
 
 
 
 
 
Figure 2. 3: Vector and restriction map for pDsRed2-C1. (Clontech Laboratories, Inc). 
Chapter 2: Materials and Methods 
52 
 
2.4.3 pCAG2LMKOSimO 
The pCAG2LMKOSimO vector was purchased from Addgene (plasmid 20866). 
The vector contains the four mouse pluripotent transription factors c-Myc, KLF4, 
OCT4 and SOX2 along with the ires-mOrange gene to allow the transfected 
cells to be detected by fluoresent microsocopy, excitation and emission maxima 
are 548 and 562 nm, respectively. 
 
 
 
 
 
 
 
 
 
 
Figure 2. 4: Vector map for pCAG2LMKOSimO (Addgene plasmid 20866)
[189]
 
2.4.4 Transformation of TOP10 competent cells 
Top10 cells from Invitrogen (Paisley, UK) were transformed with the plasmid of 
interest to generate DNA. Bacterial cell stocks were stored at -80°C before 
being thawed on ice prior to use. To each vial 50-100ng of plasmid DNA was 
added before gently tapping, to mix, and incubating on ice for 30 minutes. Vials 
were then incubated at 42°for 30 seconds to heat shock, before being returned 
to ice. 250µl of S.O.C medium was added to the vials and were shaken at 37°C 
for 1 hour at 225rpm to allow cells to recover. A sample of the cells (50-200 µl) 
was spread on LB (LB (luria broth-10g NaCl, 10g Tryptone, 5g yeast in 1litre 
dH2O) agar plates containing the required selction antibiotics, and colonies 
were left to grow overnight at 37°C. Colonies were selected and grown up for 
glycerol stocks and miniprep cultures as described in 2.4.4 and 2.4.5.  
2.4.5 Storage of DNA plasmids and glycerol stocks 
Stocks of plasmid DNA were prepared from overnight cultures before 
performing mini or maxipreps. 500μl of culture stock was mixed with 500μl of 
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glycerol before immediately mixing them and placing into -80°C for storage. 
Plasmid was produced from the stocks, if needed, by taking a small sample and 
adding it to 5ml of LB medium with the correct antibiotic and grown up overnight 
at 37°C and shaken at 220rpm. 
2.4.6 Miniprep purification of plasmid DNA 
The Qiagen miniprep protocol was followed using 1ml of overnight culture (see 
2.4.4). In brief the culture was centrifuged at 10,000 rpm for 1 minute and the 
supernatant was discarded. The bacterial pellet was then re-suspended in 250μl 
of buffer P1 (containing RNase), 250μl of buffer P2 (highly concentrated salt 
buffer containing SDS) and mixed before buffer N3 was added and mixed 
immediately. The samples were centrifuged at 13,000 rpm for 10 minutes which 
resulted in a white pellet. The supernatant was carefully removed and added to 
a Qiaprep spin column and centrifuged again for 1 minute. The column was 
again centrifuged after discarding the flow through and adding 750μl of buffer 
PE to remove excess salt. 50μl of buffer EB was added to the column to elute 
the DNA into a sterile eppendorf. The DNA was quantified as described in 2.7.5 
and  stored at -20°C.  
2.4.7 Maxiprep purification of plasmid DNA 
Maxipreps work on the same principle as minipreps but on a larger scale. 
Overnight culture of 500ml culture flasks was carried out to produce high yields 
of the DNA of interest. The Qiagen plasmid plus maxi protocol was followed. 
After centrifugation the bacteria pellet was lysed by adding buffer P1, P2 and 
after mixing, buffer S3. The lysate was then transferred to a QIAfilter cartridge 
and incubated at room temperature for 10 minutes. The sample was filtered 
through the cartridge with a plunger into a new tube before the addition of buffer 
BB. The lysate was mixed and transferred to a QIAgen plasmid plus midi spin 
column and the solution was drawn through using a vacuum source. The 
column was washed through with 0.7ml buffer ETR followed by buffer PE using 
the vacuum source, followed by centrifugation for 1 minute with buffer EB to 
elute the DNA into a clean eppendorf. DNA was quantified as described in 2.7.5 
and stored at -20°C. 
Chapter 2: Materials and Methods 
54 
 
2.5 Cytogenetic analysis of B-13 cells 
2.5.1 Preparation of metaphase spreads 
For karyotyping, cells were expanded in culture to approximately 75% 
confluency before metaphase-arrest was induced by adding 0.1 μg ml−1 
colchicine in fresh media for 1 hour. The cells were harvested by trypsinisation 
in EDTA (SigmaChem Co, Poole, UK) and washed with 1× PBS (137 mM 
NaCl,2.7 mM of KCl, 10 mM phosphate (pH 7.4)) and pelleted by centrifugation 
at 400 g for 5 minutes. The cell pellet was resuspended in 0.075 M KCl, added 
dropwise up to the volume of 10 ml before incubating the solution at 37 °C for 
10 minutes. The cells were pelleted by centrifugation and resuspended in 5 ml 
of ice cold fixative (3:1 methanol–acetic acid) with continuous gentle mixing to 
avoid clumping. Centrifugation was repeated and the cells were re-suspended 
in 2 ml of fixative; this step was repeated twice. The cells were incubated at −20 
°C overnight, re-suspended in fresh fixative and then dropped onto an angled 
glass slide under humidified conditions and left to dry in air overnight. The slides 
were  incubated in trypsin solution for 15 seconds before immediate transfer to 
saline solution (0.9% (w/v) NaCl) followed by two 5 minute washes prior to 
staining with Wright-Giesma staining solution (Sigma Chem Co, Poole, UK) for 
4 minutes. The slides were rinsed in distilled water, blot dried and mounted with 
coverslips using DPX. Images were taken on a Zeiss Axioskop and analysed 
using CytoVision®(Leica) software. Cells were karyotyped with the help of 
cytogenetic specialists Claire Schwab and Christine Harrison 
2.6 Soft agar anchorage assay 
2.6.1 Culture in soft agar 
The soft agar assay for colony formation is considered the most stringent in 
vitro assay for detecting malignant cell growth[190]. Anchorage-independent cell 
growth of B-13 cells was measured by assessing colony formation in a soft agar 
suspension using the human hepatoma HepG2 cell line and primary rat HSCs 
as positive and negative controls respectively.  A base layer of 1% w/v agar was 
mixed with an equal volume of culture media (see section 2.2.1), resulting in a 
0.5% agar base. 1ml of the mixture was put into each well of a 6-well plate and 
left to set overnight at 4°C. Cells were suspended into 0.7% w/v agar with an 
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equal volume of cell culture media to give an upper layer of 0.35% agar. 2,500 
cells were seeded per well and 0.5ml of culture media was added to the top of 
each well. Plates were incubated at 37°C, in 5% CO2 for 21 days, with media 
changes every 2-3 days. 
Following the incubation period, each well was stained with 0.5ml of 0.005% w/v 
crystal violet for one hour at room temperature. Images were taken using 
BUC2-500c camera (Bestscope International Ltd) on an Optika microscope and 
colonies were counted. 
2.7 RNA and DNA isolation/ quantification 
2.7.1 RNA isolation 
After washing cells twice with 1xPBS, 1ml of trizol was added to each well of a 
6-well plate and cells were removed and transferred to a clean eppendorf tube 
with the aid of a cell scraper; for tissue samples, the tissue was homogenised in 
trizol using a sonicator.  200µl of chloroform was added to the tube and mixed 
by vortexing before centrifuging at 12,000 rpm at 4°C for 15 minutes. The upper 
aqueous layer formed was transferred to a clean eppendorf along with 500µl of 
isopropanol, samples were incubated on ice for 10 minutes before centrifuging 
at 12,000rpm, 4°C for 10 minutes. Supernatant was removed, and the pellet 
was washed with 70% ethanol and centrifuged at 12,000 rpm, 4°C for 10 
minutes. Ethanol was discarded and the pellet was air dried before being re-
suspended in an appropriate volume of sterile dH2O. RNA samples were 
quantified and stored at -80°C. 
2.7.2 Quantification of RNA concentration and integrity 
To quantify RNA, samples were diluted 1:200 and absorbance was measured at 
260 and 280nm, with 200µl of dH2O used as a background. RNA concentration 
was calculated based on 1 absorbance unit at 260nm being equal to 25µg of 
RNA/ml.  Purity of RNA samples was checked by calculating the 260/280 ratio 
with values close to 2.0 suggesting pure RNA and values lower than 2.0 
suggesting DNA contamination. 
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2.7.3 DNase treatment of RNA 
RNA was DNase treated to remove any genomic DNA contamination. RNA 
samples were diluted in 50µl of dH2O; 0.1 volume of RQ1 10x DNase I reaction 
buffer and 0.1 volume of DNase I were added to the samples (e.g. if re-
suspended in 50µl H2O, add 5µl DNase I buffer and 5µl DNase I). The samples 
were mixed gently and incubated at 37°C for 30 minutes before the addition of 
0.1 volume of RQ1 DNAse stop solution (equal volume to DNase I). The sample 
was mixed and incubated at 65°C for 10 minutes to terminate the reaction, 
samples were stored at -20°C or -80°C. 
2.7.4 DNA isolation 
After washing cells twice with 1xPBS, 1ml of 1x PBS was added to each well of 
a 6-well plate and cells were removed and transferred to a clean eppendorf 
tube. The cells were pelleted before 200μl of genomic DNA preparation buffer 
(50mM Tris-HCl, 100mM NaCl, 10mM EDTA, 0.5% NP-40, pH8) was added 
along with 20μl of 20mg/ml proteinase K (Promega V320B in 10Mm Tris-HCl, 
pH7.5), mixing occasionally. Samples were incubated at 55°C overnight and 
allowed to cool before  50μg (5μl of a 10mg/ml stock) of RNase A (DNase free) 
was added and incubated at room temperature for 20 minutes.  200μl of 
phenol/chloroform/isoamyl alcohol (25/24/1 v/v/v) was added to the mixture 
before vortexing and pulse centrifugation. The upper aqueous phase (approx 
200μl) was carefully removed and 20μl of 3M sodium acetate pH5.2 and 450μl 
of ice cooled 100% ethanol were added and the sample was incubated on dry 
ice for 1 hour. The precipitated DNA was centrifuged at 13,000 rpm at 4°C for 
10 minutes. The supernatant was discarded before washing the pellet with 
500μl of 70% ethanol and incubated for 1 hour on dry ice followed by 
centrifugation at 13,000rpm at 4°C for 10 minutes. The supernatant was again 
discarded and the DNA pellet was re-suspended in sterile pharmacy grade H2O.   
2.7.5 Quantification of DNA concentration and integrity 
To quantify DNA, samples were diluted 1:200 and absorbance was measured at 
260 and 280nm, with 200µl of dH2O used as a background. DNA concentration 
was calculated based on 1 absorbance unit at 260nm being equal to 20µg of 
DNA/ml.  Purity of DNA samples was checked by calculating the 260/280 ratio 
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with values close to 1.8 suggesting pure DNA. Values below suggest protein 
contamination, whereas values close to 2.0 suggest RNA contamination 
2.7.6 Reverse transcription, 1st strand DNA synthesis (cDNA) 
Moloney murine leukemia virus (MMLV) reverse transcriptase RNAse H minus 
point mutant is a RNA dependent DNA polymerase used for the synthesis of 
complementary DNA (cDNA).  The –H mutant lacks RNase activity for the 
optimal generation of full length cDNA from long RNA templates. MMLV (-H) is 
thermostable, reducing any problems associated with secondary structure and 
gives higher yields of cDNA than MMLV. To create cDNA, RNA was diluted to a 
starting concentration of 200ng/μl. 4μl of RNA (800ng) was incubated with 1μl 
(50ng/µl) of random primers (Promega) at 95°C for 3 minutes.  Samples were 
placed on ice. Master mix containing (per tube) 4μl of 5x RT buffer (50mM Tris-
HCl (pH 8.3 @ 25°C), 75mM KCl,3mM MgCl2 and 10mM DTT) , 8μl dH2O, 2μl 
of 10mM dNTP’s and 1μl of MMLV was prepared on ice and added to each tube 
(15μl total volume per reaction). The RNA was incubated for 1 hour at 42°C for 
optimal cDNA synthesis. Samples were stored at -20°C. 
2.7.7 Polymerase chain reaction (PCR) 
Polymerase Chain Reaction (PCR) is a widely used molecular technique which 
allows the exponential amplification of specific DNA sequences from target 
DNA. PCR relies on thermal cycling which involves a number of cycles of 
repeated heating and cooling allowing for DNA melting, primer annealing and 
polymerase enzymatic replication of the DNA templates. Primers are designed 
specific to target genes of interest (see 2.7.8) allowing selective amplification of 
the target DNA. During the reaction, the DNA generated from earlier cycles can 
act as a target itself allowing the DNA to be exponentially amplified. Taq 
polymerase is the DNA polymerase enzyme that was used in the PCR reaction 
to amplify short segments of DNA. Taq was originally isolated from the 
bacterium Thermus aquaticus and performs in optimum temperatures of 70-
80°C. 
For PCR reactions 1μl of cDNA (40ng) was added to each reaction tube along 
with 20μl of PCR master mix which contained (per tube): 10μl 2x go-Taq green 
master mix (Taq DNA Polymerase, 1.6mM dNTPs, 3mM MgCl2 and reaction 
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buffers), 6μl dH2O, 2μl  of 10pmol/μl of up and downstream primers. PCR 
programs were optimised for each set of primers (table 2.1). The standard PCR 
program was as follows: 
 
95°C        1 minute                x1      Denature step 
95°C        1 minute                          Denature step 
40-64°C   1 minute               x35     Annealing step (dependent on primer design) 
73°C        1.5 minutes                     Elongation step 
73°C         8 minutes              x1      Elongation step 
4°C           Hold                                    
 
PCR products were then visualised by running them out on an agarose gel, (1-
2% dependent on amplicon size), as described in 2.7.9 and viewed under U.V 
light. 
2.7.8 PCR primer design 
Primer pairs were routinely designed to amplify specific DNA sequences of 
interest. DNA sequences were designed using the NCBI database 
(www.ncbi.nlm.nih.gov). Nucleotide BLAST was used to check the specificity of 
chosen primer sequences and also to assess the probability of dimer formation. 
The following guidelines were generally followed: primers should contain 40-
60% G and C and have a length of approx 18-30 bases. Primer pairs were not 
complimentary to one another to avoid the formation of primer dimers. The G 
and C content of each primer should be similar in order to keep the Tm values 
within the same region. Tm = 2 C x (A + T) + 4 C x (G + C). An optimal 
annealing temperature for each set of primer pairs was determined with a 
starting point being made at 5°C below the Tm.    
2.7.9 Agarose gel electrophoresis 
Gel electrophoresis was used to separate and identify nucleic acids based on 
charge migration. Larger nucleic acid fragments migrate slower through the 
polymerised agarose gel, thus samples can be efficiently separated according 
to size. A DNA ladder (New England Biolabs® Inc. 100bp N3231; 1kb N3232) 
was also ran so the fragment size of the samples could be identified.  An 
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electric field was applied across the agarose gel causing the negatively charged 
DNA molecules to be pulled through the agarose gel matrix and separated 
according to size. The percentage of agarose used for each gel was dependent 
upon the size of the nucleic fragment of interest, higher percentage gels were 
used for smaller fragments. In general 1.5% Agarose w/v powder was diluted in 
1 x Tris acetate- Ethylenediaminetetraacetic acid (TAE) pH 8.0.  The agarose 
was dissolved by heating and allowed to cool to ~50°C before 1μl/100ml of 
ethidium bromide (10mg/mL) was added. Ethidium bromide is a nucleic acid 
intercalating agent; upon exposure to UV light it fluoresces and allows nucleic 
acid samples to be visualised. The gel was poured into a cast with an 
appropriate comb and allowed to set at room temperature.  Once set, the gel 
was placed into the gel tank which was filled with 1 x TAE buffer and samples 
were loaded into the wells.  Agarose gels were run for approximately 45-60 
minutes at 90 volts. Gels were visualised under UV light and images were 
taken.  
2.7.10 Real-time PCR (SYBR Green qRT-PCR). 
The relative expression of the genes of interest was compared between 
samples using SYBR Green qRT-PCR for quantitative analysis. qRT-PCR 
works in a similar manner to standard PCR by amplifying sequences of interest 
with primers designed for the target, however qRT-PCR also includes the 
addition of a probe i.e. SYBR Green, which fluoresces once bound to double 
stranded DNA (dsDNA). After each cycle, the level of fluorescence is 
determined and used to calculate the amount of dsDNA present, thus allowing 
the amount of transcript of the target gene to be determined, relative to other 
samples. Reaction conditions for each set of primers were optimised individually 
and performed in a 20µl reaction. For each well of a 96-well PCR plate the 
reaction volumes were: 10µl of 2X SYBR Green Master Mix, both upstream and 
downstream primers to a final concentration of 250nM and a sufficient volume 
of nuclease free H2O to make a master mix, and 10ng of each cDNA sample. 
Each reaction was repeated in triplicate.  The plates were sealed using optical 
film, vortexed gently and centrifuged at 250g to collect the reaction mixture into 
the bottom of each well. qRT-PCR reactions were performed in an Applied 
Biosystems 7500 fast thermocycler. The gene expression was calculated 
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relative to control groups and normalised against 18S ribosomal RNA to 
account for any variations in RNA template between samples. Fold change in 
gene expression was calculated as 2(-DDCt) where DDCt is the change in Ct 
relative to 18S and experimental control. 
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Oligo ID 
 
5'-3' sequence 
Annealling 
conditions 
(35 cycles) 
 
Comments 
 
RT-PCR 
 
   
rmCYP2EUS TCGACTACAATGACAAGAAGTGT 42
o
C 
 
Will amplify a  rat CYP2E  (NM_031543) cDNA sequence of 525bp 
 rmCYP2EDS 
 
CAAGATTGATGAATCTCTGGATCTC 
 
rmhGAPDHUS 
rmhGAPDHDS2 
TGACATCAAGAAGGTGGTGAAG 
TCTTACTCCTTGGAGGCCATGT 
 
50°C Will amplify  rat (NM_017008),  human (NM_002046) or  mouse 
(NM_008084)  glyceraldehyde 3 phosphate dehydrogenase cDNA 
sequence of 243bp 
 
rCPS1US 
rCPS1DS 
 
 
ATACAACGGCACGTGATGAA 
GCTTAACTAGCAGGCGGATG 
 
 
55 °C 
 
 
Will amplify rat CPS (NM_017072.1) cDNA sequence of 390bp 
 
rmAMYLASEUS 
rmAMYLASEDS 
 
CAAAATGGTTCTCCCAAGGA 
CAAAATGGTTCTCCCAAGGA 
 
57°C Will amplify rat pancreatic amylase 2 (NM_031502.1) cDNA 
sequence of 224bp. 
 
rmhVimentin US 
rmhVimentin DS 
CGATGTGGACGTTTCCAAGCC 
ATCCACTTCGCAGGTGAGTG 
58°C Will amplify rat vimentin sequence (NM_031140.1) cDNA sequence 226bp 
 
 
rAlbumin US 
rAlbumin DS 
 
 
CGTCAGAGGATGAAGTGCTC 
CTTAGCAAGTCTCAGCAGCAG 
 
47
o
C 
 
Will amplify rat albumin (NM_134326) cDNA sequence of 471bp 
 
rC/EPBβUS 
rC/EBPβDS 
ACACGTGTAACTGTCAGCCG 
CGAAACGGAAAAGGTTCTCA 
 
55
 o
C Will amplify rat (NM_024125.4) cDNA sequences 
of 196bp 
 
rCYP2C11 US 
rCYP2C11 DS 
 
CTGCCATGGATCCAGTCCTAGTCC 
TTCCCTCTCCCAAAGCTCTGTCTCC 
 
55°C Will amplify rat ( NM_019184.2) cDNA sequence of 88bp 
)  
rCYP4A1 US 
rCYP4A1 DS 
 
GAGTGGCTGCACCATGAGCGT 
GCATTCGCCGGTGCTGGAAC 
55°C Will amplify rat CYP4a1 (NM_175837.1) cDNA sequence of 446pb 
 
rWIFI US 
rWIFI DS 
 
GTGTGATCCTCGAACTGCTG 
GCGCAGAAGGAGGGGGCCT 
 
42°C Will amplify rat wnt inhibitory factor 1 (NM_053738.1) cDNA sequence of 105bp 
mWIFI US 
mWIFI DS 
 
CTCCCTCCTTGCTCCCTCCTC  
TCAGGTGGCTGCCCTGCATC 
62°C Will amplify mouse Wnt inhibitory factor 1 (NM_011915.2) cDNA sequence of 
290bp. 
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mɑSmoothUS 
mɑSmoothDS 
 
ACGTTTTGTGGATCAGCGCCTCC 
TGATGCCATCCATGCCTGGGAATA 
58°C Will amplify mouse ɑ smooth muscle actin  (NM_007392.2) 
cDNA sequence of 251pb 
rAmylase US 
rAmylase DS 
TGTGGCTCGGGCAATAGTGCA 
CCATTCCATTTGCGAATAACTGTGCCA 
 
62°C Selectively amplifies rat pancreatic amylase 2 (NM_031502.1 ) 497bp 
fragment over mouse pancreatic amylases (NM_001190403.1, NM_0010427 
11.2, NM_001160150.1, NM_001160152.1, NM_001160151.1, XM_003084551.2) – 
at least 5 and up to 12 nucleotide mismatches between rat and mouse 
transcripts in primer hybridisation regions 
 
rCYP2E1US 
rCYP2E1 DS 
 
CCTGAAAACTTCCTGATATC 
TGATAGGAACTCTATATGCTTGGGT 
 
60°C Selectively amplify rat Cyp2e1 (NM_031543.1) 86bp fragment over 
mouse cyp2e1(NM_021282.2) – 13 nucleotide mismatches between rat 
and mouse transcripts in primer hybridisation regions. 
 
hPXR US 
hPXR DS 
ACATGGCTGACATFTCAACCTACA 
AGCTCGGTGAGCATAGCCATGAT 
64°C Will amplify  the same size amplicon from all 3 human PXR reference transcripts 
(NM_003889, NM_022002 and NM_033013) cDNA sequence of 475bp 
 
 
hCAR US 
hCAR DS 
AGAACAGTCAGCAAAAGCAT 
TGCACAAACTGTTCAAACAT 
50°C Will amplify all 15 human reference  transcripts of CAR (NM_001077469  to 
NM_001077482 and NM_005122) cDNA sequence of 293bp. 
 
hFXR US 
hFXR DS 
 
TGTGTGTTGTTTGTGGAGA 
ATCAGAGATCCACTATTTC 
41°C Will amplify human FXR (NM_005123) cDNA sequence of 701bp 
 
hGR US 
hGR DS 
 
 
GAAGCCTATTTTTAATGTC 
ATCATATCCTGCATATAAC 
42°C Will amplify all human GR transcripts (NM_000176, NM_001018074 -  
NM_001018077, NM_001020825 and NM_00102409) cDNA sequence of 607bp. 
hCYP2E1 US 
hCYP2E1 DS 
 
CCCGAGACACCATTTTCAGAG 
AGAAACAACTCCATGCGAGCC 
55°C Will amplify human CYP2E1 ( NM_000773.3) cDNA sequence of  228bp. 
hAlbumin US 
hAlbumin DS 
 
AGCTGCCTGCCTGTTGCCAAA 
AGGCGAGCTACTGCCCATGC 
55°C Will amplify albumin (NM_000477.5) cDNA sequence of 134bp. 
hAmylase US 
hAmylase DS 
 
ACATGGGGCTGGAGGAGCCT 
TGGTGGCCCAACCCAATCAT 
60°C Will amplify all human pancreatic amylase transcripts ( NM_020978.|  
NM_000699.2) cDNA sequence of 152bp. 
hCYP3A4 US 
hCYP3A4 DS 
 
TGTCCTACCATAAGGGCTTTTGTAT 
TTCACTAGCACTGTTTTGATCATGTC 
60°C Will amplify human CYP3A4 (NM_017460 ) cDNA sequence of 136pb. 
 
 
hINS v1 US 
hINS v1 DS 
 
 
GGCCATCAAGCAGATCACTGTCCT 
CCTGCGGGCTGCGTCTAGTT 
64°C Will amplify the human insulin transcript variant 1 ( NM_000207.2) cDNA of 
sequence 377bp 
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Table 2. 1: DNA oligonucleotide sequences employed in RT-PCR or genomic PCR. 
hC/EPBβUS 
hC/EBPβDS 
CCAGCCACCAGCCCCCTCACTAATA 
CCAAGCAGTCCGCCTCGTAGT 
42°C Will amplify human  C/EPBβ (NM_005194.3) cDNA of sequence 263bp 
  
 
Genomic PCR 
  
rXChromUS 
rXChromDS 
CTCTGAAGACAGAAGATTAGA 
TTGCCTTGGTCATGTGTC 
 
 
50
 o
C   Will amplify a 114bp intronic sequence of the rat zinc finger protein X-linked (Zfx) 
gene (NM_001109017.1) specifically present on the X chromosome. 
 
rYChromUS 
rYChromDS 
 
ATAGGTTTTCAGGTGTTGCCTGG 
TAATGAATGGTCAGAGAAAGCCAAC 
55 °C 
 
Will amplify a 243bp intronic sequence of the rat testis-specific 
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pecifically present on the 
Y chromosome. 
 
genomCYP2E1US 
genomCYP2E1DS 
AGAGGAGGGTGGACCAGTCCTGCACTCCT  
CTGGGGCTCCACTGTAAACTTGTAGGAATTTGCTG 
 
55°C 
 
Will amplify a 867bp promoter sequence of the rat CYP2E1 gene 
(NW_047563.2) specifically present on rat chromosome 1. 
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2.8 Protein isolation and quantification 
2.8.1 Preparation of whole tissue samples 
Tissue samples were snap frozen upon dissection and stored at -80°C until 
required. After thawing the tissue samples were homogenised in 1xPBS using a 
sonicator and pelleted by centrifugation at 13,000rpm. The pellet was re-
suspended into a known volume of 20mM Tris pH 7.4. 5µl of each protein 
sample was taken for determining the concentration by the Lowry method 
described in 2.8.3. Samples were stored at -80°C. 
2.8.2 Preparation of cell extracts 
Cells were washed twice with 1xPBS before they were scraped into 1ml (per 
well of a 6-well plate) and transferred to a clean eppendorf tube. The cells were 
centrifuged at 13,000 rpm for 10 minutes and the supernatant discarded. The 
cell pellet was re-suspended in a known volume of 20mM Tris pH 7.4, 5μl of 
each protein sample was taken for determining the concentration by the Lowry 
method described in 2.8.3. Samples were stored at -80°C. 
2.8.3 Lowry protein assay 
To determine the concentration of protein in each sample a Lowry assay was 
carried out using BSA as a standard. Standard concentrations were prepared 
which ranged from 0-20mg/ml from a 20mg/ml stock diluted into dH2O.  5μl of 
each standard and sample was diluted with 50μl of dH2O and 1ml of ABC buffer 
and left at room temperature for 10 minutes. ABC buffer was prepared fresh on 
the day of use and consisted of Lowry A (2% w/v Na2CO3/ 4% w/v NaOH), 
Lowry B (2% w/v sodium tartrate) and Lowry C (1% w/v copper sulphate) mixed 
at a ratio of 100:1:1 (v:v:v). After incubation for 10 minutes at room temperature 
100μl of Folins reagent (Fluca, Switzerland), diluted 1:1 with dH2O was added 
to each sample. Further incubation for 30 minutes occurred before absorbance 
at 750nm was determined for each sample by a spectrophotometer.  
The absorbance of the standards was used to produce a calibration curve from 
which an equation for the line of best fit was derived. This equation was re-
arranged to give concentration values for the unknown samples which were 
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then made up to stocks of known concentration as described in section 2.8.5.
  
2.8.4 Sodium-dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
Sodium-dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) is a 
method commonly used to allow proteins to be separated by their molecular 
weight, and was first described in 1970 by Laemmli[191]. Proteins are first 
denatured by heating them in the presence of a reducing agent, Dithiothreitol 
(DTT), which breaks any disulphide bonds in the tertiary structure. The proteins 
are then coated in negatively charged SDS which linearises them, allowing the 
proteins to migrate towards a positive electrode through the gel matrix. Smaller 
proteins will travel further, thus separating them according to their size. 
For SDS-PAGE, gels were cast between two glass plates held together with 
clamps and sealed at the bottom. Separating gels (9%) were made by mixing, 
9% bis-acrylamide, 375mM Tris buffer pH 8.8, 0.1% w/v SDS, 0.05% w/v 
ammonium persulphate, and 0.05% v/v Tetramethylethylenediamine (TEMED). 
After pouring the separating gel 100μl of isopropanol was layered on top to 
eliminate air bubbles and to produce a straight edge between the separating 
and stacking gel. Once set, the isopropanol was washed off before the 4% 
stacking gel was cast. The stacking gel was composed of 4% w/v acryalmide, 
125mM Tris buffer pH 6.8, 0.1% w/v SDS, 0.05% w/v ammonium persulpahte 
and 0.1% v/v TEMED. Combs were placed into the gel casts to create wells for 
the protein samples to be loaded into. Once the gels had set the wells were 
rinsed with dH2O before placing the gels into a gel tank and filled with electrode 
running buffer (ERB) comprising of 20mM Tris, 160mM glycine and 0.08% w/v 
SDS, pH 8.3. 
2.8.5 Sample preparation and electrophoresis 
Before carrying out gel electrophoresis the protein samples were diluted to 1-
2μg/μl in reducing loading buffer (62.5mM Tris buffer pH 6.8, 10% v/v glycerol, 
2% w/v SDS, 100mM DTT and 0.02% w/v bromophenol blue). The protein 
samples were denatured by heating to 90°C for 3 minutes. Once denatured, 
samples were loaded into the wells of the gel (10-30μg per well). The gels were 
Chapter 2: Materials and Methods 
66 
 
run at 100V until the samples passed into the separating gel when the voltage 
was increased to 150V. Once the samples had passed through the entire length 
of the gel, the protein was electrotransfered onto nitrocellulose for 
immunodetection 
2.8.6 Electrotransfer 
Proteins were transferred onto positively charged nitrocellulose membranes. 
Before transfer began the gels were equilibrated in ice-cooled transfer buffer to 
allow any gel shrinkage to occur. Transfer buffer comprised of 25mM Tris, 
192mM glycine and 20% v/v methanol, with a final pH of 8.3 ±0.3. Transfer of 
the proteins onto the nitrocellulose was carried out by running at 100v for 2 
hours on ice. Once transfer had occurred, nitrocellulose membranes were 
washed twice with 1 xTBST ( 0.2M NaCl, 20mM Tris, and 0.05% v/v Tween 20, 
pH7.4) to remove any excess methanol. The membranes were blocked for 1 
hour at room temperature in 3% (w/v) milk powder in 1xTBST buffer. After 
blocking the membranes were washed 3x in TBST, before immunodetection. 
2.8.7 Immunodetection 
The nitrocellulose membranes were incubated with a range of primary 
antibodies for 1 hour at room temperature. Primary antibodies were diluted in 
incubation buffer (0.05% milk powder w/v in 1xTBST) for dilutions see table 2.2. 
After primary incubation nitrocellulose membranes were washed thrice in 
1xTBS-T buffer before incubation with the relevant secondary (HRP conjugated) 
antibody, diluted in incubation buffer. Secondary incubation was left for 1 hour 
at room temperature before the nitrocellulose membrane was washed again 
thrice in 1xTBS-T buffer.  
To visualise the proteins of interest, ECL (Fisher) was applied to the membrane 
and incubated for 30 seconds. ECL is a chemillumenscent, able to bind to the 
HRP conjugated on the secondary antibody allowing detection of proteins. Any 
excess ECL was removed from the membrane before wrapping them in saran 
wrap. Xray films were exposed to the nitrocellulose membrane (hypefilm GE 
healthcare) in a dark room. The films were developed using an X-omat 
developer. 
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2.9 Immunohistochemistry and immunocytochemistry 
2.9.1 Immunohistochemistry 
All tissues samples were fixed in 10% formalin diluted in 1 x PBS for a minimum 
of 24 hours before processing. Once processed (sequentially through 
increasing concentrations of ethanol), samples were mounted in paraffin and 4-
6μm sections were cut and mounted onto super frost plus slides. Sections were 
de-waxed in xylene before re-hydrating through a series of ethanol washes 
(100%  90%  70%) and finally into dH2O. Antigen retrieval was carried out 
using 0.01M citrate buffer (see section 2.9.3). Tissue sections were incubated 
with 3% H2O2 for 10 minutes at room temperature to quench endogenous 
peroxide activity and washed for 5 minutes in 1 x PBS. Non-specific binding of 
antibodies was reduced by incubating tissue sections in 20% (v/v) FCS in 1 x 
PBS for 20 minutes at room temperature prior to incubation with primary 
antibody diluted in 0.05% FCS in 1xPBS (for dilutions see table 2.2) for 1 hour 
at room temperature or at 4°C overnight. Sections were washed 3-4 times each 
for 5 minutes in 1 x  PBS and incubated with the appropriate HRP conjugated 
secondary antibody diluted in 0.05% (v/v) FCS in 1 x PBS for 1 hour at room 
temperature followed by 3-4 5 minute washes in 1 x PBS. HRP activity was 
visualised using diaminobenzidine (DAB) chromogen (Dako) to develop colour 
essentially as outlined according to the manufacturer’s instructions. DAB was 
applied to the slide and incubated from 1-15 minutes as optimised for individual 
antibodies. In all cases, control sections were stained without primary antibody 
incubation for each individual antibody used. After incubation with DAB, slides 
were rinsed briefly in dH2O before being counterstained for 30 seconds  in 
haematoxylin, washed in acidified water for 10 seconds and then sequentially 
dehydrated through 50%, 75%, 95%, 100% ethanol and finally into xylene 
before mounting in depex™.  
2.9.2 Haematoxylin and eosin staining (H&E) 
Sections were de-waxed by immersion into xylene before rehydrating through a 
series of ethanol washes (100%→90%→70%) and finally into dH2O. Sections 
were stained with haematoxylin, a nuclear stain, for 1 minute before rinsing with 
water and differentiated in 1% acidified water for 30 seconds. Next sections 
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were counter stained with eosin, a cytoplasmic stain, for 1 minute and rinsed in 
water. To finish, sections were dehydrated through a series of ethanol washes 
(50%→70%→95%→100%) and finally into xylene before cover slips were 
mounted with depex™. 
2.9.3 Sodium citrate antigen retrieval 
Tissue sections were microwaved at full power for 2 x 10 minutes in 0.01M 
sodium citrate buffer pH6.0 and then allowed to cool in the buffer for 30 minutes 
at room temperature before beginning with the immunohistochemistry staining 
protocol. 
2.9.4 Fluorescent immunocytochemistry 
Cells were cultured in NUNC® chamber slides to allow staining directly on the 
slide, alongside controls.  Chamber slides were removed from the  incubator 
before media was removed and cells were washed twice in 1x PBS. 1ml of cell 
fixative (2% v/v formaldehyde/ 0.2% v/v glutaraldehyde in 1 x PBS pH 7.4) was 
added to each chamber and cells were incubated for 15 minutes at room 
temperature. Fixative was removed and cells were washed twice for 5 minutes 
in 1x PBS. (If not staining immediately cells were left at this stage in 1 x PBS 
and stored at 4°C).  After washing, non-specific protein binding was blocked by 
incubation with 2mls 20% (v/v) FCS in 1 x PBS per well for 20 minutes at room 
temperature whilst being gently rocked.  The blocking solution was discarded 
and primary antibody added at the required dilution (as detailed in table 2.2) in 
0.05% (v/v) FCS in 1 x PBS.  Cells were incubated in primary antibody for 1 
hour at room temperature with gentle agitation. Primary antibody was removed 
and cells were washed twice for 5 minutes in 1 x PBS. Secondary antibody was 
added at the required dilution in antibody incubation buffer and cells were 
allowed to incubate for 1 hour at room temperature with gentle agitation (for 
fluorescent secondary antibodies, incubation was carried out in the dark, i.e. 
slides were covered in foil). The secondary antibody was discarded and cells 
were washed once in 1 x PBS before being washed a further 4 times in 1 x PBS 
(5 minutes per wash). Finally, chambers were removed from the slides and 
coverslips were mounted using vectashield (anti-fade) and sealed with clear nail 
varnish, slides were visualised by fluorescence microscopy.  
Chapter 2: Materials and Methods 
69 
 
2.9.5 DAPI staining of DNA 
The nuclei of cells was stained using DAPI (4’,6-diamidino-2-phenylindole) 
which binds to AT rich regions of DNA within the minor grove of the double 
stranded helix. To stain, media was removed from the cell plates before 
washing twice with 1xPBS. The cells were fixed with 0.4% (v/v) formaldehyde in 
1xPBS for 15 minutes at room temperature. Fixative was removed and cells 
were again washed with PBS. 6μg/mL of DAPI in 1xPBS was added to the cells 
and incubated for 10 minutes at room temperature. Cells were washed with 
1xPBS and then analysed under a fluorescent microscope. 
2.9.6 Double staining 
Dual staining for CYP2E1 and amylase was carried out on both tissue and cells. 
Tissue samples were prepared for staining by de-waxing in xylene before re-
hydration through a series of ethanol washes (100%  90%  70%) and finally 
into dH2O. Antigen retrieval was carried out using 0.01M citrate buffer. Tissue 
sections were then incubated with 3% H2O2 for 10 minutes at room temperature 
(RT) to quench endogenous peroxide activity and  washed for 5 minutes in 1 x 
PBS. Cells were prepared by permeabilising in ice cooled methanol for 10 
minutes before washing in 1xPBS and fixing in 2% w/v formaldehyde and 0.2% 
gluteraldehyde in 1xPBS pH 7.4. 
Non-specific binding of antibodies was prevented in all samples by incubating in 
20% FCS in 1xPBS for 20 minutes at RT. 
Primary antibodies diluted in 0.05% FCS were applied to the samples and left to 
incubate overnight at 4°C. Sections were washed twice in 1xPBS before 
applying the appropriate secondary antibodies for 1 hour at RT. Samples were 
washed twice in 1xPBS before colour development was carried out using 
BCIP®/NBT substrate system followed by Liquid DAB+ substrate chromogen 
system for CYP2E1 (Alkaline peroxidase  activity) and amylase (HRP activity) 
expression respectively. 
In all cases, control sections were stained without primary antibody incubation 
for each individual antibody used. After colour development slides were rinsed 
briefly in dH2O and counterstained using nuclear fast red (Vector laboratories) 
when required. Samples were sequentially dehydrated through 50%, 75%, 95%, 
100% ethanol and finally into xylene before mounting in depex™.  
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2.10 Fluorescent in situ hybridisation (FISH) staining 
2.10.1 FISH staining 
Hybridisation was carried out essentially as described by Shearer et al[19] with 
some modifications. Paraffin embedded sections were mounted onto super frost 
coated slides and baked overnight at 55°C. Slides were deparaffinised in 3 
changes of xylene at RT for 10 minutes before dehydrating in two changes of 
100% ethanol for 5 minutes and air drying. Sections were incubated in 0.2M 
HCl for 20 minutes and subsequently washed in 2 changes of 2X standard 
saline citrate (SSC) for 5 minutes, followed by incubation in 1M NaSCN  at 80°C 
for 10 minutes before repeating the wash steps in 2X SSC. Tissue digestion 
was performed by incubating sections at 37°C overnight with 0.4% pepsin in 
0.001M HCl. After overnight digestion, sections were washed twice in 2X SSC 
and air dried before re-fixation in 10% buffered formalin for 15 minutes. Slides 
were washed twice with 2X SSC and air dried before 10µl of RatIDetectTM Chr Y 
FISH paint probe (Cambio) was applied to sections and sealed. Slides and 
probe were co-denatured by heating to 90°C for 5 minutes and hybridized 
overnight at 37°C in a humidified environment. After hybridisation coverslips 
were removed by soaking in 2x SSC/0.1%Tween20 at 45°C followed by two 
washes in 0.5 X SSC/0.1% Tween 20 at 45°C. Slides were briefly rinsed in 
dH2O and air dried out of direct sunlight. Samples were stained with DAPI using 
antifade compound (Vectashield), coverslips were applied and sealed. Analysis 
was perfomed on a Zeiss AxioImager microscope. 
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Antigen Mwt (kDa) Dilution Comments and Source 
 
Amylase 
 
 
57 
 
 
1:3000 WB 
1:200 IHC/ICC 
 
 
 
Rabbit  polyclonal to Pancreatic Amylase (abcam ab21156) for WB 
200μg goat polyclonal IgG from Santa Cruz (sc-12821) for IHC/ICC 
 
Albumin 
 
 
60 1:3000 WB 
1:500 IHC 
Chicken polyclonal to liver albumin (abcam ab106582) 
 
CYP2E1 
 
50 1:5000 WB 
1:500 IHC/ICC 
 
Rabbit polyclonal to CYP2E1 (abcam ab28146) 
 
β-actin 44 1:4000 WB Mouse monoclonal IgG. (Sigma Aldrich A5441). 
CYP4A 50 1:1000 WB 
1:200 IHC/ICC 
 
Rabbit polyclonal to Cytochrome P450 4A (abcam ab 3573) detects all of CYP4A family, isoforms 
CYP4A1 and 4A3 to a lesser extent 
. 
CYP3A4 58 1:2000  WB 
 
Rabbit polyclonal to CYP3A43 (abcam ab155029) 
 
Glucocorticoid 
receptor 
 
95 1:1000 WB 
1:100 IHC/ICC 
Mouse monoclonal to Glucocorticoid Receptor (abcam ab 2768) 
 
CPS-1 
 
165 1:5000 WB 
1:300 IHC/ICC 
Rabbit polyclonal to CPS1 - Liver Mitochondrial Marker (abcam ab 3682) 
 
Vimentin 57 1:2000 WB Mouse monoclonal anti-Vimentin antibody clone VIM 3B4 (chemicon CBL202) 
ɑ smooth 
muscle actin 
42 1:2000 WB Monoclonal anti actin smooth muscle antibody produced in mouse (Sigma A7607) 
 
anti rabbit-AP 
2 ° 
N/A 1:200 IHC Polyclonal to rabbit produced in donkey. Alkalike phosphtase conjugated (Abcam ab97061) 
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Table 2. 2:  Primary and secondary antibody specifications for Western blot (WB) and immunohistochemistry/immunocytochemistry (IHC/ICC). 
  
anti-goat-HRP 
2° 
N/A 1:200 IHC 
1/3000 
Polyclonal to goat produced in rabbit, horseradish peroxidise conjugated. (Sigma A5420) 
 
anti-rabbit-HRP 
2° 
N/A 1:200 IHC 
1:3000 WB 
Polyclonal to rabbit produced in goat, horseradish peroxidise conjugated (Dako P0448) 
 
anti-mouse-
HRP 2° 
N/A 1:200 IHC 
1:4000 WB 
Polyclonal to mouse produced in goat, horseradish peroxidise conjugated (Dako P0447) 
 
anti-rabbit-FITC 
2° 
N/A 1:150 ICC Polyclonal to rabbit produced in sheep. FITC conjugated (Sigma F7512) 
 
anti-rabbit-
TRITC 2° 
N/A 1:400 ICC Polyclonal to rabbit produced in swine. TRITC conjugated (Dako R0156) 
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2.11 Culturing B-13 cells in bio-artificial liver device 
2.11.1  Bioreactor and perfusion equipment 
Bioreactors composed of three independent capillary membrane systems, with 
two systems for medium perfusion (inflow and outflow) and the third for cell 
oxygenation-carbon dioxide removal which are interwoven to create an extra-
capillary space were used (figures 2.5 and 2.6). The design of the bioreactors 
was considered to support the viability and function of primary liver cells, as the 
three dimensional spatial structure created by the interwoven capillary system 
represents an artificial equivalent of the hepatic vasculature at the lobular 
level[192]. The bioreactors employed in these studies contained 40 layers of 
interwoven capillaries which were made of polyethersulphone for media flow 
(Membrana, Wuppertal,Germany) and hydrophobic multilaminate hollow-fibre 
membrane for gas flow (MHF,Mitsubishi, Tokyo, Japan). 
The perfusion tubing used to feed into the bioreactor device consisted of 
standard medical grade dialysis polyvinyl chloride (PVC) (B.Braun Melsungen, 
Germany) and was fitted with bubble traps to remove excess gas. Sterilization 
was performed by formaldehyde gas sterilisation at 60°C followed by degassing 
prior to cell inoculation.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. 5: Images to show  A) a typical jellyfish bioreactor employed for 3D culture 
studies; B) the set up of the bioreactor and the perfusion tubing within the processor-
controlled perfusion device with electronic pressure, media flow regulation and waste 
pump operation. 
A) B) 
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Figure 2. 6: A schematic diagram to show the organisation of the bioreactor devices used 
for 3D-culture. The three interwoven, independent capillary systems are shown: Red and blue 
capillaries show the counter current flow of culture media  and yellow capillaries serve to 
provide oxygen supply to the cells in the extra-capillary spaces. Cells are inoculated via a 
separate tubing system leading directly into the extra-capillary space (grey) 
2.11.2 Running of bioreactor 
Each bioreactor was integrated into a processor-controlled perfusion device 
with electronic pressure, media flow regulation and waste pump operation 
(figure 2.5). The perfusion systems contain modular pump units for recirculation 
and fresh media feed, with multichannel flow heads to allow constant pH levels 
to be maintained (between 7.3 and 7.6) and allow the rates of compressed air 
and CO2 to be regulated. Each bioreactor was run under the same conditions 
with a media flow rate into the bioreactor of 1.5ml/hour with the same amount of 
waste medium leaving the circuit through an outflow valve. Medium was re-
circulated within the bioreactor at a rate of 10ml/hour. A constant temperature of 
37°C was maintained by a heating unit within the perfusion circuit and flow rates 
of air, CO2, O2 and N2 were all regulated by a gas mixing unit at a rate of 
100ml/min consisting of 95% air and 5% CO2 by volume. Daily measurements 
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of pH, pO2, pCO2, and buffer capacity were used to adjust medium perfusion 
and gas supply rates. Each bioreactor was maintained in the perfusion system 
for either 8 or 15 days before being shut down for analysis.  
 
 
 
 
Table 2. 3: Specifications of the bioreactors and running conditions used for 3D culture 
of B-13 cells 
2.11.3 Inoculation of B-13 cells 
Once the bioreactors had been conditioned for 24 hours with re-circulating 
culture medium DMEM (Sigma D5546) 4500mg/L glucose, supplemented with 
2.5% (v/v) FCS ,80U L-glutamine, 80U/ml of penicillin and 10µM 
dexamethasone. B-13 or B-13/H cells were inoculated into the bioreactors (40-
100 million B-13 cells in 1.5ml media, or 50million B-13/H cells in 1.5ml of 
media) through the inoculation tubing system.  After inoculation the bioreactors 
were shaken to evenly distribute cells and to remove excess gas from the cell 
compartment. Cells were also cultured in 2D systems, as outlined in 2.2.2, in 
parallel for a direct comparison to 3D culture.  
2.11.4 Assessment of CYP450 activity and other parameters 
Samples from the perfused medium were taken daily from each bioreactor for 
biochemical analysis. The metabolic activity of the cells was determined by 
measuring a number of parameters including glucose consumption and lactate 
production. Other parameters were also measured such as urea secretion, 
galactose uptake, and release of lactic acid dehydrogenase (LDH), glutamate 
dehydrogenase (GLDH), alanine transaminase (ALT) and aspartate amino-
tranferase (AST). All parameters measured were also assessed in the parallel 
Parameter Condition 
Bioreactor Jellyfish, 2mL 
System volume 20mL 
Feed media speed 1.5mL/h 
Recirculation speed 10mL/h 
Gas mix 20mL/min, 5% CO2 
Serum supplementation 2.5% 
Cells B-13, (40-100 million cells) 
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2D cultures. All evaluations were performed with assays adapted for using an 
automated clinical analyser.  
 
During the pilot experiments drug metabolising activity of cells in culture was 
determined through the addition of phenacetin, diclofenac (both from Sigma-
Aldrich, St. Louis, MO), buproprion (Toronto Research Chemicals, North York, 
Canada) and midazolam (Roche, Mannheim, Germany) as a cocktail with final 
concentrations in the medium of 26µM, 9µM, 100µM and 3µM respectively for 
both bioreactor and 2D cultures (see table 2.4). Samples of media were taken 
at 1 and 3 hours after addition of substrates and frozen at -80°C until analysis. 
The concentrations of metabolites were analysed at Pharmacelsus GmbH, 
Saarbrücken, Germany, as previously described[193]. The formation rate of 
metabolites was calculated from the slope of the regression line of the 
concentration-time curve[193].A summary of the drugs and their metabolites can 
be seen in tables 2.4 and 2.5 and the metabolism pathways are shown in figure 
2.7. 
 
On days 1, 8 and 15 of the bioreactor runs CYP450 activity assays were also 
performed for each bioreactor and their 2D culture equivalents. Assays for 7-
ethoxyresorufin O-deethylase (EROD) and 7-ethoxycoumarin O-deethylase 
(ECOD) were carried out by culturing the cells with 20µM of the relevant 
CYP450 substrate. During the running of the CYP450 assays the culture media 
for the 2D cultures was replaced with CYP450 media whereas the bioreactors 
were switched into recirculation mode before 1ml of media was replaced with 
1ml of CYP450 media (to give final concentration of 20µM of ethoxyresorufin or 
ethoxycoumarin) at time point 0 hours. Samples were taken from the cultures 
every 30 minutes for 2 hours after which the bioreactor system was washed 
through with 40-60ml of media and returned into normal mode (feed and waste). 
The 2D cultures were washed twice before fresh media was added. The cells 
were left for 2 hours before the second CYP450 assay (ECOD) was carried out.  
For analysis standard concentrations of the EROD and ECOD products; 
hydroxyresorufin/dydroxycoumarin, respectively were prepared to create a 
standard curve for comparison and measured along with the samples in a black 
96-well plate in duplicate. Measurements were made using a FLUOstar reader 
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(OPTIMA, MBG LABTECH). Two measurements were taken for each assay, 
first was for the free product which was measure directly from the media 
samples taken during the assay run. The second was for the absolute product 
produced by phase II reactions representing the total CYP450 activity within the 
cell cultures. For absolute product measurement 150µl of the sample or 
standard was mixed with 150 µl Na-Acetate buffer (1M, pH 5.5) + 20 µl of the 
enzyme, beta-glucuronidase/arysulfatase, (Roche 10127698001-10 ml), 
samples were then incubated at 37°C overnight before readings were taken.  
  
 
Table 2. 4: A summary of the substrates and their concentrations used for assessment of 
CYP450 activity in bioreactor cultured B-13 cells and their 2D parallels. 
Table 2. 5: A summary of the drugs, their products and the CYP450 enzymes involved for 
the CYP450 assays to test liver functionality in bioreactor 176 metabolism studies.  
 
 
  
Substrate         Concentration of 
stock solution 
 
 
Final concentration 
in culture vessel 
Phenacetin  10mM  26µM 
Bupropion  10mM  100µM 
Diclofenac                         5mM  9µM 
Midazolam                         3mM     3µM 
Substrate        Product  CYP450 
human/rat 
Phenacetin Acetaminophen  CYP1A2 
Bupropion Hydroxybupropion  CYP2B6/1 
Dicofenac 4-Hydroxydiclofenac  CYP2C9/11 
Midazolam 1’-Hydorxymidazolam          CYP3A4/2 
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Figure 2. 7: Images to show the metabolism pathways for the drugs Phenacetin
[194]
, Bupropion
[195]
, Diclofenac
[196]
 and Midazolam
[197] 
which were used in 
metabolism assays during the  pilot bioreactor run. Images are adapted from the cited references. 
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2.11.5 Opening of Bioreactor 
After running of the bioreactors was complete, the devices were shut down and 
all tubing was disconnected. The cell compartment was accessed by drilling 
through the upper covering of the bioreactor and lifting off carefully so as to 
minimise disturbance to the cells. The cell mass (including the capillary layers) 
was cut from the cell chamber whilst being held together to maintain cell 
organisation. Samples were fixed in 10% formalin for 24 hours before 
processing and staining as described in section 2.9. Samples for protein and 
RNA analysis were also collected from the opened bioreactor and stored at -
80°C until needed. 
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3.1 Investigating the effects of B-13 and activated HSC (myofibroblast) 
cocultures on the transdifferentiation towards the B-13/H phenotype 
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The establishment of a hepatocyte-like cell from stem cell sources has been 
successfully carried out by a number of groups with a range of approaches[85]. 
The B-13 cell and the transdifferentiation into the B-13/H cell phenotype 
requires very simples culture methods where the addition of DEX to the culture 
media results in hepatocyte-like morphology and functionality within as little as 7 
days. As the transdifferentiation of B-13 to B-13/H cells is relatively simple other 
methods commonly used to enhance stem cell differentiation into hepatocyte-
like cells have never been assessed. Approaches such as feeder layers, 
cocultures and 3D culture in bioreactor systems are routinely used to promote 
hepatocyte maintenance and stem cell differentiation. Studies have shown that 
primary hepatocytes are able to survive for longer periods and maintain specific 
functions when they are cocultured with other cell types, such as the non-
parenchymal liver cells[198, 199]. The cell-cell interactions between resident cells 
of the liver may therefore be essential in maintaining and supporting 
hepatocytes. The role of hepatic stellate cells (HSCs) in liver regeneration is 
much debated, depletion of this cell population leads to a slower recovery[200]  
suggesting they play an essential role in liver regeneration, however more 
recently HSCs were reported to act as negative regulators of hepatocyte 
regeneration[201]. Furthermore HSCs have been associated with the hepatic 
progenitor cell niche where their synthesis of ECM has been suggested to 
facilitate in the appropriate expansion and specification of the cells[202] alongside 
liver macrophage cells. Boulter et al[203] have shown close associations between 
macrophages, HSCs and HPCs during liver injury where the HSCs were 
capable of influencing the progenitor cell response. The cross-talks between the 
liver cell types may therefore have important roles for modulating cell growth, 
migration, differentiation and proliferation. 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
As much attention has focused on the role of HSCs for the enhancement of 
hepatocyte survival and functions[204] they prove a good model for assessing the 
effects of cocultures with B-13 cells. As activated HSCs (myofibroblasts) have 
been shown to have important functions both in liver regeneration and as 
support cells within the liver stem cell niche, activated HSCs may be able to 
interact and promote the transdifferentiation of B-13 cells.  Thus the effect on B-
13 transdifferentiation in the presence of myofibroblast cells was assessed to 
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elucidate whether cocultures can enhance the hepatic phenotype of B-13/H 
cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3: Results 3.1 
84 
 
3.1.1 Generation of the B-13red cell line 
To allow tracking of both B-13 cells, and myofibroblasts in coculture, 
myofibroblasts were isolated from Tg(GFP) mice and B-13 cells were stably 
transfected with a construct, pDsRed2-C1 (Clontech) that encodes the 
constitutive expression of a red fluorescent protein, to generate the B-13red cell 
line (figure 2.1). Before transfecting B-13 cells with the DsRed vector the ideal 
concentration of the antibiotic, G418, needed for selection was determined.  B-
13 cells were grown with a range of G418 concentrations before cell viability 
was determined, figure 3.1.1 shows the ideal concentration was found to be 
250μ/ml as cells started dying after 5 days in this condition, a time point at 
which G418 has been shown to be effective previously[205].  To generate the B-
13red cell line, B-13 cells were transfected with the DsRed vector, using 
effectene, for 48 hours and subsequently treated with G418 for selection. 
Confirmation of successful transfection was shown by B-13red cells fluorescing 
red under the tetramethyl rhodamine iso-thiocyanate (TRITC) wavelength (541-
572nm), a varying level of red fluorescence was observed within the population 
of cells since a mixed clone, rather than a single clone of the cell line was 
produced.   
 
Before coculture experiments were performed it was necessary to ensure 
transfection with the DsRed construct had not altered the B-13 response to 
DEX, thus B-13red cells were treated with DEX for 14 days. Figure 3.1.2 shows 
that the B-13red cells showed a typical morphological change in response to 
DEX treatment and upon transdifferentiation, DsRed expression was still 
detectable although the fluorescence was present at a greater degree in the 
cytoplasm in the B-13/Hred cells when compared to B-13red cells. As DsRed is 
still detectable within B-13/Hred cells after transdifferentiation, the B-13red cells 
could be cocultured with liver myofibroblasts derived from GFP mice allowing 
both cell lineages to be easily traced. 
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Figure 3.1 1: The effect of various G418 disulphate concentrations on B-13 cell viability. 
Cell viability of B-13 cells was assessed over 192 hours to find an effective concentration for 
selection after transfection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 2: The expression of red fluorescent protein in the B-13
red
 cell line. Cells are 
treated with and without DEX treatment, with B-13 cells as controls.  
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Figure 3.1.3 shows that B-13red cells also retained their ability to differentiate 
into functional hepatocyte-like cells in response to DEX treatment at the level of 
mRNA and protein. As a direct comparison, non transfected B-13 cells were 
DEX treated in parallel to B-13red cells and RT-PCR and Western blotting results 
showed similar levels of hepatocyte-specific gene expression from both cell 
populations. These data indicate that the presence of the DsRed construct 
within the cell line does not impair their ability to become functional B-13/H red 
cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 3: RT-PCR and Western blot analysis for the expression of liver specific 
markers in B-13
red
 with or without DEX treatment. A) RT-PCR analysis comparing the 
expression of liver specific markers CYP2E1, CPS-1 and albumin at the mRNA level in B-13 
and B-13
red 
cells. Results shown are typical of three separate experiments. B) Western blot 
analysis comparing the expression of liver specific markers CYP2E1, CPS-1 and albumin at the 
protein level in B-13 and B-13
red 
cells. Results shown are typical of three separate experiments. 
  
The ability of B-13red to B-13/H red cells to transdifferentiate in response to DEX 
was also confirmed by immunocytochemistry. After transdifferentiation towards 
hepatocyte-like cells the expression of the liver-specific markers albumin and 
CYP2E1 were detectable in B-13/Hred cells compared to undetectable levels in 
B-13red cells (figure 3.1.4). B-13/Hred cells also retained a degree of pancreatic 
marker amylase expression, however it was observed at much higher levels in 
the B-13red cells.  
 
A) B) 
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Figure 3.1 4: The expression of the pancreatic marker amylase and liver markers albumin 
and CYP2E1 in B-13
red
 and B-13/H
red
 cells shown by immunocytochemistry. 
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3.1.2 Coculture of B-13red cells with myofibroblasts 
Once it had been established that B-13red cells were still able to 
transdifferentiate in response to DEX treatment, coculture experiments were set 
up in order to determine if activated HSCs (myofibroblasts) derived from GFP 
mice modulate the transdifferentiation response of B-13 cells to DEX. After 7 
days of coculture the number of hepatocyte-like cells was counted in each 
treatment. When treated with DEX, B-13red cells alone showed signs of 
transdifferentiation towards the hepatocyte-like cells at a normal rate, however 
in the presence of myofibroblasts the transdifferentiation of B-13red cells was 
greatly enhanced with around 95% of cells showing B-13/Hred phenotype after 
only 7 days. Thus the number of hepatocyte-like cells per random field of view 
after 7 days of DEX treatment was significantly higher in coculture than B-13red  
cells alone (figure 3.1.5) suggesting that the presence of myofibroblasts may 
promote the transdifferentiation towards the B-13/H phenotype.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 5: The average number of hepatocyte-like cells per random field of view  
comparing B-13
red
 cells alone, activated HSCs (myofibroblasts) alone or cocultures with 
or without DEX treatment for 7 days. Data are expressed as mean of hepatocyte-like cells 
observed± SD ***P<0.001, and are typical of three separate experiments 
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Haematoxylin and eosin (H&E) staining was performed to assess the cell 
morphologies and cell-cell interactions that may have formed between the 
different cell populations in culture. Figure 3.1.6 shows that DEX treatment on 
stellate cells alone had no effect, as with or without DEX treatments looked 
similar. After 7 days of DEX treatment for the B-13red cells, a few hepatocyte-like 
cells could be observed however the majority of cells still displayed a B-13 
phenotype similar to the non-DEX treated control. In coculture conditions with 
no DEX treatment both cell types appeared to show normal morphology. In 
coculture conditions treated with DEX a significant proportion of B-13 cells 
showed evidence of transdifferentiation displaying B-13/H morphologies. This 
observation supports findings of the cell counts where coculture with DEX was 
shown to enhance the transdifferentiation rate. Interestingly the myofibroblast 
cell population from cultures in the presence of B-13/H cells was lower whereas 
myofibroblast cultures without B-13/H cells were confluent. As the myofibroblast 
cells alone with DEX and the cocultures without DEX were found to be healthy 
this observation must be due to the presence of B-13/H cells after promoting 
their transdifferentiation.   
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 6: Haematoxylin and eosin (H&E) staining of B-13
red
, activated HSCs 
(myofibroblasts) and cocultures after 7 days of culture with or without DEX.  
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The cell cultures were stained with DAPI and imaged under the GFP and 
DsRed wavelengths to show the two individual cell populations and to ascertain 
whether any cell fusion had taken place. Using fluorescence to view the two cell 
populations it was observed that no cell fusion had taken place where only 
DsRed positive cells appeared as hepatocyte-like cells and only GFP positive 
cells showed a fibroblastic morphology (figure 3.1.7). Although through H&E 
staining the stellate population appeared to be depleted in cocultures treated 
with DEX the fluorescent images clearly show that the stellate population is not 
completely lost. 
 
The observations were further confirmed by examining the mRNA and protein 
levels by RT-PCR and Western blotting respectively (figure 3.1.8).  Both RT-
PCR and Western blotting showed that the expression of liver markers including 
CYP2E1, CPS-1 and albumin were detectable in cocultures treated with DEX 
after just 7 days, however no liver-specific genes were detected in the B-13red 
cells treated with DEX after this culture time. The levels of liver markers within 
the cocultures were comparable to control B-13/H cells that had been DEX 
treated for the standard 14 days, thus this shows that the coculture of B-13red 
cells with myofibroblasts is able to promote the transdifferentiation of the cell 
line towards the hepatic phenotype. There were no differences observed when 
comparing myofibroblast cells cultured alone with or without DEX treatment. 
Although the presence of myofibroblasts promotes transdifferentiation, the 
process is still DEX dependent as the coculture with no DEX treatment shows 
no liver marker gene expression and no change in B-13 cell morphology.   
 
Furthermore the myofibroblast cell markers vimentin and alpha smooth muscle 
actin (α-sma) were shown to decrease in the cocultures treated with DEX, 
supporting the observations made from H&E staining. Myofibroblast depletion 
has been shown to not be dependent on DEX or B-13 cells as myofibroblast 
cells are present in both conditions and with B-13 cells before the 
transdifferentiation event, thus the presence of B-13/H cells within the coculture 
is most likely to be the cause for the myofibroblast cell depletion. 
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Figure 3.1 7:  Cultures of B-13
red
 activated HSCs (myofibroblasts) and cocultures with or 
without DEX treatment for 7 days. Cells were DAPI stained to show cell nuclei before being 
viewed under GFP and DsRed wavelengths to show the individual cell populations and any cell-
cell interactions.  
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Figure 3.1 8:  RT-PCR and Western blot analysis for the expression of liver specific 
markers in coculture experiments with or without DEX after 7 days. A) RT-PCR analysis 
comparing the expression of liver specific markers CYP2E1, CPS-1 and albumin and 
myofibroblast markers ɑ-sma and vimentin, at the mRNA level in coculture experiments. Results 
shown are typical of three separate experiments. B) Western blot analysis comparing the 
expression of liver specific markers CYP2E1, CPS-1 and albumin and myofibroblast markers ɑ-
sma and vimentin at the protein level in coculture. Results shown are typical of three separate 
experiments. 
 
 
 
 
 
 
 
 
 
 
A) B) 
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3.1.3 Affects of coculture on Wnt signalling in B-13 cells 
It has previously been shown that the transdifferentiation of B-13 cells towards 
the B-13/H phenotype is dependent on the transient repression of canonical 
Wnt signalling[167]. Thus the activity of Wnt signalling in B-13 cells in different 
coculture conditions was assessed to see whether the presence of 
myofibrobalsts had any effect on B-13 Wnt signalling activity.  
B-13 cells were plated out and transfected with either the T cell factor reporter 
plasmid (TOPFLASH) or the control plasmid (FLOPFLASH). The transfections 
were left for 24 hours before coculture conditions were set up by the addition of 
myofibroblasts and DEX treatments to the relevant cultures. The firefly 
luciferase and thus Wnt signalling activities of each condition was measured at 
both 24 hours and 48 hours after DEX treatment in triplicate and values were 
normalised to the renilla luciferase control (figure 3.1.9). Results confirmed that 
in the presence of DEX there is a repression of Wnt signalling activity compared 
to the normal high activity observed in B-13 cell cultures. Interestingly in the 
presence of myofibroblasts the Wnt signalling activity in B-13 cells was also 
reduced and this effect was independent of DEX. Both coculture conditions 
showed a loss in Wnt activity, although with the addition of DEX, Wnt signalling 
appeared to be even further repressed. This suggests that myofibroblasts are 
able to repress Wnt signalling in B-13 cells although the presence of DEX may 
still be required to drive the transdifferentiation as no evidence of B-13/H cells 
was found in the coculture conditions with no DEX.  
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Figure 3.1 9: Wnt signalling activity in B-13 cells cultured with or without myofibroblasts 
after 24 or 48 hours of DEX treatment. Wnt signalling activity was determined by transfection 
with the Wnt signalling reporter TOPFLASH construct (or control FOPFLASH) and co-
transfection with RL-TK as described in methods 2.3.3. Data is typical of four separate 
experiments 
 
 
 
 
 
 
.  
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3.1.4 Identifying factors influencing enhanced transdifferentiation in 
coculture experiments 
To identify whether myofibroblast cells are releasing soluble factors during 
cocultures that are causing the promoted rate of transdifferentiation seen, 
coculture experiments were repeated but B-13 cells were also cultured with 
myofibroblast conditioned media with or without DEX.  The cells were treated 
with conditioned media for 7 days, as in previous experiments before hepatic 
markers were analysed at the protein level by Western blotting.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 10. The effects of myofibroblast conditioned media on the rate of B-13 
transdifferentiation. Western blot analysis comparing the expression of liver specific markers 
CYP2E1, CPS-1 and albumin, the pancreatic marker amylase and myofibroblast markers ɑ-sma 
and vimentin at the protein level in coculture and myofibroblast conditioned media. Conditioned 
media was shown to have no effect on the rate of B-13 transdifferentiation after 7 days culture. 
Results shown are typical of three separate experiments. 
 
Protein expression showed that myofibroblast conditioned media had no effect 
on the rate of B-13 transdifferentiation compared to cocultures (figure 3.1.10). 
This suggests that direct cell-cell contacts may be involved in promoting the 
hepatic phenotype of B-13 cells rather than a soluble factor being released. 
These observations were further supported by counting the number hepatocyte-
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like cells in each condition (figure 3.1.11). In conditioned media treated B-13 
cells the number of hepatocyte like cells observed was similar to the control B-
13 cells with DEX, in contrast to the high number of hepatocyte-like cells 
observed in cocultures treated with DEX. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 11: The average number of hepatocyte-like cells per random field of view  
comparing B-13
red
 cells alone, B-13
red
 cells treated with myofibroblast conditioned media 
or cocultures, with or without DEX treatment for 7 days. Data are expressed as mean of 
hepatocytes-like cells observed± SD ***P<0.001, and are typical of three separate experiments.  
 
To assess whether direct cell-cell contacts between the myofibroblasts and B-
13 cells is required to enhance the rate of B-13 transdifferentiation observed in 
coculture experiments, B-13 cells were cultured with membrane fractions from 
dead myofibroblasts. Membrane fractions were created by treating stellate cells 
with gliotoxin (1.5 µmol/L[71]) for 48 hours before a viability test, using trypan 
blue, was carried out to confirm cell death and the cell fractions were pelleted 
and resuspended in fresh cell media. As in all coculture experiments, B-13s 
were cultured with the membrane fractions for 7 days with or without DEX 
alongside coculture and B-13 cell controls.  Analysis of the mRNA and protein 
expression by RT-PCR and Western blotting respectively showed that culture of 
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the B-13 cells with myofibroblast cell membrane fragments and DEX treatment 
was able to promote the rate of transdifferentiation to levels comparable to the 
cocultures (figure 3.1.12). The expression of liver-specific markers such as 
CYP2E1, CPS-1 and albumin were detectable within B-13 cells treated with 
DEX and membrane fragments compared to B-13 cells treated with DEX alone 
for 14 days. These observations were also found at the protein level for CPS-1 
although no evidence for CYP2E1 was found. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 12: RT-PCR and Western blot analysis for the expression of liver specific 
markers in coculture experiments with dead myofibroblasts with or without 10µM DEX for 
7 days. A) RT-PCR analysis comparing the expression of liver specific markers albumin, 
CYP2E1, and CPS-1, at the mRNA level in cocultures of B-13 cells and dead myofibroblasts. 
Results shown are typical of three separate experiments. B) Western blot analysis comparing 
the expression of liver specific markers CYP2E1 and CPS-1 at the protein level in cocultures of 
B-13 cells with dead myofibroblasts. Results shown are typical of three separate experiments. 
B) 
A) 
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Cell counts were performed for cultures with myofibroblast cell membrane 
fragments compared to cocultures and B-13 cells alone. The findings supported 
results from the RT-PCR and Western blot results with high numbers of B-13/H 
cells observed compared to the numbers observed in B-13 cells alone treated 
with DEX (figure 3.1.13). These observations suggest that a myofibroblast 
membrane bound signal is likely to be the cause of the enhanced rate of 
transdifferentiation observed as the presence of membrane fragments is 
sufficient to promote transdifferentiation.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 13: The average number of hepatocyte like cells per random field of view  
comparing B-13
red
 cells alone, B-13
red
 cells with dead myofibroblasts or cocultures with 
or without DEX treatment for 7 days. Data are expressed as mean of hepatocyte-like cells 
observed± SD ***P<0.001, and are typical of three separate experiments. 
 
Figure 3.1.14 shows DAB staining for the pancreatic marker amylase and the 
liver marker CYP2E1 performed on cultures comparing the effects of B-13s 
alone, with myofibroblasts or with myofibroblast cell membrane fractions.  
Amylase staining was found to be positive in all B-13 cells however to a lesser 
degree after DEX treatment showing that a loss of some pancreatic function 
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had occurred. CYP2E1 expression was found in a small number of B-13 cells 
treated with DEX alone however in the presence of myofibroblasts (dead or 
alive) the number of CYP2E1 positive cells was much greater which supports 
data previously shown. Therefore a membrane bound factor present on 
myofibroblast cells is able to directly influence the rate of transdifferentiation of 
B-13 cells into B-13/H cells in the presence of DEX. 
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Figure 3.1 14: The expression of amylase and CYP2E1 in B-13 cells after cocultures 
shown by immunohistochemistry.  Images show B-13 cells, and B-13 cells cultured with 
myofibroblast cells or myofibroblast cell membrane fragments with or without 10µM DEX 
treatment for 7 days. Pictures are typical of three separate experiments. 
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3.1.5 Chapter discussion 
Data within this chapter has shown that in the presence of myofibroblasts the 
rate of DEX dependent transdifferentiation is enhanced such that the hepatic 
phenotype is observed in B-13 cells more rapidly compared to B-13s treated 
with DEX alone.  
 
One simple explanation for the enhanced rate of transdifferentiation in the 
presence of myofibroblasts may be due to the scaffolding or matrix provided by 
the fibroblastic cells. Effective scaffolds, from either cellular or synthetic 
biomaterials, have been used successfully to promote liver functions of 
hepatocytes in vitro, and so this observation could be used to explain the 
enhanced hepatic differentiation of B-13 cells compared to their normal culture 
conditions on plastic. During liver regeneration the HSC population has been 
shown to be necessary for the HPC response; the HPCs are thought to reside 
within a niche in the liver where macrophages and HSCs act as companion 
cells; activated HSCs have been shown to be key to the niche structure by the 
production of a rich ECM[206]. Observations have shown that the macrophages 
are responsible for the secretion of MMPs which results in the breakdown of the 
ECM and initiates the HPC response after injury. The importance of HSCs in 
liver regeneration has been further verified in vivo as their depletion led to a 
slowed or impaired regeneration[68]. In coculture studies between HSCs and 
hepatocyte-like stem cells it has been shown that an increase of both cell 
proliferation and cell maturation was observed[204] however it was not found 
whether these results were through direct cell contacts or via soluble factors in 
the medium. Together with the evidence from B-13 cocultures and cocultures 
from other groups it has been shown that the hepatic differentiation is enhanced 
by the presence of HSCs via a mutual synergism with the non parenchymal 
cells of the liver. Hepatocyte-like cells in the coculture might adhere firmly to the 
extracellular matrix, such as collagens, which are synthesized by activated 
HSCs[200]. 
 
To further understand the mechanisms involved in the coculture experiments it 
was necessary to clarify whether the myofibroblast-dependent promotion of B-
13 transdifferentiation observed was due to a soluble factor within the media or 
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a result of direct cell contacts. Observations using both dead myofibroblast 
fragments and myofibroblast conditioned media suggest that the promotion of 
B-13 transdifferentiation is most likely due to direct cell contacts rather than a 
soluble factor being secreted by myofibroblasts as conditioned media from 
myofibroblasts had no effect on the rate of B-13 transdifferentiation.  Findings 
from other studies have shown that soluble factors secreted from the HSCs 
were responsible for the maintenance of hepatocyte-like stem cells and that 
direct cell cocultures had less success[204]. Another group concluded that direct 
contact between hepatocytes and HSCs may play a negative role in the 
maintenance of hepatic differentiated functions but a positive role in cell 
proliferation, where increased DNA synthesis in hepatocytes was found[102]. 
From my observations it is most likely that direct cell contacts are necessary for 
the enhanced rate of transdifferentiation towards a hepatocyte phenotype. 
However once transdifferentiation had taken place the myofibroblast population 
became depleted suggesting that they may promote the hepatic phenotype in 
the B-13 cells but do not play a role in the maintenance of the functionality. It 
would therefore be interesting to investigate the coculture between B-13/H cells 
and myofibroblasts to elucidate whether myofibroblast cells are able to maintain 
the B-13/H cells for longer periods in culture and whether direct cell contacts or 
soluble factors play a role as seen by other in hepatocyte cocultures.  
 
The depletion of myofibroblasts observed once B-13 cells had 
transdifferentiated towards a B-13/H phenotype is interesting, as if this 
phenomenon occurs in vivo during regeneration, then the presence of new 
hepatocytes may lead to activated stellate cell death and thus aid in the reversal 
of the disease phenotype. The progressive death of myofibroblasts in cocultures 
was also observed by Carraro et al[102], where after 7 days of cocultures with 
hepatocyte-like cells, the HSC population viability declined . From these studies 
is was concluded that HSCs initially are able to modulate the differentiation of 
human liver stem cells (HLSCs) before HSC cell death occurs and they are no 
longer able to support the hepatocyte cells. These observations could provide 
insights into the regeneration and disease reversal process as stellate cells 
could play an essential role in stimulating hepatocyte proliferation, or hepatic 
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progenitor cell differentiation, before they themselves are programmed for death 
to reduce the disease phenotype.  
 
Wnt signalling is an essential pathway during liver development and 
specification and in addition to its role in liver development, the Wnt signalling 
pathway has been shown to be a key player in many aspects of postnatal liver 
homeostasis. It was reported that hepatocyte-specific knockout of β-catenin 
resulted in a decreased liver size and reduced hepatocyte proliferation[176, 207] 
and complementary studies have shown the opposite effects when β-catenin is 
over expressed[208]. As the transdifferentiation of B-13 cells towards a hepatic 
phenotype has been shown to be dependent on a transient repression of Wnt 
signalling the levels of Wnt activity in B-13 cells from the cocultures was 
assessed. The level of Wnt activity was found to be lower in both coculture 
conditions independent of DEX when compared to B-13s alone however only 
transdifferentiation was evident in the conditions with DEX treatment. These 
data suggest that transdifferentiation is DEX dependent, however as the 
experiments were only cultured for 7 days it would be interesting to see whether 
a repression in Wnt signalling alone through coculture could result in B-13/H 
cells after a longer culture time.  Several Wnt ligands have been found to be 
expressed by various liver cells[172] suggesting a high degree of potential for 
crosstalk between different cells of the liver. In a study by Boulter et al[203] the 
notch and Wnt signalling pathways were found to be implicated in lineage 
specification of cholangiocytes and hepatocytes respectively. It was found that 
interactions with activated stellate cells was shown to promote cholangiocyte 
specification through notch signalling and hepatocyte regeneration was shown 
to be dependent on an induction of Wnt signalling after macrophage engulfment 
of hepatocytes. Although it has been shown during regeneration, that liver Wnt 
signalling is required for hepatocyte specification; the opposite is required to 
induce a hepatic phenotype in B-13 cells. This difference may be due to the 
pancreatic origin of the B-13 cells where a repression of Wnt signalling is 
required to leave the pancreatic phenotype before it is restored to a high level in 
the B-13/H cells, and thus direct comparisons between HPCs and B-13 cells 
cannot be made. 
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The data presented in this chapter has shown a role of activated HSCs in 
promoting the hepatic phenotype of progenitor cells in vitro and they may be a 
good cell source for enhancing hepatic progenitor cell differentiation. Although 
the mechanisms by which the rate of transdifferentiation is enhanced are not 
completely understood it is evident that direct cell-cell contacts between the two 
cell populations is necessary. A repression of Wnt signalling was shown to 
occur in the presence of myofibroblasts independent of DEX treatment however 
as the rate of transdifferentiation was only enhanced in the presence of DEX 
then the mechanism cannot be solely explained through a repression of Wnt 
signalling and a crosstalk between multiple pathways is more likely.  
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3.2 Investigations into cytogenetics and tumour-like behaviour of B-13 
cells 
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The transdifferentiation events leading from the B-13 phenotype towards the B-
13/H phenotype have been extensively studied in vitro where mechanisms such 
as the Wnt signalling pathway have been shown to play key roles in the 
process[167]. However, little is understood about the potential for B-13 
transdifferentiation in vivo and what causes the cells to behave in the unique 
way that they do. Before investigations can be carried out in vivo, the 
cytogenetics and tumour forming potential of the cell line was assessed to 
establish whether any genetic abnormalities could be identified to explain the B-
13 characteristics and to see whether there is a likelihood of tumour initiation if 
they are to be injected in vivo. 
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3.2.1 Cytogenetic analysis of B-13 cells 
Cytogenetic analysis of the B-13 chromosomes was carried out alongside rat 
myofibroblasts and HepG2 cells for normal diploid rat cells and transformed cell 
controls respectively. A number of metaphase spreads were analysed for each 
cell type. This analysis was performed to see if any genetic abnormalities such 
as chromosomal gains/ losses could be observed which may explain the unique 
character of the cell line. Figure 3.2.1 shows a typical metaphase spread from 
the B-13 cells after Giesma banding (G-banding). It is evident that the B-13 cells 
do not possess a normal rat diploid chromosome count of 42 but instead appear 
near tetraploid with the majority of metaphase spreads analysed containing 84 
chromosomes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 1:  A typical G-banded metaphase spread of B-13 chromosomes. Magnification 
x100.  
 
As expected the control rat myofibroblasts showed a diploid chromosome 
number of 42 in the majority of metaphase spreads analysed. The HepG2 cell 
line had an abnormal number of chromosomes, with a significant variation 
between different cells, with each cell showing highly inconsistent karyotypes.  
Figure 3.2.2 shows examples of G-banded metaphase spreads from each of the 
3 cell types analysed and a summary of the results can be seen in table 3.2.1. 
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Figure 3.2 2: Metaphase spreads from B-13 cells, rat myofibroblasts and the human 
HepG2 cell line. B-13 cells show a near tetraploid (84) chromosome number whereas the rat 
myofibroblasts show the rat diploid chromosome number of 42. The HepG2 cell line shows a 
variable chromosome number ranging from 68-83.  
 
Table 3.2 1: The average number of chromosomes per metaphase spread analysed from 
each cell type. 17 spreads were analysed for B-13 cells, 11 for rat myofibroblasts and 13 
spreads for HepG2 cells. 
 
Once metaphase spreads had been G-banded, the chromosomes from the B-
13 cells were sorted for karyotyping. Figure 3.2.3 shows a typical B-13 cell 
karyotype, illustrating its tetraploid karyotype of 84 chromosomes. It is evident 
that a number of structural abnormalities within some of the chromosomes were 
found resulting in G-banding that prevented identification in confidence, and so 
Cell type Spreads 
analysed 
Number of 
chromosomes 
(observed/cell-
mean±SD) 
Range 
(chromosomes/
cell min-max) 
Mode 
(chromosomes/
cell) 
Number of 
chromosomes/
cell 
B-13 17 82.4±1.73 79-84 84 84 
Myofibroblasts 11 41.6±0.67 40-42 42 42 
HepG2 13 75.9±6.07 68-83 80 Variable 
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the identities of some chromosomes was ambiguous and were termed marker 
chromosomes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 3:  A typical G-banded karyotype of the B-13 cells. The karyogram shows a 
tetraploid karyotype with 8 marker chromosomes that could not be identified/placed. 
 
Karyotyping clearly suggests that the B-13 cell line is derived from a male rat. 
To test this, the presence of the Y chromosome in the B-13 cell line was 
confirmed by PCR using male and female rat DNA as controls. PCR results 
verified the findings of the cytogenetic analysis (figure 3.2.4) 
 
 
 
 
 
 
 
 
 
Figure 3.2 4: PCR for the sex chromosomes in B-13 cells. The presence of the Y 
chromosome detected in cytogenetic analysis was confirmed. Male and female rats were used 
as positive controls. Data typical of three separate experiments.  
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Table 3.2 2: Summary of the B-13 cell karyotype. 
 
 
 
 
 
 
 
 
 
Chromosome 
number 
Copies 
positively 
identified/cell 
Abnormalities Unidentified 
(therefore presumed 
marker 
chromosome) 
Comments 
1 4 n/d   
2 3  1 1 chromosome 
appears to have 
fragile site at 2q14 
3 4 n/d   
4 4 n/d   
5 4 n/d   
6 4 n/d   
7 4 n/d   
8 2 n/d 2  
9 4 n/d   
10 3 n/d 1  
11 4 n/d   
12 4 n/d   
13 4 n/d   
14 2 n/d 2  
15 2 n/d 2  
16 3 n/d 1 Marker 2? 
17 4 n/d   
18 4 n/d   
19 4   All copies appear 
different 
20 4 n/d   
X 
Y 
2 
2 
n/d 
n/d 
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3.2.2 Agar anchorage assay 
As cytogenetic analysis of the B-13 cells revealed some chromosomal 
abnormalities, an agar anchorage assay was performed to investigate whether 
the cell line shows any tumour-like behaviour. The agar anchorage assay is an 
established method to monitor anchorage independent growth and is 
considered the most appropriate in vitro assay to detect the malignant 
transformation of cells[190], where cells able to proliferate independent of 
anchorage to a substratum are likely to initiate tumours in vivo  
 
B-13 cells, rat myofibroblasts and HepG2 cells were all cultured in soft agar 
supplemented with cell media for 14 days, after which the cultures were stained 
with crystal violet to show any colonies formed. Figure 3.2.5 and 3.2.6 show 
examples of the stained 6-well plates and close up images of the cell colonies 
formed respectively. After 14 days of culture, both rat myofibroblast and B-13 
cells failed to proliferate and no cell colonies were observed within any of the 
cultures. The HepG2 cell line showed clear evidence of colony formation 
suggesting that the cell line is independent of anchorage for cell proliferation 
and is likely to give rise to tumours in vivo. As shown in figure 3.2.7 the 
presence of colonies was only observed in HepG2 cultures which suggests that 
they are the only cell tested capable of anchorage independent growth. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 5: Crystal violet staining to show colony formation after culture in agar. An 
agar anchorage assay was carried out on B-13 cells, rat myofibroblasts and HepG2 cells and 
colonies were stained with crystal violet after 14 days. Cell colonies were observed in HepG2 
wells only. Data is typical of three separate experiments.  
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Figure 3.2 6: The presence of cells or cell colonies after growth in soft agar for 14 days. 
B-13 cells and rat myofibroblasts failed to proliferate independent of anchorage and showed no 
colony formation. HepG2 cells showed large colonies throughout the agar. Data is typical of 
three separate experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 7: Colony formation after growth in soft agar. The average number of cell 
colonies observed per random field of view after 14 days culture in soft agar of B-13 cells, rat 
myofibroblasts, HepG2 cells and a no cell control. Data are expressed as mean of colonies 
observed ± SD. ***P<0.001, and are typical of three separate assays. 
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3.2.3 In vivo assessment of tumour forming potential 
To further assess their tumour-like behaviour, B-13 cells were injected 
subcutaneously into non-obese diabetic severe combined immunodeficient 
(NOD-SCID) mice, to investigate whether tumour initiation and/or metastasis  
was possible in vivo. HepG2 cells and PBS were used as positive and negative 
controls respectively. Mice were left for 6 weeks, with regular checks, before 
analysis of tumour formation was carried out. Contrary to the agar anchorage 
assay, the formation of tumours in the B-13 injected mice was observed. 
Tumours were only observed at the site of injection under the skin and no 
evidence of metastasis was found. Through RT-PCR and Western blot analysis 
the tumours were found to be composed of B-13 cells and showed no signs of 
transdifferentiation towards the B-13/H phenotype. Figure 3.2.8 shows that the 
expression of the pancreatic marker amylase was found only in the tumour and 
pancreas of the B-13 injected groups but no other organs. No evidence of 
tumour formation was observed in the PBS control and HepG2 injected mice at 
the time of culling.  
 
Morphological analysis showed that the tumours were tightly packed clusters of 
B-13 cells and had a uniform patterning with no other cell types within the 
tumour. Figure 3.2.9 shows high expression of the pancreatic marker amylase, 
by IHC, confirming the presence of B-13 cells within the tumours, and no 
expression of the liver marker CYP2E1 which suggests no transdifferentiation 
towards B-13/H cells occurred. 
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Figure 3.2 8: RT-PCR and Western blot analysis of the expression for the pancreatic 
marker amylase in organs from NOD-SCID mice injected with B-13 cells, HepG2 cells and 
PBS. A) RT-PCR analysis comparing the expression of amylase at the mRNA level. Results 
shown are typical of three separate experiments. B) Western blot analysis comparing the 
expression of amylase at the protein level in coculture. Results shown are typical of three 
separate experiments. 
B) 
A) 
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Figure 3.2 9: The expression of amylase and CYP2E1 in tumours formed in B-13 injected 
NOD/SCID mice shown by immunohistochemistry. Liver and pancreas sections are used as 
positive controls for CYP2E1 and amylase expression respectively. Pictures are typical of 5 
stained sections.  
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3.2.4 Chapter discussion 
Cytogenetics analysis has demonstrated that the B-13 cell line has a tetraploid 
karyotype. Although an abnormal karyotype has been detected, this 
phenomenon is relatively common in cell lines such as embryonic stem cell 
lines that are propagated for some time and probably reflects the progressive 
adaptation of self-renewing cells to their culture conditions[209]. The karyotypic 
instability of human embryonic stem cells was reported by Draper et al[210] and 
Buzzard et al[211] where they concluded that bulk passaging of cells resulted  not 
only in abnormal karyotypes of cells but also led to quantitative differences in 
gene expression. Chromosomal abnormalities have been observed after as few 
as 23 passages in embryonic stem cells and chromosomal aneuploidy was 
found to be in conjunction with aberrant gene expression[212]. The AR42JB-13 
cell line was isolated in the mid-1990s and has been extensively expanded in 
culture for at least 18 years; in this time the cell line has retained both its 
proliferative capacity and the transdifferentiation response to dexamethasone. It 
is therefore likely that the tetraploid karyotype may be a result of a mis-division 
during its expansion and has not had any detrimental effects to the cells 
character, or alternatively the abnormal karyotype has always been present and 
may give the cells their unique characteristic. One explanation of the abnormal 
karyotypes often observed in embryonic stem cells is that it is a consequence of 
in vitro selection, where hESCs with enhanced proliferative ability, due to 
increased expression of the relevant genes, may out grow other cells[212]. It 
would be of interest to carry out cytogenetic analysis on the parent AR42J cell 
line, from which the B-13 cell line was derived, to clarify whether any karyotypic 
abnormalities can be observed. An understanding of the genetic changes which 
generate the B-13 phenotype may enable a human equivalent to be engineered 
which would have significant utility in basic and clinical science. 
 
Due to the cytogenetic results, tumorigenicity tests were carried out on the B-13 
cell line to assess whether they may give rise to tumours if they are to be used 
for in vivo studies.  The soft agar anchorage assay is a conventional method 
used to monitor anchorage independent growth and is considered the most 
appropriate in vitro assay to detect malignant transformation of cells[190]. B-13 
cells were found to not grow in soft agar which indicates they retain a 
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requirement for anchorage-dependent growth and responsiveness to factors 
which present uncontrolled cell death. However many studies have reported 
that in vitro methods of tumorigenicity testing do not always reliably reflect 
tumour initiation properties in vivo and thus in vivo testing is needed to 
demonstrate the cell behaviour reliably[213]. In vivo studies were therefore 
carried out with B-13 cells to see if tumour initiation could be detected. Tumours 
were formed at the site of inoculation after 4 weeks and appeared to consist of 
B-13 cells only with no signs of transdifferentiation. Analysis of all other tissues 
and organs showed no signs of B-13 metastasis. Due to the origin on the 
AR42J cell line being from pancreatic carcinomas, the ability of the B-13 cell to 
initiate tumours in not surprising. These data are in agreement with many 
findings that there is no direct relationship between anchorage independent 
growth and the ability to initiate tumour growth, thus care should be taken when 
using in vitro tests for tumorigenicity testing. As tumour initiation is strongly 
influenced by both the immune system and the microenvironment, cell growth 
may in part reflect the ability of the cells to interact with the microenvironment in 
which they are placed and thus may be dependent on the site of inoculation.  
The term tumorigenicity can be defined by the capacity of a cell population 
inoculated into an animal model to produce a tumour by proliferation at the site 
of inoculation and/or at a distant site by metastasis[214]. Although B-13s failed to 
grow in soft agar as tumour formation was observed in vivo, a much more 
stringent tumorigenicity test, it can be concluded that B-13 cells are tumorigenic; 
however they are unlikely to metastasise and instead grow at the site of 
inoculation. Although B-13 cells are capable of tumour formation they still are a 
powerful cell model for the study of pancreatic to hepatic transdifferentiation and 
may provide insights that may facilitate in  finding a human equivalent. 
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3.3 Investigations for the in vivo potential of the B-13 cell line as a liver 
progenitor cell 
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Since the first reports of pancreatic to hepatic transdifferentiation of the B-13 
cell line, there has been much work into identifying the mechanisms involved 
and the functionality of the B-13/H cell. Much is now understood about the 
events that lead to the transdifferentiation process including a transient 
repression of the Wnt signalling pathway and an induction of SGK1 after 
glucocorticoid interactions with the glucocorticoid receptor. However the key 
goals for understanding these events are to assist us in identifying a hepatic 
progenitor cell from humans that could be an alternative or bridge to organ 
transplantation. It is therefore of interest to understand how the B-13 cell line 
behaves in vivo and whether it is able to engraft and transdifferentiate within the 
liver environment.  
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3.3.1 Determination of paracetamol and B-13red cell dosage 
Before investigating whether B-13 cells are able to engraft into the liver and are 
able to transdifferentiate in vivo, a pilot study was performed to find optimal 
doses of paracetamol treatment for mice. It has previously been reported that 
the mouse is much more sensitive than the rat to paracetamol[215], and a study 
was carried out to find whether a mild injury dose to the rat (i.e. 20mg/kg (body 
weight)) could still induce liver damage in the mouse. By this method small 
amounts of liver damage could be induced in the mouse without affecting B-13 
cell viability. Two groups of mice, (group 1 female and group 2 male) received 
20mg/kg of paracetamol intraperitoneally (i.p.). Elevated levels of serum alanine 
transaminase (ALT) was observed in both groups 48 hours after paracetamol 
dosing, suggesting low levels of damage had been caused (figure 3.3.1).  H&E 
staining of the liver sections confirmed the serum data by showing low levels of 
liver necrosis in all mice (figure 3.3.2); with inflammation and infiltration of 
macrophage cells observed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 1: Levels of alkaline phosphatase and alanine transaminase in paracetamol 
treated mice.  Serum levels show elevated levels of ALT in both male (Group 1) and female 
(Group 2) mice 48 hours after treatment with 20mg/kg paracetamol. 
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Figure 3.3 2: Morphology of livers from paracetamol treated mice and a non-treated 
control. Haematoxylin and Eosin staining after 20mg/kg paracetamol treatment. Small levels of 
liver necrosis can be observed with signs of inflammation and cell death. Images are typical of 
three mice per group. 
 
As small amounts of damage were observed a pilot study investigating whether 
B-13 cells can engraft to the liver was carried out. The B-13red cell line was 
chosen so that cells could be tracked in vivo using the DsRed transgene. Before 
injection, B-13red cells were visualised using an in vivo imaging system (ivis) to 
determine how many B-13red cells are required for detection both in vitro and in 
vivo. Under the DsRed wavelength as little as 0.1 million B-13red cells could be 
detected in vitro, however the biggest flux output was from 10 million cells as 
expected (figures 3.3.3 and 3.3.4). As B-13 cells are of rat origin, female non-
obese diabetic/ severe combined immuno-deficient (NOD/SCID) mice were 
used to avoid rejection, and so that the Y chromosome of the B-13 cells could 
also be used for tracking, if required.  Three 10-12 week old female NOD/SCID 
mice were pretreated with 20mg/kg of paracetamol three days prior to, and on 
the day of B-13red cell injections to stimulate a moderate level of liver damage.  
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Figure 3.3 3: B-13
red
 cells were visualised under the DsRed wavelength using an in vivo 
imaging system (ivis). Cells could be detected in all tubes compared to PBS and B-13 cell 
controls. Cell numbers left to right: 0.1 million, 0.5 million, 1 million, 5 million and 10 million.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 4: Total fluorescence detected in varying numbers of B-13
red
 cells under 
DsRed wavelengths using an in vivo imaging system (ivis). Cells could be detected in all B-
13
red
 samples but not in PBS and B-13 cell controls 
B-13
red
 cells 
B-13 cells 
PBS  
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To determine whether B-13red cells are able to engraft into the liver analysis of 
the livers of NOD/SCID mice was carried out by Western blot. As amylase 
expression has been shown to be retained in the B-13/Hred cells in vitro, the 
expression of amylase was employed as a marker to screen all tissues of the 
mice.  Figure 3.3.5 shows that amylase expression was detectable in two of the 
three mice injected in the pilot study suggesting the presence of B-
13/pancreatic cells within the livers. This was further confirmed by 
immunohistochemistry for amylase, which was performed in all tissues, where 
the presence of amylase positive cells was observed in the livers only and no 
other tissues. All tissues were observed under the DsRed wavelength to search 
for B-13red cells however no DsRed positive cells were found, including in the 
livers where amylase positive cells had been observed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 5: Western blot analysis and immunohistochemistry for the pancreatic marker 
amylase in pilot studies for injections of B-13
red
 cells into NOD/SCID mice. A) Western blot 
analysis to show the protein expression of CYP2E1 and amylase in the livers and bone marrow 
of NOD/SCID mice after B-13
red
 injection. B) Immunohistochemistry for amylase for two mice 
shown to have amylase expression in the liver by Western blot. Amylase positive cells were 
observed suggesting the B-13 cells successfully engrafted to the liver. No Amylase was 
detected in other tissues. 
A) 
B) 
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3.3.2 The B-13 cell is able to engraft to the liver independent of 
paracetamol treatment. 
As B-13 cells engrafted to the periportal regions of the liver, and not the central 
lobular regions where paracetamol induced injury occurs, a larger study was 
performed where mice received B-13red cell injections with or without 
paracetamol treatment to evaluate whether liver damage is necessary for B-13 
cell engraftment. Immunohistochemistry for amylase was performed on the 
livers and a number of other tissues of NOD/SCID mice. Figures 3.3.6 and 3.3.7 
show that clusters of amylase positive cells were found within the portal tracts of 
some of the livers indicating B-13 cell engraftment. Interestingly, amylase 
positive cells were observed in livers of both of the groups suggesting that 
engraftment of the B-13 cells to the liver is independent of paracetamol 
treatment prior to cell injection. No amylase positive cells were observed in any 
other tissues including the heart, lung, brain, kidneys, spleen, thymus, bone 
marrow and adipose tissue. 
 
RT-PCR was performed to determine whether the presence of amylase within 
the livers could be confirmed at the mRNA level. Figure 3.3.8 shows that livers 
from all groups of the study displayed amylase expression at the mRNA level 
although only levels of amylase were detected in some livers suggesting less 
successful engraftment/injections of the cells. The expression of amylase was 
also found at the protein level in B-13red injected NOD/SCIDs by Western blot 
analysis (figure 3.3.9), no amylase expression at the mRNA or protein levels 
were detected in the PBS-injected controls.  
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Figure 3.3 6: The expression of the pancreatic marker amylase in WT rat pancreas and 
liver and B-13
red
 injected NOD/SCID mouse pancreas, liver, heart and lung shown by 
immunohistochemistry. A number of amylase positive cells were observed in the livers of 
NOD/SCID mice around the portal tracts. No amylase expression was detected in other non-
pancreatic organs such as the heart and lung. All images x20 magnification and are typical of 
animals from each group. 
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Figure 3.3 7: The expression of the pancreatic marker amylase detected within the livers 
of NOD/SCID mice after intravenous injections of B-13
red
 cells shown by 
immunohistochemistry. Amylase positive cells were found around the portal tracts of the 
livers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 8: The expression for the pancreatic marker amylase in B-13
red
 injected 
NOD/SCID mice shown by RT-PCR.  All groups of injected NOD/SCID mouse showed the 
presence of amylase mRNA within their livers suggesting B-13
red 
engraftment independent of 
paracetamol treatment. No amylase expression was detected in any other organs, in agreement 
with IHC performed.  
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Figure 3.3 9: Expression of amylase at the protein level in various organs of NOD/SCID 
mice after B-13 injections and non injected controls shown by Western blot. Data is in 
agreement with RT-PCR and IHC that amylase positive cells are present within the livers and 
pancreata but no other organs. 
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Although B-13red cells carried the DsRed transgene to allow tracking in vivo, 
DsRed positive cells could not be detected using the ivis imaging system 
following injection. Thus B-13 cells were tagged using the CellVue® NIR815 
labelling agent to allow in vivo tracking of B-13 cells in the whole bodies and 
organs of injected mice. CellVue® NIR815 is a lipophilic near-infrared labelling 
reagent, optimally excited at 786 nm and has a peak emission of 814 nm. 
NOD/SCID mice were injected with Cellvue labelled B-13 cells or PBS for 
controls and left for 24 hours prior to imaging with the ivis. No Cellvue® NIR815 
conjugated B-13 cells were detected in the whole bodies, however following 
dissection, fluorescence at the near-infrared wavelengths was detected in the 
liver of the B-13 injected animals only (figures 3.3.10 and 3.3.11). These 
observations confirm that the B-13 cells are present in the liver following 
injection, and no other tissues. No Cellvue® NIR815 conjugated B-13 cells were 
detected within the pancreata, although this could be due to the short 24 hour 
study which was restricted by the CellVue® NIR815 labelling agent. 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
Figure 3.3 10: Organs from NOD/SCID mice injected with Cellvue® NIR815 conjugated B-
13 cells were visualised under the near infrared wavelength using an in vivo imaging 
system (ivis). Florescence could be detected in the liver B-13 of injected mice only and not in 
PBS injected controls. No fluorescence could be detected prior to dissection of the organs. Data 
is typical of two separate experiments. 
 
Order of organs:              Brain 
Heart   lung 
Liver   kidneys 
stomach  spleen 
pancreas 
                                           
                                           
                                           
Cellvue® NIR815 
conjugated B-13 cells 
PBS injected 
Cellvue® NIR815 
 B-13 injected 
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Figure 3.3 11: Total radiance detected from the organs of Cellvue® NIR815 B-13 cell 
injected NOD/SCID mice and non-injected controls. Fluorescence was detected in the liver 
of injected mice only, suggesting the presence of B-13 cells. Data is typical of two separate 
experiments and ***P<0.001. 
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3.3.3 Amylase positive cells within the livers are of B-13 origin 
To further confirm that the amylase positive cells observed within the livers of 
the injected NOD/SCID mice were derived from B-13red cells, fluorescent in situ 
hybridisation (FISH) was undertaken. As the B-13 cells have been previously 
shown to be male and thus carry the Y chromosome, (chapter 3.2) a probe 
designed to specifically hybridise to the rat Y chromosome was used to track B-
13 cells within mouse tissues.  Figure 3.3.12 shows that the probe successfully 
hybridised specifically to the rat Y chromosome as positive cells were only 
visualised in male rat liver and not in female rat liver or male mouse liver. 
Successful hybridisation with the probe was also established in B-13 cells. FISH 
and amylase IHC were performed on serial sections of NOD/SCID livers, and in 
areas where amylase positive cells had been observed, cells positive for the Y 
chromosome were also detected (figure 3.3.13). Interestingly, more cells 
positive for the Y chromosome than amylase were within the same area 
suggesting that the expression of amylase may be fully repressed in vivo. 
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Figure 3.3 12: Fluorescent in situ hybridisation (FISH) staining performed on rat liver 
(male and female), mouse liver (male) and B-13 cells. Analysis confirmed that the probe was 
specific to the rat Y chromosome with positive staining observed in both the male rat and B-13 
cells only. No cross reactivity with the mouse Y chromosome was seen.  
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Figure 3.3 13: FISH and amylase staining in serial sections from B-13 injected NOD/SCID 
mice livers. Sections where amylase positive cells were located also stained positively for the 
rat Y chromosome showing that amylase positive cells detected are most likely to be of B-13 
origin rather than the hosts own pancreatic cells 
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3.3.4 B-13 cells engraft to the liver and pancreas but show hepatocyte-
like phenotype in the liver only. 
No evidence was found for the engraftment of B-13 cells to other organs, 
however as only amylase has been used as a marker for B-13 cell engraftment 
it is not easy to determine whether B-13 cells engrafted to the pancreas. Thus 
the DsRed transgene expressed by the injected cells was used as a marker 
(FISH could not be performed in the pancreas due to the digestion steps).  
Sections from all organs were DAPI stained and observed under the DsRed 
wavelength. Interestingly DsRed positive cells were observed in both the 
pancreas and livers of B-13red injected NOD/SCID mice (figure 3.3.14), however 
the number of DsRed positive cells detected within the pancreata was limited. 
Within the liver, DsRed positive cells showed a clear hepatocyte-like 
morphology which was not evident in cells that engrafted within the pancreas.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 14: Sections of liver and pancreas from B-13
red
 injected NOD/SCID mice 
visualised under the DsRed wavelength show evidence of B-13 cell engraftment. Sections 
were DAPI stained and visualised under the DAPI and DsRed wavelengths.  The expression of 
the DsRed transgene within pancreas and liver tissue from NOD/SCID was detected in cells 
within both organs suggesting B-13
red 
engraftment. No DsRed positive cells were detected in 
other organs. Images are shown at x40 and x63 magnification. 
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Primers designed to amplify the rat specific transcripts for amylase and the 
hepatocyte marker CYP2E1 were used to confirm the engraftment of B-13red 
cells into the pancreata as detected under the DsRed wavelength. Figure 3.3.15 
shows that B-13 cells engrafted into both the livers and pancreata of NOD/SCID 
mice but not in any other tissues. Interestingly the rat specific CYP2E1 was 
detected within the livers where B-13 cells had engrafted, but not within the 
pancreata suggesting that in vivo B-13 cells are able to transdifferentiate 
towards the B-13/H phenotype within the liver environment, but remain as 
pancreatic B-13 cells within the pancreas. These data are supported by the fact 
that the morphology of the engrafted cells appear hepatocyte-like suggesting a 
B-13/H phenotype. Furthermore immunocytochemistry for the liver marker 
albumin was performed and showed DsRed positive cells were also positive for 
albumin (figure 3.3.16). 
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Figure 3.3 15: Rat specific amylase and CYP2E1 mRNA was detected in the livers and 
pancreata of B-13
red
 injected NOD/SCID mice. Primers designed to amplify rat specific 
transcripts of amylase and CYP2E1 were used for RT-PCR in organs of NOD/SCID B-13
red
 
injected mice. Rat amylase mRNA expression was detected within NOD/SCID livers and 
pancreata only. CYP2E1 was only detected in the livers and no other organs, and was only 
detected in livers that also showed positive amylase expression, suggesting both engraftment of 
the B-13 cells and transdifferentiation within the liver to B-13/H cells.  
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Figure 3.3 16: DsRed and albumin expression in B-13
red
 injected NOD/SCID mice. 
Immunocytochemistry for the liver marker albumin was performed on livers of B-13
red
 injected 
and PBS-injected NOD/SCID mice. The expression of DsRed was shown to be found in cells 
also expressing albumin suggesting that B-13 cells had transdifferentiated towards the B-13/H 
phenotype in vivo. 
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3.3.5 Chapter discussion 
Data presented in this chapter demonstrates for the first time that the B-13 
progenitor is able to engraft specifically to the liver and pancreas of NOD/SCID 
mice. Hepatocyte transplantation has been widely investigated as the need for 
an alternative to organ transplantation is greatly needed. In humans it has been 
demonstrated that although possible, engraftment is not easy and producing 
direct evidence is difficult due to the invasive nature of liver biopsies[214]. Studies 
have shown that transplanted cells do not always engraft directly to the liver 
structure but instead can survive and function in the portal vasculature where 
they lead to thrombi [216]. In our study there was no evidence for engraftment 
within the portal vasculature and no evidence of tumour formation. Despite the 
fact that paracetamol injures the centrilobular region of the liver lobule, (zone 3 
of the acinus) B-13 cells were consistently found to be present within the 
periportal region of the lobule in both control and paracetamol pre-treated mice. 
Furthermore hepatic engrafted cells were shown to differentiate into hepatocyte-
like cells and appeared to completely down regulate amylase expression (which 
is downregulated but not lost completely in vitro) as they move further from the 
portal tracts. As B-13s appear to favour engraftment to the periportal region this 
may be infact due to a supportive environment such as a stem cell niche, which 
has previously  been reported to exist within the canals of Hering, close to the 
site of engraftment observed[67]. In addition, the expression of amylase was 
shown to be lost in B-13 cells as they moved into the liver parenchyma, which is 
in support of the streaming hypothesis where progenitor cells migrate towards 
the central vein as progressively differentiated daughter hepatocytes[81]. 
However more studies would be needed to clarify whether the local 
environment is supporting the engraftment and transdifferentiation of the B-13 
cells towards functional hepatocyte-like cells.   
 
Another interesting observation is that the B-13 cells were also found to engraft 
into the pancreas. However within the pancreas, no sign of transdifferentiation 
towards B-13/H cells was observed. These findings suggest that the in vivo 
environment in which the cells engraft has an important role in the maintenance 
of cell identity; within the hepatic environment the hepatocyte phenotype was 
promoted and within the pancreatic environment the pancreatic phenotype of 
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the B-13s was maintained. In a study by Jiang et al[217] it was shown that 
multipotent adult progenitor cells were able to engraft and differentiate into 
tissue-specific cells in response to local cues from the organ in which they 
engrafted.  These data are in support with the findings of this chapter and if the 
mechanisms that drive these changes in vivo could be identified then this could 
have great use in creating functional hepatocytes for transplantation therapies.   
 
Although successful engraftment of the B-13 cells was observed into the liver, 
engraftment was also observed within the pancreas. In a study by Turner et 
al[218] restricted localisation to the liver was achieved with the use of hyaluronan 
grafts. The grafting strategies use matrix biomaterials that can be gelled into 
place, which are tailored to the microenvironment thus restricting the desired 
target tissue. These alternative methods offer possible strategies to reduce 
engraftment to the pancreas and may allow liver specific engraftment of B-13s 
only.  
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3.4 Culture of B-13 cells in 3D bio-artificial liver devices 
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There is currently no treatment for end stage liver disease, and at present the 
only option is organ transplantation. Recent advances in bioreactor technology 
bring  new opportunities for assisting or replacing  failing organs, where they 
can act as extracorpeal devices until transplantation can be performed[74].  
Bioreactors have been developed to provide a 3D environment for cells which 
aim to create conditions as close to the true cellular origin as possible, and thus 
support the cells to function as they would in vivo. The bioreactor systems used 
to support hepatocyte cells in Zeilinger’s lab are composed of a 3D network of 
three separate interwoven capillary membranes with integrated oxygenation 
and decentralised mass exchange, which are designed to represent an artificial 
equivalent of the hepatic vasculature at the level of the liver lobule[192]. 
Bioartificial liver devices have been shown to support the recovery and 
maintenance of primary human hepatocytes with relatively stable metabolic 
activities for longer periods than achieved in 2D culture[74]. After an initial 
adaptation phase following isolation, metabolic data has shown that 
hepatocytes can be functionally stable in the bioreactor systems for up to four 
weeks [219].  
 
To date, a number of different bioartificial liver support systems have been 
developed for patients with liver disease and tested in phase I clinical trials[220]. 
Various clinical treatments with bioreactor extracorpeal devices have been 
successful, where primary human hepatocytes from discarded transplant 
organs were used[221].  As the potential of extracorpeal liver support for end 
stage liver disease is now being realised, it is the lack of available hepatocytes 
that is now limiting the advance of this new technology. All extracorpeal liver 
support systems that are currently under clinical investigation are based on the 
use of human or porcine hepatocytes [222], and thus an equivalent to human 
hepatocytes is required. A number of cell lines such as embryonic stem cell-
derived hepatocytes, the human HepaRG, and xenogenic or tumour cell lines 
have been tested, however they carry many drawbacks such as low yields, poor 
functionality, and  zoonotic  or malignant potential[223].   
 
Alternative cell lines are needed to provide a supply of functional hepatocytes, 
thus the B-13 cell line was cultured to test the hypothesis that ‘dexamethasone 
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induced generation of B-13/H cells is expected to be possible in 3D bioreactor 
cultures by adapting the treatment regimen established in 2D cultures’. If 
transdifferentiation of B-13s towards B-13/H cells can be conducted in 3D 
cultures then finding the human equivalent would provide a cell line for use in 
liver bioreactor technology. 
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3.4.1 Establishing optimal culture conditions for bioreactor cultures 
Before seeding of the B-13 cells into the bioreactors could take place, a number 
of experiments were carried out to find optimal culture conditions. As the 
bioreactor system is composed of 40 layers of tightly packed capillaries there is 
a risk that the high levels of proteins in FCS could lead to frothing and/or 
blockage and therefore failure of the device. A lower FCS concentration of 2.5% 
rather than the normal 10% was therefore suggested for the bioreactors culture 
media.  In addition to the new concentration of FCS, a higher DEX treatment of 
10µM, compared to the standard 10nM, was chosen to promote a quicker 
transdifferentiation and to reduce the chance of DEX being absorbed by the 
capillaries before reaching the cellular compartment. To ensure that lower FCS 
concentrations are still able to support growth and transdifferentiation of the B-
13s into B-13/H cells, 2D cultures were set up using the modified media. Cells 
cultured in 2.5% FCS with 10µM DEX showed a typical B-13/H morphology 
(figure 3.4.1) suggesting that transdifferentiation can still take place in low FCS 
containing media, though it was evident that the rate of proliferation was slowed 
(figure 3.4.2). The first bioreactor experiment was planned for 8 days and so 
after this period, samples were collected from each treatment for analysis at the 
mRNA and protein level. Results showed that B-13 cells treated with 10µM DEX 
expressed a number of hepatocyte-specific markers such as CYP2E1, CPS-1 
and albumin confirming that the modified media is still able to support the B-13 
transdifferentiation (figures 3.4.3). To confirm whether the CYP450 enzymes 
expressed were correctly folded and therefore functional a carbon monoxide 
binding assay was performed. CYP450 enzymes possess characteristic 
spectral properties due to a non-covalently bound protoporphyrin IX and this 
haem is able to bind carbon monoxide. When CYP450s are correctly folded and 
therefore functional, the binding of carbon monoxide yields a spectral peak at 
approximately 450nm, compared to a spectral peak of 420nm in the presence of 
a biologically inactive CYP450[224]. Results from the assay demonstrated the 
presence of functional CYP450 enzymes with a peak at 450nm after exposure 
to carbon monoxide (figure 3.4.4). Together, these data show that the proposed 
media alterations for culture within the bioreactor devices does not affect the 
cell viability or inhibit the transdifferentiation towards functional B-13/H cells. 
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Figure 3.4 1: Typical cell morphology of B-13 cells treated with 10µM DEX in media 
containing 10% or 2.5% FCS. Both media types resulted in the appearance of B-13/H cells 
after 7 days of 10µM DEX. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 2: Proliferation of B-13 cells in 10% or 2.5% FCS containing media with or 
without 10µM DEX treatment. Both DEX treatment and 2.5% FCS containing media result in a 
slower cell proliferation. All cell counts were made on 10 randomly selected fields of view at x20 
magnification Data are expressed as mean of cells per random field of view observed± SD. 
**P<0.01, ***P<0.001, and are typical of three separate experiments.  
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Figure 3.4 3: RT-PCR and Western blot analysis for the expression of liver specific 
markers after culture with 10% or 2.5% FCS containing media ±10µM DEX. A) RT-PCR 
analysis comparing the expression of liver specific markers CPS-1 and CYP2E1 at the mRNA 
level in B-13 cells treated with high DEX (10µM) and low FCS (2.5%), compared to normal 
conditions of 10nM DEX and 10% FCS. Results shown are typical of three separate 
experiments. B) Western blot analysis comparing the expression of liver specific markers 
CYP2E1, albumin and CPS-1 at the protein level in B-13 cells treated with high DEX (10µM) 
and low FCS (2.5%), compared to normal conditions of 10nM DEX and 10% FCS. Results 
shown are typical of three separate experiments.  
A) 
B) 
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Figure 3.4 4: Cytochrome P450-carbon monoxide complexes in B-13/H cells and primary 
rat hepatocytes. A carbon monoxide binding assay indicating the CYP450 functionality in rat 
hepatocytes and B-13/H cells cultured in media containing 2.5% FCS and 10μM DEX. Peaks 
can be observed at 450nm suggesting the presence of correctly folded and functional CYP450 
enzymes. Results are averages of four separate samples.  
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3.4.2 Pilot study in bioreactor (BR) 176 
A pilot study was carried out to assess whether the B-13 cell line can be 
cultured and transdifferentiated in response to DEX treatment in the 3D 
bioreactor environment. A summary of the study can be seen in figure 3.4.5 
where the timescale, the length of DEX treatment and the points at which 
CYP450 assays were performed are indicated. The cells were inoculated into 
the cell compartment before being left to recover overnight prior to the start of 
DEX treatment. In contrast to previous bioreactor studies that have used 
primary hepatocytes, the B-13 cell line is proliferative, and thus the standard cell 
number inoculated of 150 million, was reduced to 100 million, to avoid 
overcrowding within the cell compartment. During culture, daily measurements 
for a number of parameters were taken as described in methods section 2.11.4 
and CYP450 assays were performed at the start and end of the bioreactor 
cultures. For comparison 2D cultures were set up in 6-well plates in parallel to 
the bioreactor system.  
 
 
 
 
 
 
 
 
Figure 3.4 5: The timescale of the pilot bioreactor study (BR 176) and the 2D parallel 
cultures. 100 million cells were seeded into the device 24 hours prior to DEX treatment was 
started.  
During culture a number of parameters were measured to assess the condition 
and performance of the cells. Figure 3.4.6 shows the lactate release and 
glucose consumption for both the 2D and bioreactor cultures. Both the lactate 
production and glucose consumption in the 2D culture was considerably higher 
than the bioreactor culture suggesting that the cells may have been proliferating 
at a much quicker rate in 2D. The parameters for metabolism in both cultures 
rose at a steady rate and therefore the differences in 2D and bioreactor cultures 
are likely due to the local environment and available space for the cells to grow. 
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Figure 3.4 6: Cell metabolism of B-13 cells cultured in bioreactor 176 and parallel 2D 
cultures. Cultures were over 8 days with 10µM DEX. Lactate and glucose levels were 
measured on a daily basis to calculate the levels of production and consumption respectively.  
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The amount of LDH, GLDH, AST and ALT released from the cell cultures was 
measured on a daily basis (figure 3.4.7). The levels detected were found to be 
at much lower and more stable levels in bioreactor cultures compared to the 
parallel 2D cultures. The pattern of release also matched that of the cell 
metabolism data where in bioreactor cultures day 6 showed a peak in all 
parameters. In 2D cultures, a higher and more varied level of enzyme release 
was observed, however this may be due to the higher metabolic activity 
observed in the 2D cultures or due to a quicker rate of transdifferentiation 
towards the hepatocyte phenotype.  To assess whether there were any signs of 
transdifferentiation towards B-13/H cells the production of urea was measured 
(figure 3.4.8). Previously, urea has been shown to be an excellent parameter for 
hepatocyte cell performance as it corresponds to all other evaluated parameters 
and accordingly is ideal for describing general metabolic activity and function of 
hepatocytes[225]. No urea was detectable in 2D cultures over the 8 day study, 
however after just 2 days of DEX treatment urea production was observed in 
the bioreactor culture. This data suggests that transdifferentiation of the B-13 
cell line can occur in the 3D bioreactor environment and form functional 
hepatocyte-like cells. More importantly, this is the first time that urea production 
has been shown in the B-13 cell line after transdifferentiation.  
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Figure 3.4 7: Enzyme release from B-13 cells cultured in bioreactor 176 and parallel 2D 
cultures. The enzyme release of lactate dehydrogenase (LDH), glutamate dehydrogenase 
(GLDH), alanine aminotransferase (ALT) and aspartate transaminase (AST), over 8 days with 
10μM DEX. Enzyme levels were measured on a daily basis.  
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Figure 3.4 8: Urea production by B-13 cells cultured in bioreactor 176 and parallel 2D 
cultures. Cultures over 8 days with 10µM DEX, measured on a daily basis. 
Samples of the cellular compartment were collected to assess the cell 
morphology. H&E staining showed that the cells still displayed a B-13 cell 
morphology rather than the expected B-13/H morphology after 7 days of 10μM 
DEX treatment (figure 3.4.9). The cells also appeared very tightly packed 
together and thus the apparent overcrowding may have restricted their 
proliferation and transdifferentiation.  
 
DAB immunohistochemistry staining was performed to observe the expression 
of the liver markers albumin and CYP2E1, as well as the pancreatic marker 
amylase. Staining revealed that the expression of the liver markers albumin and 
CYP2E1 were detectable in bioreactor cultured cells, however at much lower 
levels compared to the parallel 2D cultures (figure 3.4.10). The differences in 
cell morphology between 2D and bioreactor cultures were also very apparent 
with clear hepatocyte-like cell morphology observed in 2D cultures only. 
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Figure 3.4 9: H&E stains of B-13 cells cultured in BR176 shown at x10 and x40 
magnification. The morphology resembles that of B-13 cells rather than the expected B-13/H 
cells suggesting little transdifferentiation has occurred during culture. 
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Figure 3.4 10: Typical DAB staining for samples from BR176 and parallel 2D cultures. 
Staining for the hepatocyte markers albumin and CYP2E1 and the pancreatic marker amylase 
was performed. Rat liver and pancreas tissues were used as positive controls. All images are 
viewed at x40 magnification.  
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RT-PCR analysis was performed to look at the expression of liver markers at 
the mRNA level in samples from both the 2D and bioreactor cultures (figure 
3.4.11). The RT-PCR data was somewhat mixed as the expression of some 
liver markers such as CYP4A1 and CYP2E1 were found to be only expressed in 
cells cultured in the bioreactor, in contrast other liver specific markers such as 
CYP2C11 were observed only in the 2D cultures. Interestingly the expression of 
CYP4A1 was detected in bioreactor cultured cells and not in B-13/H cells 
suggesting that the 3D environment may enhance expression of hepatocyte-
specific enzymes not normally expressed in 2D cultures. However due to the 
conflicting results between 2D and bioreactor cultures caution should be taken 
in any review of this data.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 11: RT-PCR analysis of mRNA samples from BR176 and parallel 2D cultures. 
Expression of liver specific markers and the pancreatic maker amylase were analysed at the 
mRNA level. B-13 cells were cultured in both bioreactor and 2D cultures for 8 days with 10μM 
DEX treatment.  
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In addition to RT-PCR and morphological data, functional data was obtained by 
carrying out CYP450 assays at the start and before the termination of the 
bioreactor and 2D cultures. Four different drugs were administered to the 
culture systems at the same time, before the levels of their respective 
metabolites were measured. A summary of the drug and the CYP450 activity 
being assessed can be seen in table 2.5 (material and methods). The data from 
the CYP450 assay showed that in the 2D cultures all of the drugs were 
metabolised into the products at 8 days, suggesting that functional B-13/H cells 
were present (figure 3.4.12). This data is in agreement with the morphological 
data where hepatocyte-like cells can clearly be seen. In contrast, no CYP450 
activity was found in bioreactor cultures as no products were measured. 
Although the production of urea was detected in the bioreactor cultures and the 
expression of a number of liver specific markers were found by RT-PCR the 
morphological and metabolic data demonstrate that little transdifferentiation has 
occurred. Optimisation of bioreactor cultures for the B-13 cells is therefore 
needed to promote and enhance the B-13/H phenotype.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 12: CYP450 metabolism assay of B-13 cells in BR176 and parallel 2D cultures 
at 8 days. The activity of four different CYP450 enzymes was measured by the conversion of 
the drugs into their respective metabolites by B-13 cells after 8 days with 10µM DEX treatment 
(see table 2.5).   
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3.4.3 Identifying factors affecting B-13 culture in BR176 
Before further bioreactor studies can be carried out, reasons why the rate of 
transdifferentiation was restricted during the pilot run were investigated.  From 
previous bioreactor studies it has been shown that the capillaries, which are 
made of polyethersulphone, can absorb some chemicals and thus disrupt their 
transport across the membrane into the cell compartment. The absorbance of 
DEX into the capillary membrane could perhaps provide an explanation for the 
low rate of transdifferentiation towards the B-13/H phenotype observed. Three 
different dexamethasone isoforms (H2O soluble DEX, 21-Acetate DEX and 21 
phosphate disodium DEX) were tested in 2D culture to see whether they can 
still promote the B-13/H phenotype in the hope that the different isoforms may 
not be absorbed by the capillaries. B-13 cells were treated with the three 
different DEX solutions for 7 and 14 days at a concentration of 10µM. RT-PCR 
analysis showed that all three of the alternative DEX solutions tested were able 
to drive transdifferentiation of B-13 cells towards a B-13/H cell phenotype, 
where the liver specific markers CYP2E1, CPS-1 and albumin were detected 
after both 7 and 14 days treatment (figure 3.4.13). These results show 
alternative forms of DEX may be used to allow transdifferentiation if the DEX is 
being absorbed by the capillary membranes within the bioreactor cultures.  
 
To confirm whether DEX was being absorbed into the capillary membranes, 
media samples, which were collected from both the 2D and bioreactor cultures 
on days 2, 4 and 6, were sent to Pharmacelsus® for Liquid chromatography–
mass spectrometry analysis to calculate the levels of DEX within the media. The 
media samples collected from the bioreactor were taken after passing through 
the bioreactor system and so if any DEX was absorbed by the capillaries an 
obvious difference between the cultures would be observed. Results showed 
similar concentrations of DEX present in the bioreactor culture and in parallel 
2D cultures, indicating that there is no significant binding of DEX in the system 
(figure 3.4.14). As these data show that the DEX is not absorbed across the 
capillary membrane it should be acceptable to use the same DEX treatment 
used in the pilot study for future experiments. 
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Figure 3.4 13: RT-PCR analysis for the expression of liver specific markers CYP2E1, CPS-
1, and albumin, and the pancreatic marker amylase, at the mRNA level in B-13 cells 
cultured with a range of different 10µM DEX solutions. Data is typical of three separate 
experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 14: Comparison of absolute levels of DEX (nM) measured in media samples 
from BR176 and parallel 2D cultures of B-13 cells on days 2, 4 and 6 of culture.   
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Another possible explanation for the limited transdifferentiation observed within 
the bioreactor system was the number of cells inoculated into the device. As 
previously discussed, the bioreactors are usually inoculated with non-
proliferating cells and thus the proliferation of the B-13 cells may have led to 
overcrowding. To investigate whether the rate of transdifferentiation into B-13/H 
cells is density dependent, B-13 cells were cultured in T75 flasks with starting 
numbers of 5, 10 and 15 million. The B-13 cells were DEX treated for 96 hours 
with total cell counts and the number of B-13/H cell counts made every 24 
hours. The rate of transdifferentiation was found to be significantly dependent 
on the confluency of the B-13 cells, as shown in figure 3.4.15, where lower 
seeding densities resulted in a much faster appearance of B-13/H cells. Any 
further bioreactor experiments will therefore need to use a much lower seeding 
cell number to allow optimal conditions for promoting the transdifferentiation 
towards the B-13/H phenotype.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 15: The effect of seeding density on the rate of B-13 transdifferentiation. The 
percentage of B-13/H cells after 24, 48, 72 and 96 hours of DEX treatment in B-13 cell cultures 
at different seeding densities was calculated by performing cell counts in random fields of view. 
Data are expressed as mean of percentage of B-13/H cells observed± SD. *P<0.05, **P<0.01, 
***P<0.001, and are typical of three separate experiments.  
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3.4.4 Culturing of B-13 and B-13/H cells in a 3D environment 
Once the problems from the pilot study had been addressed a number of new 
bioreactor runs were carried out. A repeat of the 8 day study  was ran alongside 
another bioreactor with an increased culture time of 15 days; both of which had 
a reduced cell inoculation number of 40 million as opposed to 100 million cells 
seeded in the pilot study. As B-13 cells showed a reduced rate of 
transdifferentiation in the pilot study, B-13/H cells which had been DEX treated 
for 5 days were inoculated into another bioreactor for 15 days. This second 
approach will allow an assessment of whether transdifferentiation prior to 
inoculation leads to more functional B-13/H cell cultures or whether 
transdifferentiation within the device is preferable. Figure 3.4.16 shows a 
timescale for the bioreactor runs for B-13, B-13/H and rat hepatocyte cells. 
Primary rat hepatocytes were cultured in a bioreactor as a control bioreactor so 
that functionality could be directly compared to the B-13 bioreactors. For details 
on all the bioreactors cultures and their parameters see table 3.4.1.  
 
 
 
 
 
 
Figure 3.4 16: The timescale of bioreactor cultures 196-199 and the 2D parallel cultures. 
Bioreactors were inoculated with either B-13, B-13/H or rat hepatocytes to find optimal 
bioreactor culture conditions for promoting the B-13/H phenotype.  
Throughout the bioreactor runs a number of daily parameters were measured 
as for the pilot study. Cell metabolism was monitored by lactate production and 
glucose consumption, which showed similar patterns for each bioreactor (figure 
3.4.17). The two bioreactors inoculated with B-13 cells (BR196 and BR197) 
showed the highest levels of lactate production and glucose consumption which 
can most likely be explained due to the proliferation of the cells. BR198, which 
was inoculated with B-13/H cells, showed a steady rate of lactate production 
and glucose consumption suggesting a stable culture performance. The rat 
hepatocyte (control) bioreactor showed significantly lower levels of lactate 
production and glucose consumption with a drop in glucose consumption after 5 
days. 
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Figure 3.4 17: Cell metabolism of bioreactors 196, 197, 198 and 199 over 8/15 days. 
Bioreactors 196 and 197 were inoculated with B-13 cells, bioreactor 198 with B-13/H cells and 
bioreactor 199 with rat hepatocytes. Lactate and glucose levels were measured on a daily basis 
to calculate the levels of production and consumption respectively 
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For all three bioreactors containing B-13 or B-13/H cells the levels of enzymes 
LDH, GLDH, ALT and AST released from the cultures were found to be at 
relatively low and stable levels throughout the whole cultures (figure 3.4.18). 
These data are in agreement with the pilot study where the bioreactor culture 
resulted in low enzyme release compared to the 2D cultures. A slight increase 
in enzyme release was observed in bioreactors 197 and 198 after prolonged 
culture suggesting cell death may be occurring. For the first 2-4 days of culture 
the levels of enzyme release in the rat hepatocyte control culture (BR199) was 
substantially higher most likely due to the stress of cell isolation prior to 
inoculation.  
 
In bioreactors inoculated with B-13 cells (BR196 and BR197) urea was detected 
within 3-4 days of DEX treatment and was found to be at levels comparable to 
the control rat hepatocyte bioreactor (BR199) (figure 3.4.19). The urea 
production in BR198, which was inoculated with B-13/H cells, was much lower 
than the B-13 bioreactor cultures. Although no urea was detected on certain 
days, this may be due to the levels being below the limit of detection rather than 
the absence of urea production and thus a more sensitive assay would possibly 
provide more reliable results.  
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Figure 3.4 18: The enzyme release in bioreactors 196, 197, 198 and 199 over 8/15 days. 
Bioreactors 196 and 197 were inoculated with B-13 cells, bioreactor 198 with B-13/H cells and 
bioreactor 199 with rat hepatocytes. Enzyme levels of Lactate dehydrogenase (LDH), 
Glutamate dehydrogenase (GLDH), Alanine Aminotransferase (ALT) and Aspartate 
transaminase (AST) were measured on a daily basis. 
Chapter 3: Results 3.4 
164 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 19: Urea production in bioreactors 196, 197, 198 and 199 over 8/15 days. 
Bioreactors 196 and 197 were inoculated with B-13 cells, bioreactor 198 with B-13/H cells and 
bioreactor 199 with rat hepatocytes. Urea levels were measured on a daily basis. 
 
After termination of the bioreactor cultures the morphology of the cells was 
assessed by H&E staining (figure 3.4.20). A B-13/H morphology was observed 
in all B-13 bioreactor cultures even after 8 days suggesting that the reduced cell 
seeding number allowed a more successful transdifferentiation. B-13/H cells 
inoculated also showed a hepatocyte-like morphology, however some cells 
appeared enucleated with a rough membrane suggesting cell stress or death.  
The rat hepatocytes also showed evidence of enucleated cells; however this is 
not representative for the whole bioreactor as other data clearly shows the cells 
were still metabolically active. Due to the difficulty of preparing samples for 
morphological analysis from the bioreactors, the samples used may not be 
representative of the entire bioreactor culture. 
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Figure 3.4 20: H&E staining of bioreactors 199, 196, 197 and 198. Bioreactors 196 and 197 
were inoculated with B-13 cells, bioreactor 198 with B-13/H cells and bioreactor 199 with rat 
hepatocytes. Images are shown at magnifications of x40 and x100. All images are 
representative of typical cell morphology found within the sections.  
Further morphological analysis by DAB immunohistochemistry showed the 
expression of the liver markers albumin and CYP2E1 in both B-13 cell 
inoculated cultures (BR196 and BR197) and rat hepatocytes (BR 199), however 
no CYP2E1 was observed in B-13/H inoculated bioreactor (BR198) (figure 
3.4.21). Although CYP2E1 and albumin were observed in both BR196 and 197 
the intensity of staining for albumin was much stronger for BR197 and a loss of 
the pancreatic marker amylase was also observed suggesting that the longer 
culture time allowed a more accomplished transdifferentiation towards B-13/H 
cells.  
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Figure 3.4 21: Typical images of DAB immunohistochemistry for bioreactors 196-199 after 8/15 days culture. Staining is for the expression of liver markers 
albumin and CYP2E1 and the pancreatic marker amylase in B-13 cells after bioreactor cultures with no primary controls. Rat liver and pancreas act as positive 
controls for expression. All images are viewed at x40 magnification.  
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Analysis for expression of liver specific markers at the mRNA and protein level 
was carried out by RT-PCR and Western blotting respectively (figure 3.4 22). In 
contrast to the pilot bioreactor results, analysis showed expression of a number 
of liver markers from cells cultured in all bioreactor cultures. RT-PCR data 
showed a reduction in expression of liver markers such as CYP2E1 in 
bioreactor cultured rat hepatocytes compared to primary rat hepatocytes, 
however this was not confirmed by western blot analysis. To compare fold 
changes in gene expression real time PCR (qPCR) was performed for the liver 
specific markers, CYP2E1, albumin, CPS-1, CEBP/β and the pancreatic marker 
amylase compared to B-13 cells (figures 3.4.23-27). B-13/H cells cultured in 2D 
showed small fold changes in CYP2E1, CPS-1 and CEBP/β compared to non 
DEX treated B-13 cells. However the fold changes in liver marker expression 
from cells cultured in bioreactors were found to be significantly higher. 
Bioreactor 197 showed the highest up-regulation of liver specific markers with 
levels of expression higher than rat hepatocytes for all markers with the 
exception of albumin. These data show that the reduced cell number inoculated 
into the bioreactors along with the longer timescale has resulted in successful 
culture and transdifferentiation of B-13 cells in a 3D bioreactor system.  
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Figure 3.4 22: RT-PCR and Western blot analysis for the expression of liver specific 
markers in bioreactors 196-199. A) RT-PCR analysis comparing the expression of liver 
specific markers CYP2E1, CPS-1 CYP2C11 and albumin and the pancreatic marker amylase at 
the mRNA level in different BR culture approaches. Results shown are typical of three separate 
experiments. B) Western blot analysis comparing the expression of liver specific markers 
CYP2E1, CPS-1 albumin and CYP3A1 and the pancreatic marker amylase at the protein level 
in different BR approaches. Results shown are typical of three separate experiments. 
A) 
B) 
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Figure 3.4 23: Fold changes of CYP2E1 mRNA detected by real time PCR in different 
bioreactor cultures 196, 197, and 198  compared to B-13 cells. Freshly isolated rat 
hepatocytes are also shown for comparison. Data are expressed as mean of the ddCt values ± 
SD. *P<0.05, **P<0.01, ***P<0.001= significantly different to control B-13 cells (Students t-test, 
two tailed). Data is typical of three separate PCR runs for each of the bioreactors samples.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 24: Fold changes of albumin mRNA detected by real time PCR in different 
bioreactor cultures 196, 197, and 198 compared to B-13 cells. Freshly isolated rat 
hepatocytes are also shown for comparison. Data are expressed as mean of the ddCt values ± 
SD. *P<0.05, **P<0.01, ***P<0.001= significantly different to control B-13 cells (Students t-test, 
two tailed). Data is typical of three separate PCR runs for each of the bioreactors samples.  
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Figure 3.4 25: Fold changes of CPS-1 mRNA detected by real time PCR in different 
bioreactor cultures 196, 197, and 198 compared to B-13 cells. Freshly isolated rat 
hepatocytes are also shown for comparison. Data are expressed as mean of the ddCt values ± 
SD. *P<0.05, **P<0.01, ***P<0.001= significantly different to control B-13 cells (Students t-test, 
two tailed). Data is typical of three separate PCR runs for each of the bioreactors samples.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 26: Fold changes of C/EBPβ mRNA detected by real time PCR in different 
bioreactor cultures 196, 197, and 198 compared to B-13 cells. Freshly isolated rat 
hepatocytes are also shown for comparison. Data are expressed as mean of the ddCt values ± 
SD. *P<0.05, **P<0.01, ***P<0.001= significantly different to control B-13 cells (Students t-test, 
two tailed). Data is typical of three separate PCR runs for each of the bioreactors samples.  
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Figure 3.4 27: Fold changes of amylase mRNA detected by real time PCR in different 
bioreactor cultures 196, 197, and 198 compared to B-13 cells. Freshly isolated rat 
hepatocytes are also shown for comparison. Data are expressed as mean of the Delta-Delta-Ct 
(ddCt) ± SD. *P<0.05, **P<0.01, ***P<0.001= significantly different to control B-13 cells 
(Students t-test, two tailed). Data is typical of three separate PCR runs for each of the 
bioreactors samples.  
Ethoxyresorufin-O-deethylase (EROD) assays were conducted during 
bioreactor runs to test the functionality of cells through the activity of CYP1A1 
(figure 3.4.28). EROD activity describes the rate of the CYP1A1 mediated 
deethylation of the substrate 7-ethoxyresorufin to form the product resorufin and 
thus the rate is an indication of the amount of enzyme present.  On day 1 no 
formation of the product was observed in all bioreactor cultures, however by day 
8, the B-13/H inoculated bioreactor (BR198) had formation rates that were close 
to levels of the control rat hepatocytes. At the same time point no activity was 
found for BR196 and BR197 which may explain why metabolic activity was not 
observed in the pilot studies after 8 days. By day 15 the metabolic activity in 
bioreactors inoculated with B-13 cells was similar to levels of BR198 which 
suggests that longer periods are required for the cells to transdifferentiate and 
become metabolically functional in 3D bioreactor systems. As a result even 
longer culture periods may lead to even higher formation rates and hepatic 
functionality of B-13/H cells. 
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Figure 3.4 28: EROD CYP450 assay for bioreactors 196, 197, 198 and 199 performed on 
day 1, day 8 and day 15 of bioreactor cultures. The figure shows the formation rate of the 
product hydroxyresorufin from 7-ethoxyresorufin O-deethylase in cultures, representing the 
CYP450 activity within the culture systems. Bioreactors 196 and 197 were inoculated with B-13 
cells, bioreactor 198 with B-13/H cells and bioreactor 199 with rat hepatocytes. 
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Table 3.4 1: A summary of the bioreactor cultures carried out with details of the length of 
culture, cell type and cell number 
 
 
 
 
 
 
Bioreactor Cell type and 
number/culture time 
Comments 
BR176 B-13 cells- 100 million    / 
8 days 
BR 196 B-13 cells- 40 million    /8 
days 
 
BR 197 B-13 cells -40 million      / 
15 days 
BR 198 B-13/H cells- 100 million 
/15 days 
BR 199 Primary rat hepatocytes-
150 million /8 days 
 
BR 218 B-13 cells- 40 million      
/22 days 
Cells appeared to die 
around day 19 after 
variable pH 
BR 219 B-13 cells- 40 million      
/15 days 
BR 220 
 
Primary rat hepatocytes-
150 million /8 days 
BR 221 B-13 cells- 40 million     /5 
days 
 
No DEX (B-13 control) 
Chapter 3: Results 3.4 
174 
 
3.4.5 Chapter discussion 
Data presented in this chapter demonstrates for the first time that the B-13 
progenitor cell is able to transdifferentiate in response to DEX within 3D 
bioreactor systems to form functional B-13/H hepatocyte-like cells. We have 
shown that low cell numbers and longer culture periods result in the most 
optimal culture conditions for transdifferentiation into functional B-13/H cells. 
The high cell numbers of cells cultured within the 3D systems allowed the 
detection or urea production for the first time, which was previously not detected 
in standard 2D cultured B-13/H cells. This finding has identified a further 
essential role of hepatocytes that B-13/H cells are able to perform, making the 
cell line a suitable candidate for metabolism studies and drug screening. In 
addition, compared to the control rat hepatocyte cells which lose functionality 
over time, the B-13 cell has demonstrated an increase in performance over time 
and it may be possible to culture these cells within bioreactors for extensive 
periods beyond that achievable in 2D. We have also shown that although B-
13/H cells inoculated into the bioreactor are functional and produce urea, after 8 
days, their culture performance declines, thus allowing transdifferentiation to 
occur within the bioreactor device is the best strategy.  
 
Interestingly is has been shown that the longer bioreactor culture of 15 days for 
B-13 cells resulted in the most functional B-13/H cells with the highest 
expression of liver markers. Even though after 8 days of culture a number of 
liver specific markers are detectable, the EROD CYP450 assay only showed 
activity in cells cultured for 15 days. Therefore it may be possible that the 
transdifferentiation towards functional B-13/H cells takes longer in 3D, and 
cultures longer than 15 days may result in B-13/H cells with even higher liver 
functionality and expression of liver markers.  
 
The bioreactor studies have allowed the functionality of B-13 cells to be further 
explored and B-13/H cells were shown to perform to similar or higher levels as 
primary rat hepatocytes in culture. As there is a lack of human hepatocytes 
available for use in extracorpeal bioreactor devices both in the clinical and 
laboratory setting, the use of alternative cell sources is the only option. The 
isolation or creation of a human equivalent to the B-13 cell line would provide an 
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unlimited supply of human hepatocyte-like cells that could be used both in the 
clinic to support the treatment of end stage liver disease and for toxicity 
screening for drugs using bioreactor cultures.  
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3.5 Culture of human pancreatic acinar cells for the generation of human 
hepatocyte-like cells 
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The B-13 cell line has shown great insight into the mechanisms of pancreatic to 
hepatic transdifferentiation in response to glucocorticoids in vitro. The 
progenitor cell appears to be hypersensitive to glucocorticoids with respect to 
hepatic differentiation, as the appearance of hepatocytes within the rodent 
pancreas has been shown to occur in response to physiologically abnormal high 
concentrations of glucocorticoids[168].  Previous work from our lab and other 
groups has shown that markers of liver gene expression can appear in rodent 
pancreata [154, 226-228] and human foetal acinar cells[229]. In addition we have 
shown that this mechanisms can take place in humans in vivo as tissues from a 
patient treated with glucocorticoids for at least 20 years was shown to express 
liver markers at levels comparable to human hepatocytes within the acinar 
regions of the pancreas[183]. We therefore sought to establish whether adult 
human pancreatic acinar cells are capable of transdifferentiating into 
hepatocyte-like cells in vitro in response to the glucocorticoid DEX. With the 
breakthrough of iPS technology in 2006[4], cell differentiation and lineage 
specification is now understood to be a reversible process allowing alternative 
approaches of generating differentiated adult cells to be explored[230]. Utilising 
the findings from work with the B-13 cell line and translating to human acinar 
cells will allow us to investigate whether the transdifferentiation of adult human 
acinar cells to hepatocyte-like cells is a feasible outcome in vitro. 
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3.5.1 The human pancreatic acinar cell (HPAC) line shows slowed 
proliferation in response to DEX. 
The human pancreatic acinar cell (HPAC) line is a pancreatic adenocarcinoma 
epithelial cell line derived from a pancreatic adenocarcinoma after engraftment 
into nude mice. The cell line has been reported to express a functional 
glucocorticoid receptor (GR), the first reported human pancreatic 
adenocarcinoma cell line to do so, and in addition cell proliferation has been 
shown to be suppressed by dexamethasone and other glucocorticoids[187]. B-13 
cells also exhibit a slowed proliferation in response to glucocorticoids, and thus 
it was hypothesised that similarities may exist between B-13 and HPAC cell 
lines in response to DEX treatment. 
 
HPAC cells were cultured with 10μM DEX or an ethanol vehicle control for 7 
days to assess the effects of DEX treatment on cell proliferation. Figure 3.5.1 
shows that after 7 days of culture there was a significant difference in cell 
numbers between HPACs treated with DEX compared to controls. These 
observations confirm those previously reported[187]. In addition to an inhibited 
growth, HPACs showed an altered morphology after culture with DEX. Whilst in 
the control conditions HPACS reached confluency and possessed a fibroblast-
like morphology when confluent, cells treated with DEX were tightly packed 
rounded cells with more distinct cell boundaries (figure 3.5.2). The changes in 
HPAC morphology observed following DEX treatment suggest that DEX 
influences more than cell proliferation alone.  Analysis of gene expression with 
and without DEX may provide further insights into the alterations occurring at 
the transcriptional level.  
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Figure 3.5 1: HPAC cell proliferation with 10μM DEX treatment or ethanol vehicle 
controls. The average cell number per field of view was calculated using at least 4 separate 
observations for each treatment on each day.  
 
 
 
 
 
 
 
 
 
 
Figure 3.5 2: Typical morphology of HPACs treated with ethanol vehicle and HPACs 
treated with 10μM DEX for 7 days. Control HPACs grown under standard cell culture 
conditions show typical HPAC morphology whereas after DEX treatment HPACs appear 
rounded and tightly packed with clear cell junctions. 
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3.5.2 Expression of liver-specific markers is induced in HPACS following 
DEX treatment and is depedent on activation of the GR. 
As morphological changes were observed in HPACs following treatment with 
DEX, RT-PCR analysis was performed to determine any changes in gene 
expression. HPACs were treated with 10μM DEX for 7 or 14 days before 
samples were collected.  
 
Analysis of gene expression at the mRNA level indicated that the liver-specific 
markers CYP2E1 and albumin were expressed following DEX treatment (figure 
3.5.3A). These observations suggest that the HPAC cell line is able to 
transdifferentiate towards a hepatocyte-like cell in response to glucocorticoids 
as is observed in the B-13 cell line. To verify if the changes were also taking 
place at the protein level, Western blots were carried out. Figure 3.5.3B shows 
that after DEX treatment, no CYP2E1 protein was detected in HPAC cells, 
however low levels of albumin were observed after 7 and 21 days of culture. 
Although no protein expression of CYP2E1 was found in DEX treated HPACs 
by Western blotting, immunocytochemistry showed that CYP2E1 was induced 
in some cells after 7 days of DEX (figure 3.5.4). Although some cells were 
shown to express CYP2E1 by immunocytochemistry, only small areas were 
positive and therefore this may explain why no expression was detected at the 
protein level by Western blot. These results suggest that although changes in 
gene expression after DEX treatment occur, HPACs do not up-regulate the 
expression of hepatocyte-specific genes as convincingly as is observed in the 
B-13 cell line.  The initial observations however are still exciting as they show 
the possibility of a human equivalent to the B-13 cell line, and may allow the 
mechanisms of pancreas to liver transdifferentiation to be further investigated 
with an in vitro model.  
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Figure 3.5 3: RT-PCR and Western blot analysis for the expression of liver specific 
markers in HPACs and HPACs treated with DEX. A) RT-PCR analysis comparing the 
expression of liver specific markers CYP2E1, albumin and CYP3A4 at the mRNA level in 
HPACs with or without culture with DEX for 7 or 14 days. Results are typical of three separate 
experiments. B) Western blot analysis comparing the expression of liver specific markers 
CYP2E1 and albumin at the protein level in control HPACs and DEX treated HPACs for 7, 14 or 
21 days. Results are typical of three separate experiments.  
A) 
B) 
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Figure 3.5 4: Immunocytochemistry for CYP2E1 in B-13 and HPAC cells with or without 
DEX. All images are viewed at x40 magnification and are typical of 3 separate staining 
experiments.   
 
As previously reported, the HPAC cell line is the first reported human pancreatic 
adenocarcinoma cell line to express a functional GR[187]. RT-PCR and 
immunocytochemistry were performed to confirm the presence of the GR in 
HPACs in control cultured and DEX treated cells. As glucocorticoids are a 
member of the nuclear receptor family, RT-PCR was performed for other 
nuclear receptors known to be involved in regulating the expression of liver 
specific genes, including pregnane X receptor (PXR), farnesoid X receptor 
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(FXR) and constitutive androstane receptor (CAR) to see if they are expressed 
in HPAC cells.  Figure 3.5.5 and 3.5.6 show that expression of the GR was 
detected in both HPACs and DEX treated HPACs by both RT-PCR and 
immunocytochemistry respectively. Interestingly treatment with DEX resulted in 
a higher expression of the GR compared to WT HPAC cells.  No other nuclear 
receptors were detected in the HPAC cultures, suggesting that the effects of 
DEX treatment observed are dependent on interactions with the GR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 5: RT-PCR analysis for the expression of nuclear receptors in HPAC cells. The 
expression of the nuclear receptors, glucocorticoid receptor (GR), pregnane X receptor (PXR), 
farnesoid X receptor (FXR) and constitutive androstane receptor (CAR) was carried out in 
control and DEX treated HPACs. Results are typical of three separate experiments.  
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Figure 3.5 6: Immunocytochemistry for the glucocorticoid receptor (GR) in control and 
DEX treated HPACs. All images are viewed at x40 magnification and are typical of 3 separate 
staining experiments.   
 
To further confirm that the changes in morphology and gene expression 
observed in DEX-treated HPACs are through activation of the GR, HPACs were 
treated with a range of other nuclear receptor activators including: phenobarbital 
(PB), rifampicin (RIF) and metyrapone (MET) [231-234].  HPACs were treated for 7 
days with the various nuclear receptor activators before mRNA analysis was 
carried out by RT-PCR (figure 3.5.7). Interestingly the induction of CYP2E1 and 
albumin expression was only observed in DEX-treated HPACs and no other 
treatment conditions. These results support the hypothesis that induction of liver 
specific genes in HPAC cells by DEX are likely to be dependent on GR 
activation. 
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Figure 3.5 7: RT-PCR analysis for the expression of liver specific markers in HPACs 
treated with various nuclear receptor activators. HPACs were treated with either 10μM DEX, 
1mM PB, 20μM RIF or 200μM MET for 7 days
[235]
. The expression of liver specific genes, 
CYP2E1, albumin and CYP3A4 were analysed. Results are typical of three separate 
experiments.  
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3.5.3 Expression of liver specific markers through DEX treatment is 
inhibited in cocultures with liver myofibroblasts. 
Induction of liver specific genes has been shown to occur upon DEX treatment 
in HPAC cells, however when comparing to the B-13 cell line the effects 
observed are minimal. It has previously been shown that the rate of 
transdifferentiation towards the B-13/H phenotype was enhanced through 
coculture with liver myofibroblasts. Coculture experiments were therefore set up 
for HPACs as carried out with B-13 cells to see if the induction of liver specific 
genes could be enhanced.  
 
During culture the morphological changes in HPACs normally observed during 
DEX treatment were not seen. Instead in regions where myofibroblasts were 
growing, large areas could be observed where HPACs had detached (figure 
3.5.8). This effect was seen for all cocultures independent of DEX treatment. 
These observations suggest that the presence of myofibroblasts leads to HPAC 
death rather than the supportive role hypothesised.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 8: Cocultures of control and DEX treated HPACs and liver myofibroblasts. 
Cells were DAPI stained before being visualised. Images are typical of two separate 
experiments. 
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Analysis of the liver-specific markers at the mRNA level was carried out by RT-
PCR and revealed that in coculture conditions the treatment with DEX failed to 
induce the liver-specific marker CYP2E1, however albumin was still detectable 
(figure 3.5.9)  These results show that the enhancing effects of coculture on 
transdifferentiation observed in B-13 cells is not found in HPACs. In contrast, 
coculture with myofibroblasts appears to not only have inhibited the induction of 
CYP2E1 expression but also promoted death of HPACs in proximity to 
myofibroblasts. These results were further confirmed by immunocytochemistry 
where CYP2E1 expression was only detected in HPACs treated with DEX not in 
the presence of myofibroblasts (figure 3.5.10).  These results highlight clear 
differences between the HPAC and B-13 cell lines and thus the mechanisms 
occurring in the HPACs during liver gene induction need to be investigated 
further to identify optimal conditions for reprogramming HPACs towards a 
hepatocyte-like cell.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 9: RT-PCR analysis for the expression of liver-specific markers in HPAC 
coculture experiments. HPACs, liver myofibroblasts or cocultures were treated with either 
10μM DEX or ethanol controls for 7 days. The expression of liver specific genes CYP2E1 and 
albumin and GR, amylase and α-sma were analysed. Results are typical of two separate 
experiments.  
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Figure 3.5 10: Immunocytochemistry for CYP2E1 and albumin in HPACs and cocultures 
of myofibroblasts and HPACs ± 10μM DEX. All images are viewed at x40 magnification and 
are typical of two separate experiments.   
 
 
 
 
 
 
 
 
 
 
 
Chapter 3: Results 3.5 
189 
 
3.5.4 Expression of pluripotency inducing factors in HPACS 
Expression of pluripotency inducing factors in adult somatic cells to create iPS 
cells has transformed approaches in regenerative medicine[4, 20]. Using non viral 
techniques, adult fibroblasts from both rodents and humans have been 
converted into iPS cells with ES like morphology using the pCAG2LMKOSimO 
vector which comprises the coding sequences of the four pluripotency factors c-
Myc, KLF4, OCT4 and SOX2[189]. Since B-13 cells express these four 
pluripotency factors, we used the same approach in HPAC cells to see if the 
progression towards a more pluripotent state would permit more complete 
induction of liver-specific genes following DEX treatment.  
 
HPACs were transfected with pCAG2LMKOSimO and pCYL43 and stable 
transfectants were generated through antibiotic (G418) selection as judged by 
constitutive expression of IRES-mOrange. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 11: Visualisation of HPAC and pCAG HPAC cells under excitation/emission 
549 and 565nm respectively. HPACs and pCAG HPACS treated with or without DEX were 
cultured and visualised to show successful transfection with the pCAG2MKOSimO vector 
through detection of IRES orange expression. 
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Figure 3.5.12 shows that successful transfection of HPACs with the 
pCAG2MKOSimO construct resulted in an altered cell morphology. Cells were 
small and rounded compared to the normal epithelial morphology of WT 
HPACs. pCAG HPACS were cultured with DEX for 14 days to investigate 
whether hepatocyte-like cells would more readily appear after constitutive 
expression of the four pluripotent factors. No change in morphology was 
observed following DEX treatment, cells remained small and rounded and grew 
to confluency. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 12. Bright field images of pCAG HPACS in standard or DEX treated cultures. 
Images are shown at x20 and x40 magnification and show typical representations of the cells 
morphology.  
 
Figure 3.5.13 demonstrates that RT-PCR analysis confirmed pluripotent 
markers such as SOX2 were highly expressed in pCAG HPACS compared to 
normal HPAC cells. Treatment with DEX resulted in a loss of SOX2 expression 
in HPACs, however in pCAG HPACs no loss of SOX2 expression was observed 
and no induction of the liver specific gene CYP2E1 was found. This observation 
fits with those found in the B-13 cell line where KLF4, OCT4 and SOX2 
expression falls as B-13 cells transdifferentiate towards B-13/H cells and the 
forced over expression was shown to block differentiation towards B-13/H cells 
in response to DEX. Thus over expression of the four pluripotency factors 
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through transfection with pCAG2MKOSimO has resulted in an inhibited 
expression of liver-specific markers such as CYP2E1 in pCAG HPAC cells 
following DEX treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 13: RT-PCR analysis for the expression of liver specific markers and 
pluripotency markers in WT and pCAG HPACS. HPACs and pCAG HPACS were treated with 
either 10μM DEX or ethanol controls for 7 days. The expression of liver specific genes CYP2E1 
and albumin and SOX2 and c-Myc were analysed. Results are typical of two separate 
experiments.  
 
The results of the RT-PCR were confirmed by immunocytochemistry where no 
CYP2E1 induction was observed after treatment with DEX (figure 3.5.14). The 
expression of the pluripotency factor OCT4 was still highly expressed following 
DEX treatment. An induction of CYP2E1 and a loss of OCT4 expression can be 
seen in normal HPAC cells following DEX treatment, however the opposite 
observations were found in pCAG HPACS where no CYP2E1 was detectable 
after DEX treatment, and OCT4 was still highly expressed.  
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Figure 3.5 14: Immunocytochemistry in HPAC and pCAG HPAC cells with and without 
DEX treatment. Cells were stained for CYP2E1 and OCT4, no primarys are shown. Images are 
all shown at x40 magnification and are typical of 2 separate experiments. 
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3.5.5 Culture of human primary acinar cells.   
In addition to work on the HPACs, primary pancreatic acinar cells were cultured 
to establish whether adult human pancreatic acinar cells are capable of 
transdifferentiation into hepatocytes-like cells in vitro. Primary human exocrine 
cells from the fractions that are a by-product of the islet isolation procedure 
were cultured and the effects of DEX treatment on their morphology and gene 
expression profile were examined. The exocrine enriched fractions were placed 
in culture where the cells readily attached to the culture vessels and expanded 
into a monolayer of proliferative cells  
 
Over time cultured acinar cells adopted a fibroblastic morphology, an 
observation previously reported by Lima et al[236] where cells are thought to 
undergo epithelial to mesenchymal transition (EMT) and dedifferentiate in 
culture. Reports have shown that the co-expression of amylase and vimetin at 
around day 10 confirmed that the cells were undergoing differentiation towards 
a mesenchymal phenotype[236]. Figure 3.5.15 shows the typical morphology of 
the acinar cells over 21 days following isolation. Interestingly the 
dedifferentiation of primary acinar cells was slowed in the presence of DEX, 
where an epithelial morphology was maintained for around 10 days before 
fibroblastic cells appeared, compared to around 5 days in control cultures. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 15: Typical morphology of human primary acinar cells cultured over 21 days. 
Cells cultured in basal media and media containing 10μM DEX were observed over 21 days of 
culture. EMT resulted in the dedifferentiation of acinar cells towards a fibroblastic morphology 
which was slowed in the presence of DEX. Images are at x20 magnification and are typical of 4 
separate acinar isolations.  
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RT-PCR analysis revealed that following DEX treatment primary acinar cells 
were found to express a number of hepatic markers such as CYP2E1 and 
albumin which were not detectable in cells cultured in basal media (figure 
3.5.16). Interestingly the highest levels of CYP2E1 and albumin were found 
after 7 days of DEX, and not 14, after which cells continued to adopt a 
fibroblastic morphology and hepatic gene expression was lost. Expression of 
the pancreatic marker amylase was also shown to be reduced in response to 
DEX treatment, whilst vimentin expression was gained overtime, suggesting 
that cells were losing expression of pancreatic markers as cells adopted either 
hepatic or fibroblastic gene profiles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 16: RT-PCR analysis for the expression of liver, pancreatic  and fibroblast 
specific markers in primary acinar cells. Primary acinar cells were treated with either 10μM 
DEX or standard basal media for 7 and 14 days. The expression of liver specific genes CYP2E1 
and albumin, the pancreatic marker amylase and the fibroblast marker vimentin were analysed. 
Results are typical of four separate cell isolations.    
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Although a loss of amylase expression was shown, the cultured cells retained 
some expression of amylase, thus DEX treatment resulted in the co-expression 
of the acinar marker and the liver specific marker CYP2E1. These findings were 
confirmed by dual immunohistochemistry staining for CYP2E1 and amylase 
(figure 3.5.17). Cells that were cultured in basal media showed no CYP2E1 
expression whereas cells cultured with DEX for 3 or 7 days showed cells 
expressing both amylase and CYP2E1, suggesting cells are undergoing 
transdifferentiation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 17: Co-expression of amylase and CYP2E1 in primary acinar cells shown by 
immunohistochemistry. Primary acinar cells were treated with basal media or 10μM DEX for 3 
or 7 days prior to staining. CYP2E1 expression was found in DEX treated cells only, and cells 
were shown to co-express the pancreatic marker amylase. Images are typical of four separate 
cell isolations and are shown at x20 magnification. 
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3.5.6 Chapter discussion 
Results in this chapter have demonstrated that the transdifferentiation of 
pancreas to liver in response to the glucocorticoid DEX can be achieved in adult 
human pancreatic acinar cells. Although pancreatic to hepatic 
transdifferentiation has been observed multiple times in rodents both in vivo and 
in vitro, the observations shown in the HPAC cell line and primary acinar cells 
may prove a valuable model for studying the mechanisms for this process in 
human. 
 
The mechanisms involved in the induction of hepatic gene expression in the 
HPAC cell line still need to be further explored, however initial findings suggest 
that the role of the GR may play a critical role as has been shown for the B-13 
cell line[184]. Further experiments with the glucocorticoid antagonist RU486, 
which is effective at blocking dexamethasone binding to the GR[233], could be 
conducted to verify whether the induction of liver-specific genes in HPACs 
following DEX treatment is dependent on the GR. 
 
DEX acts through the GR[237], which is expressed in the HPAC cell line[187]. 
However reports have shown that glucocorticoid sensitivity is not only 
dependent on GR expression but can be modulated by other factors such as 
type II bone morphogenic receptor (BMPRII) which is thought to influence 
glucocorticoid sensitivity[238]. Mechanisms of glucocorticoid sensitivity are 
largely unknown, however they may explain why certain cell lines such as the 
B-13s transdifferentiate in response to low concentrations of DEX, whereas the 
induction of transdifferentiation in vivo requires much higher doses. As a 
transient repression of Wnt signalling had been shown to play an early and 
critical role in the transdifferentiation of B-13 cells[167], it would be interesting to 
investigate the activity of Wnt signalling within the HPAC cell line. Elucidating 
any similarities in the mechanisms will allow a greater understanding of the 
pancreatic to hepatic transdifferentiation process and allow optimal conditions 
for promoting the hepatic phenotype to be found. Although similarities have 
been shown between HPACs and B-13 cells, some differences have also been 
observed, for example in coculture experiments myofibroblasts promoted 
transdifferentiation for B-13 cells but inhibited hepatic gene expression in 
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HPACs. The differences observed highlight the need for caution to be taken 
when translating findings from rodent to man.  
 
Induction of pluripotent genes resulted in inhibition of hepatic gene expression 
in response to DEX, which has also be shown in the B-13 cell line[239]. It may be 
possible that following induction of pluripotency, other factors other than DEX 
may be needed to induce hepatocyte-specific gene expression. Two recent 
studies reported that ectopic expression of Gata4, HNF1α and foxa3[124] or 
HNF4α plus one of Foxa1/Foxa2/Foxa3[125] in adult mouse fibroblasts directly 
reprogrammed cells into hepatocyte-like cells. C/EBPβ has also been shown to 
be important in hepatic differentiation and was identified as an early marker in 
B-13 transdifferentiation[163]. Thus the ectopic expression of a number of genes 
involved with early hepatocyte development may enhance the hepatic gene 
expression in HPAC cells, instead of firstly driving cells towards a pluripotent 
state. 
 
Although we have shown that induction of liver-specific genes in primary adult 
human pancreatic acinar cells in response to DEX treatment is possible in vitro, 
the maintenance of the cells at this point is problematic as they eventually 
dedifferentiate. The rapid dedifferentiation of acinar cells into a mesenchymal 
monolayer has been previously reported[236] where genetic lineage studies have 
confirmed the occurrence of epithelial-mesenchymal transition (EMT). In spite of 
the delayed dedifferentiation through DEX treatment, hepatic expression could 
not be maintained; primary acinar cells still eventually go through EMT and lose 
both acinar and hepatic markers. EMT has previously been shown to play 
important roles in embryogenesis [240-242] where multiple tissue types and organs 
are derived from the mesoderm. Recent work by Lima et al[236] has shown that 
during reprogramming of exocrine pancreas towards β-like cells in vitro 
inhibition of EMT resulted in an enhanced reprogramming. By using inhibitors of 
TGF-β1 and Rho-kinase signalling pathways, TGF-β1 inhibitor and ROCK, EMT 
of the exocrine cells was suppressed and allowed enhanced reprogramming to 
functional β-cells. These findings suggest that the early inhibition of EMT in 
primary exocrine cultures, instead of allowing the culture to expand, enables the 
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maintenance of acinar cell gene expression and may result in enhanced 
reprogramming towards hepatic gene expression in future cultures.
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Work in this thesis has shown for the first time that adult human pancreatic 
acinar cells induce the expression of hepatocyte-specific genes in response to 
glucocorticoid exposure. Although much of the work carried out in this thesis 
was on the rat B-13 cell line, there seems to be a great deal of overlap between 
rodents and humans with regards to morphologic and transcriptional changes 
during pancreatic development [243]. We have shown that hepatocyte-like cells 
appeared in the adult human pancreas in response to glucocorticoids and thus 
the pathophysiological response to elevated glucocorticoid exposure exists in 
man[183] as in rodents[166]. In addition induction of hepatocyte-specific genes has 
been shown for the first time to be possible in vitro in adult human acinar cells 
as well as the B-13 cell line. Therefore it is reasonable to predict that due to the 
similar mechanisms that have been shown between rodents and humans, with 
respect to pancreatic to hepatic transdifferentiation, that a human pancreatic 
acinar cell line could be identified that would have extensive utility for both 
bench and clinic. 
 
Glucocorticoids play an important role in cellular differentiation as well as their 
role in metabolism; during late pregnancy a rise in glucocorticoid levels parallels 
organ maturation. An example of their central role is shown in lung development 
where respiratory distress in premature births can be reduced with 
glucocorticoid based therapies[244]. The B-13 and HPAC cell lines both express 
high levels of GR and this may explain why relatively low concentrations of DEX 
are required for hepatocyte gene induction compared to in vivo studies[166]. 
Although the expression levels of GR may play a central part, other factors have 
been shown to affect GR activation and sensitivity. For example GR activity has 
been shown to be modulated by chaperone machinery composed of Hsp70 and 
Hsp90 chaperones, modulated by their respective co-chaperones, in a complex 
process which is likely to be in response to the cellular environment[245].  In 
addition GR trans-activation is modulated by physical interactions with an 
adapter protein within the nucleus; modulator of non-genomic action of the 
estrogen receptor (MNAR), the nature of this complex is known to be dependent 
on cell type[246]. Lastly tissue glucocorticoid sensitivity has been shown to be 
modulated by many factors such as BMPRII[238], although the mechanisms are 
still largely unknown, therefore any of these elements could play a role in 
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inhibition of hepatocyte differentiation in vivo. The mechanisms that affect GR 
activation may be used to explain the observation of the in vivo studies in 
NOD/SCID mice. We have shown for the first time that the B-13 cell line is able 
to engraft and transdifferentiate into B-13/H cells in vivo; however the 
transdifferentiation was restricted to cells that engrafted to the liver, whereas 
cells in the pancreas maintained the acinar B-13 phenotype. Despite no 
glucocorticoid treatment being giving to cells prior to inoculation, 
transdifferentiation was still observed in vivo suggesting that the circulating 
levels of glucocorticoids were sufficient to promote the B-13/H phenotype within 
the liver environment, or that glucocorticoids are not required in vivo. The high 
levels of GR expressed in B-13 cells makes them sensitive to glucocorticoids 
and thus it is not surprising that normal physiological levels in vivo are adequate 
to promote transdifferentiation. However as there was no evidence for the B-
13/H phenotype within the pancreas, this implies that other factors may be 
influencing GR sensitivity and inhibiting B-13/H identity. Since pancreatic tissue 
is a default state of differentiation for embryonic pancreatic cells capable of 
being directed towards a hepatic phenotype[247] it is likely this mechanism may 
allow normal adult cells to transdifferentiate only when exposed to sufficiently 
high levels of glucocorticoids. In addition glucocorticoids have been shown to 
play a role on modulating the balance between endocrine and exocrine cell 
differentiation within the normal pancreas, where pancreatic buds treated with 
DEX have a decrease in insulin-producing cells and a doubled acinar population 
[248]. As a consequence it is critical that normal physiological levels in vivo do 
not promote the hepatic phenotype. It would be interesting to investigate 
whether abnormally high levels of circulating glucocorticoids would lead to B-13 
transdifferentiation within the pancreatic environment, as hepatocytes have 
been observed in previous in vivo studies after high glucocorticoid exposure[166]. 
 
Another interesting finding was the effects of cocultures with liver myofibroblasts 
on B-13 transdifferentiation in vitro. Although the mechanisms have not been 
fully elucidated the presence of myofibroblasts were found to increase the rate 
of transdifferentiation towards the B-13/H phenotype by further repression of the 
Wnt signalling pathway. Liver myofibroblasts, along with liver macrophages, 
have been identified as key components of the hepatic stem cell niche where 
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they can direct cell fate[249]. It was reported by Boutler et al[203] that macrophage 
cells drove hepatocyte regeneration through induction of Wnt3a expression, 
whilst myofibroblasts promoted biliary regeneration through notch signalling. 
Although these findings seem to oppose those from the coculture experiments it 
must be considered that promoting the hepatocyte phenotype from hepatic 
progenitor cells and inducing hepatic transdifferentiation of a pancreatic 
progenitor cell are very different events and thus may require different 
molecular signalling cues. Nonetheless it would be interesting to investigate the 
effects of coculture with liver macrophages or a combination of myofibroblasts 
and macrophages on B-13 transdifferentiation. The Wnt and notch signalling 
pathways play essential roles during acinar cell development and expansion, 
and sustained Wnt activity promotes proliferation of the cells[39, 250, 251], therefore 
a suppression of Wnt signalling may be essential to allow loss of the acinar 
phenotype before Wnt signalling is re-established to promote the hepatic 
phenotype.  
 
No increased rate of transdifferentiation was observed in cocultures of HPACs 
and myofibroblasts, but instead myofibroblasts seemed to suppress induction of 
hepatic genes. It is important to investigate whether Wnt signalling plays a role 
in the HPAC cell line during induction of liver specific genes as the mechanisms 
have yet to be elucidated.  
 
The hepatic stem cell niche is thought to be located within the terminal bile 
ductules known as the canals of Hering[67] where hepatic progenitor cells are 
supported by liver macrophages, myofibroblasts and a rich laminin matrix[249]. 
The laminin matrix is thought to maintain the progenitor cells in an 
undifferentiated phenotype and forms as a response to liver damage[249]. 
Although paracetamol was used to induce liver damage, which occurs primarily 
around the central lobular area, during in vivo studies the B-13 cells were found 
to engraft in portal tract areas, which is in proximity to the proposed hepatic 
niche. These findings suggest that signals originating from the niche may have 
influenced B-13 engraftment. Furthermore FISH analysis showed that cells 
further from the portal tracts lost amylase expression completely which indicates 
that cells in close proximity to the niche were maintained as progenitors whilst 
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those further from the portal tracts were more differentiated towards hepatocyte-
like cells. These observations give further support to the ‘streaming hypothesis’ 
where progenitor cells proliferate within the smallest branches of the 
intrahepatic biliary tract before migrating towards the central vein as 
progressively differentiated daughter hepatocytes[81]. 
 
In recent years there have been advances in the field of regenerative medicine 
which have been fuelled by the first findings in iPS cell technology[4]. The 
knowledge that adult somatic cells do not have a restricted differentiated state 
but instead are maintained through active gene expression, and thus can be 
reprogrammed, has allowed researchers to explore the developmental potential 
and provided new insights into creating cells of specific lineages. In addition to 
reducing the differentiation pathway needed to drive the cells towards the 
desired cell type, working with adult-derived cells avoids much of the ethical 
issues associated with embryonic stem cells.  There are still many risks of 
contamination by undifferentiated pluripotent cells, which could lead to teratoma 
formation in vivo, or the accumulation of genetic abnormalities after cellular 
reprogramming, which may result in excessive proliferation[252], and therefore 
translation to the clinic have been slow. 
 
Stem cells, whether embryonic or adult, should not be considered the only 
potential source from which to generate hepatocytes; the strategy of cellular 
transdifferentiation which often does not involve extensive cell proliferation 
stands out as a feasible mechanism for generating specific cell types. Studies in 
recent years have shown many examples of somatic cells undergoing 
transdifferentiation into various cell types through transcription factors and/or a 
cytokine-dependent manner[230]. iPS technology has inspired researchers to 
ectopically express combinations of transcription factors in differentiated adult 
cells, where cell fate can be overcome and the cells are driven towards other 
cell lineages. Two recent studies reported that ectopic expression of Gata4, 
HNF1α and foxa3[124] or HNF4α plus one of Foxa1/Foxa2/Foxa3[125] in adult 
mouse fibroblasts directly reprogrammed cells into hepatocyte-like cells. In 
addition Zhou et al showed that ectopic expression of the transcription factors 
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Pdx1, MafA and Neurog3 in acinar cells was able to drive cells to adopt a β-cell 
identity[253]. 
 
The process of transdifferentiation is generally seen from adjacent areas in the 
developing embryo such as pancreatic to hepatic[159] and a greater 
understanding of this process will allow us to clarify what molecular 
mechanisms distinguish neighbouring regions. Elucidating the mechanisms of 
pancreatic to hepatic transdifferentiation at the molecular level will aid in 
identifying a human equivalent to the B-13 cell line.  Many  transcription factors 
have been  associated with hepatocyte cells within the pancreas such as HNF-
1, HNF-3α, HNF-3β, HNF-4, C/EBPα, C/EBPβ and C/EBPγ rats [155, 156] which 
were termed liver-enriched transcription factors (LETFs), these may  be 
involved in the mechanisms underlying the process of transdifferentiation. As 
C/EBPβ is not expressed in the normal pancreas this transcription factor may 
play a key role in promoting the hepatocyte phenotype in pancreatic cells, and 
this has been shown to be induced at an early stage of B-13 
transdifferentiation[157]. Therefore ectopic expression of C/EBPβ along with 
other liver enriched transcription factors or genes involved in early liver 
development may drive human pancreatic acinar cells successfully to more 
functional hepatocyte-like cells. 
 
The ultimate goal of regenerative medicine is to produce healthy human cells 
for cell-based therapies[230]. Utilising cellular transdifferentiation allows patients’ 
own tissues to be used, bypassing immune-rejection related problems[254] and 
concerns with regards to ethical issues associated with embryo sourced cells. In 
addition, if an unlimited supply of hepatocyte-like cells could be produced, they 
would not only have great utility in the clinic but also in toxicity screening in pre-
clinical drug trials. 
The B-13 cell line is a powerful in vitro model that permits the changes 
occurring at the individual cellular and molecular levels during pancreatic to 
hepatic transdifferentiation to be studied. Data presented as part of this thesis 
has shown that human acinar cells have the potential to transdifferentiate 
towards the hepatic phenotype in response to glucocorticoids in vitro; as has 
been shown in the B-13 cell line. The challenge however still remains in 
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isolating and expanding the human equivalent capable of forming fully 
functional hepatocyte-like cells similar to the B-13/Hs. The HPAC cell line and 
primary acinar cells will be a great tool for elucidating the mechanisms in 
human, allowing us to understand the molecular and cellular changes, and 
support us to move closer to the ultimate goal of creating an unlimited supply of 
human hepatocyte-like cells.  
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THE HEPATIC PROGENITOR B-13 CELL LINE ENGRAFTS INTO THE 
MOUSE LIVER AND TRANSDIFFERENTIATES IN VIVO 
E.A. Fairhall1, C. Schwab2, C. Harrison2, K.A. Charlton1, K. Wallace1, 
M.C. Wright1.  
1Institute or Cellular Medicine, 2Northern Institute for 
Cancer Research, Newcastle University, Newcastle upon Tyne, UK 
 
Background and Aims: The AR42J-B-13 (B-13) cell line is a rat pancreatic 
acinar cell line capable of transdifferentiating into hepatocyte-like cells (B-13/H) 
in response to glucocorticoids. The transdifferentiation mechanisms have been 
shown to be dependent on a transient repression of WNT signalling upstream of 
an induction of liver enriched transcription factor C/EBPb [1,2]. B-13s thus have 
great potential in vitro, as an unlimited supply of functional hepatocytes, for a 
wide range of uses such as toxicological screening. Our aims were to 
investigate whether the progenitor cells can engraft to the liver of severe-
combined immuno-deficient (SCID) mice after paracetamol damage. 
Methods and Results: Cytogenetic analysis confirmed that B-13s carry the Y 
chromosome thus female SCID mice were dosed with paracetamol to induce 
liver damage prior to intra-venous injections of B-13 progenitor cells. Immuno-
histochemistry, for the pancreatic marker amylase was performed in all tissues 
to determine if any B-13 cells were present. Clusters of amylase positive cells 
were found within the portal tracts of the liver but not in other tissues and 
showed hepatocyte morphology. To confirm the origin of amylase positive cells, 
fluorescent in situ hybridisation (FISH) was performed to probe for the rat Y 
chromosome and confirmed the presence of the B-13 cells within the mouse 
livers. Protein expression for the pancreatic marker confirmed the presence of 
amylase within the livers positive by immuno-histochemistry. More interestingly 
RT-PCR for rat specific amylase and CYP2E1 showed that B-13 cells only 
engrafted to the liver and pancreas and transdifferentiation was only observed 
within the liver suggesting that within the liver environment their hepatic-
phenotype is promoted. 
Conclusions: These data show that the B-13 cell line is capable of engrafting 
to the damaged liver and differentiates into a hepatocyte-like morphology. This 
ability to transdifferentiate in vivo as well as in vitro brings new insights into the 
cell line and the isolation of a human equivalent would have great clinical 
potential for the treatment of liver disease. 
 
Reference(s) 
[1] Wallace K et al, J Cell Sci. 2010 Jun 15; 123(pt12): 2103–10. 
[2] Wallace K et al, J Cell Sci. 2011 Feb 1; 124(pt3): 405–13 
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The hepatic progenitor B-13 cell engrafts into the Mouse liver. 
Emma A. Fairhall, Claire Schwab, Christine Harrison, Keith A. Charlton, Karen 
Wallace, Matthew C. Wright 
Institute of Cellular Medicine, Medical School, Newcastle University, Newcastle Upon 
Tyne, United Kingdom. 
 
The AR42J-B-13 (B-13) cell line is a rat pancreatic acinar cell line capable of 
transdifferentiating into hepatocyte-like cells (B-13/H) in response to 
glucocorticoids. The transdifferentiation mechanisms have been shown to be 
dependent on a transient repression of the WNT signalling pathway upstream of 
an induction of the transcription factor C/EBP β[1,2] . Thus B-13 cells have great 
potential in vitro, as an unlimited supply of functional hepatocytes, for a wide 
range of uses such as toxicological screening. 
We investigated whether the progenitor cells can engraft to the liver of severe- 
combined immuno-deficient (SCID) mice after paracetamol damage. 
Female SCID mice were dosed with paracetamol to induce liver damage prior to 
intra-venous injections of B-13 cells. Immuno-histochemistry, for the pancreatic 
marker amylase, was performed in all tissues to determine the presence of B-13 
cells. Amylase positive cells with hepatocyte morphology were observed within 
the portal tracts of the liver but not in other tissues. Protein expression for the 
pancreatic marker confirmed the presence of amylase within the livers. To 
establish the origin of amylase positive cells, fluorescent-in-situ-hybridisation 
(FISH) was performed to probe for the rat Y chromosome and confirmed the 
presence of the B-13 cells within the liver. 
These data show that the B-13 cell line is capable of engrafting to the damaged 
liver and transdifferentiates into hepatocyte-like cells. This ability to 
transdifferentiate in vivo brings new insights into the cell line. The isolation of a 
human equivalent would have great potential in screening for drug and chemical 
toxicity. 
 
 
[1] Wallace K et al, J Cell Sci. 2010 Jun 15; 123 (pt12): 2103-10. 
[2] Wallace K et al, J Cell Sci. 2011 Feb 1 ; 124 (pt3) : 405-13 
  
 
 
 
 
 
 
 
 
 
 
 
Publications and abstracts 
226 
 
 
 
Myofibroblasts modulate the transdifferentiation of hepatic progenitor 
cells in vitro 
Emma A. Fairhall, Karen Wallace, Keith A. Charlton, Matthew C. Wright 
Institute of Cellular Medicine, Medical School, Newcastle University, Newcastle Upon 
Tyne, United Kingdom. 
 
Background 
Fibroblasts are known to regulate the pluripotency of embryonic stem cells (e.g. 
fibroblast feeder layers) (1). Since liver myofibroblasts secrete a variety of soluble 
factors (i.e cytokines, chemokines), we hypothesised that liver myofibroblasts would 
modulate progenitor cell differentiation to hepatocytes. 
 
Objectives 
To test this hypothesis, liver myofibroblasts stably expressing green fluorescent protein 
(GFP+) and an hepatic progenitor (B-13) cell  (2) stably expressing a red fluorescent 
protein were generated.  Fluorescently tagging cells ensured that the origin (from 
myofibroblast or progenitor) of any hepatocyte in cultures can be determined.  The 
differentiation of the progenitor cell was then examined in culture alone or in coculture 
with liver myofibroblasts or in medium conditioned by liver myofibroblasts. 
 
Methods and Results 
Cocultures of liver myofibroblasts and B-13 cells were set up for 7 days and were 
treated ±10nM dexamethasone (DEX), a synthetic glucocorticoid which directs B-13 
cells into hepatocytes via a modulation of Wnt signalling activity (2).  After 7 days of 
treatment, the numbers of hepatocytes (which were all expressing the red fluorescent 
protein and were therefore derived from the progenitor cells) was significantly 
enhanced by the presence of myofiboblasts.  An hepatocyte phenotype was observed 
in 96.43%± 2.14 of the cells derived from the progenitor cells whereas in the absence 
of myofibroblast cells, only 30.25%±4.3 of the progenitor cells differentiated into 
hepatocytes.  Interestingly, a significant proportion of liver myofibroblasts had 
undergone apoptosis in the presence of differentiating progenitor cells. 
 
Analysis of protein and mRNA levels confirmed phenotypic observations: myofibroblast 
marker expression was reduced in cocultures treated with DEX and hepatic markers 
such as cytochrome P4502E1, carbamoyl phosphate I (HepPar I) and albumin 
expression significantly enhanced. 
 
The effects of liver myofibroblast coculture on progenitor cell differentiation were lost 
when coculture was replaced with medium conditioned by liver myofibroblasts.  This 
indicates that cell-cell interactions, rather than soluble factors alone from liver 
myofibroblasts, play a role in enhancing the differentiation of liver progenitor cells into 
hepatocytes. 
 
Conclusions 
These data identify an important role for liver myofibroblasts in progenitor cell 
transdif ferentiat ion into hepatocytes through cell-cell interact ions. 
 
References 
1. Resnick, J.L., Ortiz, M., Keller, J.R., Donovan, P.J. 1998, Biol Rep 59, 1224-1229. 
2. Wallace, K., Marek, C.J., Hoppler, S., Wright, M.C. 2010, J. Cell. Sci 15, 2103-2110. 
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